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11. INTRODUCTION
1.1. Cholesterol and cancer
 
 Cholesterol content in tumoral tissues has been the topic of investigations 
since the beginning of  20th century 1-3 (Fig. 1 A). The first evidences already showed 
that cholesterol was greatly increased in cancer cells and in the surrounding tissues, 
as compared with the normal tissues from which the transformed cells derived 1-3 
(Fig. 1 B). Nevertheless, it remains unclear whether such changes play a role in 
disease progression or are merely byproducts of other metabolic changes in cancer 
cells 4. In other words, it remains unknow if cholesterol accumulation in transformed 
tissues promotes cancer appearance, or whether it is consequence of the neoplastic 
transformation. Only epidemiological studies revealed that prolonged use of lowering 
cholesterol drugs (statins) can be associated with prevention of some kinds of tumors 
such as prostate and kidney cancers, then suggesting that cholesterol accumulation 
could contribute to the appearance of a malignant neoplasm 5,6.
 Cholesterol is critical for the synthesis of cell membranes 7, it follows that rapidly 
proliferating tumor cells require more cholesterol than normal cells 8,9. In this regard, 
alterations in cholesterol regulation, have been detected in a wide number of solid 
and hematological cancers 1,9. Cancer cells have been reported to show: 1) enhanced 
endogenous cholesterol biosynthesis by increased 3-hydroxy-3-methylglutaryl CoA 
reductase activity (HMG-CoA-reductase; rate-limiting enzyme of the metabolic 
mevalonic pathway that generates cholesterol); 2) increased exogenous cholesterol 
uptake by over-expression of low-density lipoprotein (LDL)-receptor, LDLs being the 
major bloodstream transporters of cholesterol; 3) increased cholesterol acyltransferase 
enzyme activity (ACAT) that mediates cholesterol esterification for intracellular 
2storage; and 4) lower cholesterol efflux mediated by high-density lipoproteins (HDL)-
receptor 9 (Fig. 1 C).
Figure 1- Alterations in the mechanisms that underline the basis of cholesterol regulation in tumoral tissues. 
(A) Report about cholesterol content in cancer cells from the beginning of the 20th century. (B) Cholesterol 
accumulation in tumor cells and surrounding tissues (neighboring cell) has been reported in a large variety of 
tumor types.(C) Deregulation in biosynthesis, uptake, storage and efflux of cholesterol have been detected in 
cancer cells leading to cholesterol homeostasis breakedown. 
 The control of cholesterol content is a narrow balance between metabolic 
processes intrinsic to the cell and the regulation of cholesterol distribution in the 
organism. Extensive evidences indicate that this complex homeostatic mechanism 
breaks down not only in cancer, but also in aging tissues 6,10,11. In addition to the 
cholesterol implication in cancer cell signaling that we will discuss later, cholesterol is a 
key component in cell membranes. Cholesterol is a major regulator of lipid organization, 
3Introduction
promoting phase separation and stabilizing the formation of microdomains, with 
closely packed acyl chains of phospholipids, known as lipid rafts 4,5,7 .
1.2. Lipid rafts
  
1.2.1. Historical overview 
 Membranes of mammalian cells are composed of a tremendous variety of lipid 
species still not yet fully identified, including glycerophospholipids, sphingolipids, 
mono-, di- or triglycerides, fatty-acid and sterol-based structures 12. Plasma membrane 
was first defined as a fluid lipid bilayer with floating proteins, considered key 
components for membrane functionality, and subjected to random mixing -Singer-
Nicholson model or “fluid mosaic”- 13,14 (Fig. 2 A). It is now clear that far from being 
disordered, plasma membranes are complex, compartmentalized dynamic structures 
15 containing multiple microdomains with specialized functions. These microdomains 
comprise focal adhesions, tight and adherens junctions, clathrin-coated pits, among 
others 6. Non-random distributions of proteins and lipids (assemblies of sphingolipids 
and cholesterol) were proposed to form microdomains in plasma membranes named 
as lipid rafts. This hypothesis was postulated in 1997 by Kai Simons and Elina Ikonen 
16 (Fig. 2 B). The main functions of lipid rafts were initially thought to be related to 
transport of selected membranes (membrane trafficking) and cellular signaling 12,16 
(see Rafts Redefinition and Function).
 Lipid raft hypothesis was developed based on epithelial cell polarity and 
lipid behavior in artificial model membrane studies 16. A key aspect for lipid raft 
preliminary models was the observation that assemblies of cholesterol, sphingolipids 
and glycosylphosphatidylinositol (GPI)-anchored proteins were meant to be 
delivered to the apical plasma membrane from the Golgi apparatus. This aspect 
being determinant for epithelial cell differential lipid content in apical (sphingolipid 
enriched) and basolateral (phosphatidylcoline enriched) plasma membranes –lateral 
heterogeneity-16-18.  This was the first indication that cell membranes were also able to 
segregate different lipid species, as artificial models membranes predicted. Cellular 
membranes were not just random mixtures of lipids. Despite the complexity of cellular 
membranes, some insight into their behavior was also anticipated by analyzing lipid 
mixtures in artificial model membranes that reveled phase separation between sterol-
dependent liquid-ordered (Lo), and liquid disordered (Ld) phases, predicting that this 
phenomena can also occur under physiological conditions 14,19.
4Figure 2- Singer-Nicolson vs. lipid raft model. (A) Plasma membranes were first defined as a lipid bilayer with 
proteins “floating”, picturized as a “lipid sea” where lipids could diffuse freely through the membrane. (B) Lipid 
raft hypothesis gives lipids some protagonism, and rafts were first defined as mobile microdomains in the cell 
membrane specialized in signaling and membrane trafficking, enriched in cholesterol and sphingolipids with 
saturated acyl chains. Cholesterol fills interstitial spaces between lipids, confers rigidity and closely packs acyl 
chains promoting phase separation in the lipid membrane. Interaction with cholesterol forces hydrocarbon 
chains into more extended conformations, increasing membrane thickness. GM1 is a ganglioside associated 
with rafts currently used as a lipid raft marker.
1.2.2. Lipid raft characterization
 After the postulation of lipid raft model, an intense debate emerged in this field; 
the isolation techniques employed and the impossibility of in vivo visualization of rafts 
were the main topics of controversy 14. In this sense, raft size is below the resolution of 
light microscope, the isolation process of rafts is detergent-based, and only after cross-
linking with exogenous ligands raft constituents cluster together to form micrometer-
size patches able to be detected by light microscopy. All these aspects gave raise to 
some doubts on whether rafts were a real phenomenon. The knowledge of the precise 
raft size and dynamics was limited by the available methodology at the time 14. 
 Rafts are usually referred to as Lo or detergent-resistant membrane (DRM) 
fractions, leading to some confusion about its meaning. Lo phases were observed 
in artificial model membranes, enriched with raft components: sphingolipids, 
cholesterol and saturated lipids. The equivalent structures in biological membranes 
are called rafts surrounded by a contiguous “sea” of unsaturated lipids equivalent to 
Ld phase in model membranes. DRMs are the residue that remain insoluble after non-
ionic detergent extraction and that includes rafts, clustered rafts and caveolae (Fig. 
3). Non-ionic detergent extraction and ultracentrifugation in sucrose gradients is 
the usual biochemical technique for lipid raft isolation. However, this procedure is 
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not able to discriminate among rafts, clustered rafts and caveolae 12,14,19. Caveolae are 
microdomains isolated by the same detergent-based technique, but they are easily 
detected by electron microscopy (EM) due to their typical “cave” structure. They are 
characterized also by the presence of the caveolin protein 20. Caveolae show a more 
restricted tissue distribution than rafts, which appear to be ubiquitous in eukaryotic 
cells. Caveolae are abundant in muscle cells, endothelial cells, adipocytes, and 
fibroblasts, but its presence is rare or absent in lymphocytes and most neuronal cells 
13,20. Although the noncaveolar form of lipid rafts is less defined than caveolae, the 
biophysical properties of both microdomains are similar. It has been suggested that 
rafts can supplant caveolae functions in free caveolae tissues 6,21. 
  
Figure 3 - Detergent-resistant membrane isolation. Lipid rafts are isolated with non-ionic detergents such as 
Triton X-100 at low temperature (4ºC), followed by ultracentrifugation in sucrose gradients. The membranes 
isolated by this method are called detergent resistant membranes (DRMs). This is the most common method 
used for lipid raft isolation, although it does not differentiate between lipid rafts and caveolae domains. 
Following cell stimulation, rafts can form platforms with sizes able to be detected with conventional microscopy. 
Caveolae or “little caves” and lipid rafts have been related with many cellular functions as endocytosis and signal 
transduction. Caveolae microdomains are characterized by the presence of caveolin protein.
 Lipid rafts are more abundant at the plasma membrane than in intracellular 
membranes, being positively correlated with sterol content, but they can also be 
found in endocytic and secretory pathways; however, the situation for intracellular 
membranes is less clear 12-14,17. 
 
1.2.3. Raft redefinition and function
 The development of new techniques with high temporal and spatial resolution 
6allowed the visualization/detection of rafts before patches formation, supporting 
and redefining raft existence 14,22. These imaging approaches include single particle 
tracking (SPT), single fluorophore video tracking (SFVT), fluorescence resonance 
energy transfer (FRET), homo-FRET and EM 19. In the light of these new approaches, 
rafts are now described as dynamic, nanoescale, sterol/shingolipid-enriched, ordered 
assemblies of proteins and lipids, in which the metastable raft resting state can be 
stimulated to coalesce into larger, more stable raft domains by specific lipid-lipid and 
protein-protein oligomerizing interactions 14. Lipid rafts act as a membrane organizing 
principle in cellular processes, basically, they can facilitate protein-protein interactions 
by selectively exclude or include proteins. Lipid rafts have been implicated in signal 
transduction, endo and exocytose, membrane trafficking and viral infection 13,14,19. 
 The evolution of the lipid raft hypothesis from the original concept of stable 
pre-existing domains to one of more transient, dynamic platforms has been viewed 
with some skepticism because of the very short time- and length-scale recordings 
for nanodomains in living cells 15. However, John F. Hancock and colleges 15,19 
additionally using computational modeling studies, argue that it is precisely the above 
properties that make lipid rafts (or nanodomains at the light of their dimensions) ideal 
components for building biological signaling circuits. Thus, nanodomains protect the 
system from signal degradation during the information transfer across the plasma 
membrane. They conclude that transient and short life-time protein interactions with 
small lipid-raft domains facilitate useful biochemical reactions 15,19. 
1.2.4. How do proteins sort in lipid rafts?
 A number of proteins in different cells show reversible association to rafts in 
response to appropriate signals 13. The physical segregation of proteins into lipid rafts 
may regulate the accessibility of those proteins to regulatory or effector molecules 13. 
The precise mechanisms by which proteins sort into rafts are not fully understood. 
For example, lipid shells hypothesis proposes that specific membrane proteins bind 
complexes of cholesterol and sphingolipids that confer lipid buoyancy independently 
of raft/caveolae association. These shells are dynamic within the membrane and they 
are attracted to lipid raft domains in which shells are miscible 14,23. However, recent 
evidences are not compatible with this hypothesis, pointing that raft proteins can 
function as surfactants, reducing line tension between lipid raft (ordered) and non-raft 
domains (disordered), with preferential protein localization in the domain boundaries 
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19. In the first instance of lipid raft hypothesis, it was considered that rafts function as 
protein transporters, promoting protein interactions in the cell membrane. Now, it is 
believed that proteins help capturing and stabilizing raft domains 19. 
 
Figure 4- How proteins are sorted into lipid rafts? Proteins can be sorted to lipid rafts depending on the length 
of the hydrophobic transmembrane domains and on the partitioning properties of their “hydrophobic tails”. 
Proteins containing GPI tail as well as myristoylated or palmitoylated tails are signaled for raft incorporation. 
Prenylated proteins are excluded from rafts. Proteins may be sorted through binding to another raft membrane 
protein. Proteins with pleckstrin homology domains (PH) can be sorted to lipid rafts as rafts are specially 
enriched with phosphatidylinositols. “Lipid shell” hypothesis says that proteins with raft destination have shells 
with a lipid composition similar to raft domains. Cholesterol increases the bilayer thickness and in some extent 
might affect protein sorting, depending on the transmembrane domain length. 
 The elevated levels of cholesterol in rafts have been argued to determinate 
transmembrane protein sorting; cholesterol increases membrane thickness and 
therefore proteins with short transmembrane domains could be excluded from rafts 
4,12,13. Furthermore, some protein localization in raft domains can be determined by 
post-translational lipid modifications known as “hydrophobic tails” 13. For proteins 
with lipid or fatty-acid anchors, the preference to raft or non-raft domains depends on 
the properties of the acyl chains. In this regard, GPI-anchored proteins have preference 
8for lipid rafts because phosphoinositide anchors typically have saturated chains. 
Likewise, many myristoylated and palmitoylated proteins sort to lipid rafts (Fig. 4). In 
contrast,  prenylated anchors tend to disordered domains due to the unsaturation of 
the isoprenyl groups 4,13,24. 
 The most important role of rafts at the cell surface may be their function in signal 
transduction 17,25. Rafts might form concentrating platforms for individual receptors, 
where the signaling complex is protected from non-raft enzymes such as membrane 
phosphatases that otherwise could affect the signaling process. In general, raft binding 
recruits proteins to a new micro-environment, where the phosphorylation state can 
be modified by local kinases and phosphatases, resulting in downstream signaling 17,25. 
 The importance of lipid rafts domains in the transmission of growth promoting 
and apoptotic signaling will be analyzed in the following chapters. The scope of 
this Introduction is not to cover all raft molecules mentioned in literature. Instead, 
it would be briefly summarized the role of lipid rafts in the activation of PI3K/Akt 
and Fas/CD95 pathways, as prominent examples of cell survival and death signaling 
pathways, as well as to understand the action of some antitumor compounds, which 
target cancer cells by a cholesterol-lipid raft-dependent mechanism.
1.3. Rafts and signaling 
1.3.1. Akt Pathway
 The Akt signaling pathway is one of the most frequently hyperactivated signaling 
pathways in human cancers, with a wide range of cellular targets 26,27. The oncogenicity 
of Akt arises from activation of both proliferative and anti-apoptotic signaling routes. 
Furthermore, Akt contributes to tumor progression by promoting cell invasiveness and 
angiogenesis 26,27. Hyperactivation of Akt protect cancer cells against apoptotic insults, 
and is found more frequently activated in poorly differentiated tumors that are more 
invasive, grow faster and respond less to treatment 28. Thus, the pathological finding 
of hyperactivated Akt in primary tumors is considered to be a negative prognostic 
marker for disease outcome 28.
 Membrane recruitment is crucial for Akt activation, being promoted by the 
Akt pleckstrin homology domain (PH) which has high-affinity to membrane inositols 
27,29. In different types of cancer, it has been found a mutation at Akt1 PH domain. This 
mutation leads to permanent Akt membrane association, then resulting in a constitutive 
activation of Akt 28,30. The membrane localization protects Akt from inactivation 
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by phosphatases 27. This observation is in agreement with the lipid raft hypothesis 
which suggests that rafts environment protects protein signaling complexes. In this 
regard, elevated levels of lipid rafts in cancer cells 31, which are specially enriched with 
inositols 30,32,33, have been related with oncogenesis by promoting overactivation of Akt 
signaling pathway 34. Furthermore, other kinases implicated in Akt activation such 
as mammalian target of rapamycin (mTOR), phosphoinositide-3-kinase (PI3K) and 
3-phosphoinositide protein dependent-kinase-1 (PDK1) have been detected in lipid 
rafts, reflecting the importance of these domains for Akt pathway regulation 30,32.
 An overwhelming evidence of raft implication in Akt pathway regulation comes 
with the use of high resolution techniques that were able to track Akt in vivo. Reports 
from Lasserre 32 and Gao 34 laboratories maintaining live-cell context, determined that 
lipid rafts were indispensable for Akt membrane recruitment and activation.
1.3.2. Fas/CD95 Pathway
 Cell death can be triggered by several pathways and different kinds of cell 
death have been described, including, necrosis, apoptosis, lipoptosis, necroptosis, 
autophagy among others 35. In some cases, cells show a mixture of the different 
types of cell deaths. In the simplest and classical way, cell death is usually defined as 
programmed cell death -apoptosis- or necrotic cell death. In apoptotic cell death, two 
major pathways have been extensively described, namely: extrinsic pathway, mediated 
by death receptors and intrinsic pathway mediated by mitochondria 35. Fas/CD95 is a 
well known death receptor, and its proper function is essential for the elimination of 
viral or transformed cells 36. 
 Signaling of death pathways has been related with lipid rafts, including death-
receptor-mediated signaling pathways 22,37-39. It is still unknown how the strongly raft-
disfavoring transmembrane domains of death receptors are arranged with respect 
to the raft bilayer. Despite it has been described that some death receptors have an 
“hydrophobic tail”, some are palmitoylated proteins, it might be expected that death 
receptors prefer lipid raft boundaries, positioning their transmembrane domains in 
disordered domains and their palmitate chains adjacent to raft domains 33. 
 The death receptor Fas/CD95 and its natural ligand Fas ligand (FasL/
CD95L) can be palmitoylated 36,40,41. In this regard, some reports have shown that the 
partitioning of both FasL/CD95L and Fas/CD95 into rafts is necessary for efficient 
cell death signal transduction 36,38-40,42, promoting an efficient Fas/CD95-FasL/CD95L 
interaction, first described in our group 37,38,41,42. Upon binding to FasL/CD95L, Fas/
10
CD95 receptor is activated, then initiating apoptotic signaling cascades in Fas/CD95-
expressing cells. However, Fas/CD95 can aggregate and become active in the absence 
of FasL/CD95L 35,37,43. It has been proposed that redistribution of Fas/CD95 into 
lipid rafts is important in the activation of ligand-independent Fas/CD95-induced 
apoptosis 35,37,44. The redistribution of this receptor in lipid rafts was firstly described 
during research conducted with chemotherapeutic drugs that we will discuss later 37-39. 
Thus, Fas/CD95 redistribution into lipid rafts can occur naturally promoted by “death 
cytokines”, such as FasL/CD95L, but also by chemotherapeutical agents that have the 
potential to mimic such cytokine effect 37,45. In addition, other death receptors, such as 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, have been 
reported to be palmitoylated for lipid raft partitioning and proper signal transduction 
activation 46.  
 Furthermore, it has also been proposed that ceramide formation from the 
conversion of sphingomyelin (SM) (a type of sphingolipid) can promote lipid raft 
platform formation, Fas/CD95 clustering and triggering apoptotic signaling 35,47. 
1.3.3. Additional raft-dependent processes
 The formation of raft signaling platforms has been extensively reported during 
T-cell immunological synapse 14. In this process, T-cell receptors (TCRs) are first 
engaged and activated in TCR microclusters, then transported towards the central 
supramolecular activation cluster (cSMAC), where raft-platforms are stabilized and 
many proteins are involved 14. Larger and stable platforms seem to be required for 
protein trafficking endocytosis, and for highly specialized function such as T-cell 
synapse 14. 
 Raft clustering seems to be critical as well for Ras signaling 19. Three different 
Ras isoforms, H-Ras, N-Ras and K-Ras, have been reported to occupy distinct rafts 
(nanoclusters) that have different structural requirements for actin, cholesterol and 
various scaffold proteins. One of the core signaling pathways activated by Ras is the 
mitogen activated protein kinase (MAPK) cascade that comprise Raf, MEK and 
extracelular signal-regulated protein kinase (ERK) 15. 
  Finally, the involvement of rafts in cancer is reaching a new exciting field as 
they are being related with the invasive capacity of cancer cells. Tumor cell structures 
named invadopodia are specialized raft-like membrane domains, where cholesterol 
levels are tightly regulated, and active transport of protease-delivering carriers is 
required for their function 18.
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 Lipid rafts may provide an important subcellular microenvironment in which 
signals are processed, including central signals for tumor cell growth, resistance to 
apoptotic signals, and other aggressive characteristics 48. In the following chapter we 
will discuss the possibility of targeting lipid rafts as a selective therapy for cancer. 
Summarizing the above data we can envisage that cancer cells are enriched in 
cholesterol/lipid rafts,  and these domains are critical platforms for the signaling of 
survival pathways. 
1.4. Changing rafts, changing cancer cell fate: raft-targeting drugs
1.4.1. Modulation of Akt signaling by altering colesterol levels through statins and 
cholesterol-depletion agents
 Tumor cell survival and death are susceptible to be modulated by altering the 
cellular cholesterol content.  Different kinds of tumors undergo cell death through the 
inhibition of endogenous cholesterol synthesis by statins 49,50 or by cholesterol depletion 
from membranes, this lethality being related  to the disruption of Akt signaling 31,50-52.
  On the other hand, elevated circulating levels of cholesterol have been shown 
to promote tumor cell growth. Freeman and colleges 49, using in vivo models, provide 
evidences that elevated circulating cholesterol leads to increased cholesterol content 
in the lipid rafts of cells isolated from xenograft tumors. They also detected increased 
phosphorylation of Akt and reduced apoptosis in these cells, thus suggesting that 
some kinds of tumors can become dependent on a cholesterol-regulated Akt pathway 
for cell survival 48,49 (Fig. 5 A). 
 Despite the above relationship between rafts and Akt upregulation in tumor cells, 
inactivation of the tumor suppressor PTEN (phosphatase and tensin homolog), the 
Akt upstream phosphatase, is usually present. However, Akt activity can be regulated 
by cholesterol, even when PTEN is mutated. Thus, despite Akt overactivation has been 
typically associated to mutated PTEN, cholesterol depletion can downregulate Akt 
activity. In this regard, lipid rafts could play a major role for constitutive Akt signaling 
in tumor cells. Previous reports with statins have shown that these compounds 
preferentially inhibit Akt phosphorylation at Ser473, that usually takes place in lipid 
rafts. On these grounds, targeting lipid rafts could be a possible therapeutic approach 
for Akt downregulation 51.
 In this regard, cancer cells with a higher content of  cholesterol-rafts have been 
related with their higher sensitivity to undergo apoptosis by cholesterol-depleting 
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agents 31. Interestingly, Akt has been implicated in the transcriptional induction of 
Figure 5- Cholesterol modulates Akt pathway in cancer cells. (A) In vivo experiments showed that diets with high 
contents of cholesterol lead to raft expansion and promotes activation of Akt pathway in xenograft tumors. 
Circulating cholesterol can promote survival signaling. (B) Raft environment can affect the affinity of Akt for 
its substrates, suggesting that differential Akt localizations can lead to different signaling routes. Furthermore, 
Akt can promote its own activation by regulating the expression of genes involved in the synthesis of raft 
components such as cholesterol and fatty acids.
enzymes involved in cholesterol and fatty acid biosynthesis, including: HMG-CoA-
reductase, HMG-CoA synthase and fatty acid synthase 53. Therefore, Akt activity may 
be related with to the mentioned cholesterol accumulation in tumors 53. Furthermore, 
Akt can  promote its own activation in tumor cells, by supplying substrates for the 
synthesis of membrane components, including raft components 53. A positive feedback 
mechanism seems to exist, whereby signals transmitted by raft-located Akt can lead to 
enhanced cholesterol synthesis, expansion of the cholesterol-rich compartment, and 
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increased localization of Akt to rafts 48. Furthermore, raft-located Akt could promote a 
distinct Akt-substrate preference, leading to a signal transduction different from that 
of non-raft Akt 48. These findings suggest that tumor cells possibly contain discrete Akt 
populations that trigger distinct signals depending on their subcellular location (Fig. 5 
B) 48,49. It has been suggested that antiapoptotic signals are transmitted, at least in part, 
by raft-resident Akt 48. In addition, differences in substrate preference might result from 
a change in conformation of Akt in rafts or from a differential association of Akt with 
interacting proteins enriched in distinct subcellular compartments 48.Taken together, 
these results suggest that cholesterol inhibitors may be used for chemoprevention or 
cancer therapy, likely in combination with other chemotherapeutic drugs 6,48,49.
1.4.2. Anticancer alkylphospholipids (APLs) or antitumor lipids (ATLs)
 ATLs are metabolically stable analogs of lysophosphatidylcholine 56-60. The 
selectivity and antitumor properties both in vitro and in vivo of some of these ATLs 
were first described by Munder and colleges 54,55. Among these ATLs, edelfosine 
appeared as a very effective anticancer compound, and become the prototype in 
antitumor activity trials 56-60. Edelfosine was found to promote selectively apoptosis in 
cancer cells, whereas normal cells were spared 59. The mechanism of action of ATLs 
differs from classical chemotherapeutic drugs, since their molecular targets are located 
at the cellular membranes rather than at the DNA. Due to their chemical structure, 
with essentially one long non-polar hydrocarbon chain, ATLs easily insert into the 
plasma membrane lipid bilayer 39,56,61,62. Even though the selective uptake of edelfosine 
is suggested to be protein-mediated59, it has been also hypothesized that edelfosine 
selectivity to tumor cells was, at least in part, affected by its affinity to membrane 
cholesterol, as there is a geometric compensation of the “cone shape” of sterols and 
the “inverted cone shape” of edelfosine that leads to the formation of stable bilayers 
8,61,63,64. In this regard, several reports relate ATL antitumor activity with lipid rafts. It 
has been reported that ATLs accumulate in lipid rafts undergoing a subsequent raft-
mediated internalization 56,65,66, and that ATLs can induce raft clustering into larger 
platforms 37-39,56,57,67. 
 Van Blitterswijk 68 and colleagues have shown that mouse lymphoma cells 
resistant to ATLs have no biosynthesis of the raft constituent SM due to the complete 
downregulation of sphingomyelin synthase (SMS1) 68. SMS1 is usually located in trans-
Golgi network. SMS1 not only produces SM, then facilitating new lipid raft formation, 
but it is also necessary for membrane raft vesicular trafficking towards (anterograde) 
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and from (retrograde) the plasma membrane 56. 
1.4.2.1. ATLs in hematological malignancies
 ATLs can activate apoptosis in cancer cells by multiple signaling pathways, 
one of them is extensively documented in hematological cancers, and implies the 
translocation and co-capping of lipid rafts and death receptors 38,64,69,70. Fas/CD95, a 
member of the tumor necrosis factor (TNF) receptor gene superfamily, was primarily 
described to be recruited in tumor cell lipid rafts from tumor cells following ATL 
incubation, this phenomena being related to the triggering of cell death 37-39,69. 
Subsequently, TRAIL death receptors, have also been reported to be recruited in 
rafts after ATL incubation 64,69. These findings led to the hypothesis that ATLs were 
activating apoptosis after redistribution of Fas/CD95 into lipid rafts, independently 
from its natural ligand FasL/CD95L 37,39,43,71. The lipid raft localization of Fas/CD95 
can promote the recruitment of downstream signaling apoptotic proteins leading to 
tumor cell death 37,67,69, and to the concept of CASMER (cluster of apoptotic signaling 
molecule-enriched rafts) 42,72,73 (Fig. 6). The stimulation of Fas/CD95 by its natural 
ligand or by specific cross-linking antibodies results in receptor aggregation, drives the 
formation of DISC (death-inducing signaling complex), which comprises the adaptor 
protein FADD (Fas-associated death domain-containing protein) and procaspase-8; 
then oligomerization drives procaspase-8 activation through self-cleavage, activating 
downstream effector caspases and leading to apoptosis 37,56. ATLs not only promoted 
DISC formation in rafts, but also additional recruitment of downstream apoptotic 
signaling proteins, including c-Jun N-terminal kinase (JNK), procaspase-10 and BH3 
interacting domain death agonist (Bid) 37,67,69,72,74. Persistent JNK activation is associated 
with apoptosis, and Bid has been shown to act as a bridge between Fas/CD95 signaling 
and the mitochondrial-dependent apoptotic pathway 37,73. In accordance with this Bid 
localization in rafts, it has been reported a lipid raft connection between extrinsic 
and intrinsic pathways mediated by ATLs 72. Redistribution of death receptors into 
lipid rafts also sensitizes cells to death receptor stimulation by their cognate ligands or 
agonistic cytotoxic antibodies, despite de novo FasL/CD95L synthesis is not essential 
for the induction of apoptosis 69. Thus, ATLs promote redistribution of pre-existing 
Fas/CD95 and FasL/CD95L into clusters 37,39,75. 
 Activation of the apoptotic machinery in tumor cells constitutes an attractive 
and promising therapeutic approach for cancer treatment. This strategy takes 
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advantage of the apoptotic machinery that is still functionally available in tumor cells 
in order to direct their own demise 37. The first demonstration of the recruitment of 
Fas/CD95 in lipid rafts was made in acute lymphoblastic leukemia (ALL) and acute 
myeloid leukemia (AML) cell lines after edelfosine incubation 38. Subsequently, similar 
results were obtained in other hematological malignancies: multiple myeloma (MM) 
38,64, mantle cell lymphoma (MCL) 70 and chronic lymphocytic leukemia (CLL) 70. 
  
 
Figure 6- Lipid raft-mediated apoptosis in hematological cancers by the action of ATLs. ATLs can promote the 
activation of two major apoptotic pathways, namely: mitochondria-mediated intrinsic pathway, which leads 
to liberation of cytocrome C, formation of reactive oxygen species (ROS), mitochondrial potential loss (ΔΨm loss) and activation of caspase-9; and extrinsic pathway, mediated by the recruitment death receptors in lipid 
rafts. ATL incubation leads to co-capping of death receptors and lipid rafts and mobilization of downstream 
apoptotic signaling molecules. Not just DISC components (Fas/CD95, FADD and procaspase-8), but also JNK 
and Bid can be recruited in rafts. This accumulation of apoptotic molecules in rafts has led to the notion of the 
so-called CASMER. ATLs can promote a strong apoptotic response due to the activation of different apoptotic 
pathways, eventually leading to DNA degradation and cell death.
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 The Fas/CD95 recruitment in lipid rafts has been reported not only for ATLs 
and in hematological cancers, but also in solid tumors cells and by the action of distinct 
compounds. Among others, we can list the following ones: resveratrol in colon cancer 
cells 76,77, cisplatin in colon cancer cells 78, anandamide in cholangiocarcinoma cells 79, 
aplidin in leukemic cells 42, and several others that surprisingly do no share similar 
chemical struture 37.
 The Fas/CD95 activation in rafts, can be promoted not only by exogenously 
added compounds, but the same phenomenon has been observed being induced with 
the so called “death cytokines”. Taking all data together, these findings reinforce the 
notion that different chemical stressful agents can reactivate a physiological mechanism 
of cell death that remains “dormant” in transformed cancer cells. Since increasing and 
accumulating evidence indicates that the clustering of apoptotic molecules in lipid rafts 
is a general process involved in apoptosis, the concept of CASMER has been proposed 
to represent a novel lipid raft-based supramolecular entity that seems to play a critical 
role in the regulation of apoptosis 73,80. CASMERs act as death-promoting scaffolds 
where death receptors and downstream signaling molecules are brought together, 
thus facilitating protein-protein interactions and the transmission of apoptotic signals 
73,80. 
 Additional data suggest that the key molecular target for inhibition of cell 
proliferation and/or induction of cell death following the action of ATLs may depend 
on the cell type. Thus, endoplamatic reticulum (ER) accumulation of ATLs and 
inhibition of phosphatidylcoline synthesis leads to ER-stress and apoptotic induction 
in several tumor cells 56,57,81,82 (See general discussion). As well as the inhibition of Akt 
pathway has been implicated the mechanism of action of ATLs 83. 
 Inhibition of Akt pathway has been implicated in the mechanism of action of 
ATLs 83. Once ATLs accumulate in cell membranes it might be envisaged that they 
could interfere with lipid-dependent signaling process. In this regard, it has been 
shown that the ATL perifosine can prevent the recruitment of Akt to the membrane 
56. Interestingly, Akt inhibitors can promote Fas/CD95 redistribution and activation in 
lipid rafts 84. 
Since these compounds target membranes of cancer cells instead DNA, ATLs 
can have synergistic or additive effect in combination with conventional therapy 56,168. 
In fact, it has been already shown that ATLs sensitizes tumor cells to radiotherapy168.
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2. HYPOTHESIS
 
 Cholesterol is a critical component for lipid raft formation and function. In the 
last years, lipid raft investigation in tumor cells has started to establish a link between 
irregular cholesterol content in cancer cells and unsettled signaling. A number of 
recent evidences suggest that rafts could be an important target for chemotherapeutic 
drug action. Rafts can function as gateways and platforms for apoptotic signaling 
recruitment. Additionally, new data start to reveal that rafts play a role in the metastatic 
feature of cancer cells. The possibility of targeting cancer cells through rafts in order 
to induce critical changes on raft proteomic content, driving cancer cells to apoptosis 
and/or proliferation blockage has been explored as new a framework for cancer 
therapy. Here, we will analyze how apoptosis can be triggered by agents considered 
“lipid raft-targeting drugs”. 
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3. OBJECTIVES:
1- Analysis of the role of lipid rafts and Fas/CD95 in the cell death induced 
by resveratrol in MM and T-cell leukemic cells.
2- Characterization of the role of lipid rafts in Akt activation and cell death 
induced by ATLs in MCL cells. 
3-  In vitro assessment of combined therapies, between lipid raft-targeting 
drugs (resveratrol and ATLs) and compounds that do no target lipid rafts 
(bortezomib, histone deacetylase inhibitors and interferon gamma).
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The results generated in this work have led to the following manuscripts: 
1. Reis-Sobreiro M, Gajate C, Mollinedo F. Involvement of mitochondria and 
recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated 
antimyeloma and antileukemia actions. Oncogene. 2009; 28:3221-3234. 
2. Reis-Sobreiro M, Roue G, Mouros A, Gajate C, de la Iglesia-Vicente J, 
Colomer C, Mollinedo F. Lipid raft-mediated Akt signaling as a therapeutic 
target in mantle cell lymphoma. Blood Cancer Journal. 2013; 3:e118.
3. Reis-Sobreiro M, Gajate C, Mollinedo F. The antitumor lipid edelfosine in 
combination therapy for multiple myeloma. Submitted to publication. 
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4.MATERIALS AND METHODS
4.1. Reagents
 Resveratrol (RESV; Sigma, St Louis, MO, USA) was prepared as a 100 mM stock 
solution in dimethylsulfoxide (DMSO). Pancaspase inhibitor z-VAD-fmk (Alexis 
Biochemicals, Lausen, Switzerland), caspase-8 inhibitor z-IETD-fmk (Calbiochem, 
San Diego, CA, USA), caspase-10 inhibitor z-AEVD-fmk (R&D Systems, Minneapolis, 
MN, USA) and JNK inhibitor SP600125 (Calbiochem) were prepared as 10 or 20 mM 
stock solutions in DMSO. Velcade® (bortezomib) was from Millenium Pharmaceuticals 
(Cambridge, MA, USA).
 Edelfosine (Inkeysa, Barcelona, Spain) and perifosine (Zentaris, Frankfurt, 
Germany) were prepared as 2 mM stock solutions in culture medium. Anti-CD40 
immunoglobulin was a kind gift from Francisco Lozano (Immunology Department, 
Hospital Clínic-IDIBAPS, Barcelona, Spain). Caspase inhibitor benzyloxycarbonyl-
Val-Ala-Asp(OMe)-fluoromethylketone (z-VAD-fmk; Enzo Life Sciences, Lausen, 
Switzerland) was prepared in DMSO as a 100 mM stock solution. Akt inhibitor 1/2, Akt 
inhibitor III, Akt inhibitor X (Calbiochem/Merck, Darmstadt, Germany), and PI3K 
inhibitor wortmannin (Cell Signaling, Irvine, CA, USA) were prepared in DMSO as 10 
mM and 2 mM stock solutions. ERK inhibitor PD98059 and JNK inhibitor SP600125 
(Calbiochem/Merck) were prepared as 10 or 20 mM stock solutions in DMSO. 
 SAHA and MS-275 (histone deacetylases inhibitors, Sigma) were prepared as 
20 mM, 5 mM and 10 μM stock solutions, respectively. Edelfosine was prepared as 
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a 2 mM stock solution in culture medium. Velcade® (bortezomib) purchased from 
Millenium Pharmaceuticals (Cambridge) was prepared as 1 mM stock solution. 
4.2. Cell culture
 The human acute T-cell leukemia Jurkat cell line; the human MM cell lines: 
MM1S, MM144, MM1R and U266; the MCL cell lines: Z-138, JVM-2, Jeko-1, HBL-
2 as well as the stromal HS-5 cell line were grown in RPMI-1640 culture medium 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; Life 
Technologies, Carlsbad, CA, USA), 2 mM L-glutamine, 100 U/ml of penicillin, and 
100 μg/ml streptomycin at 37ºC in humidified 95% air and 5% CO2.
 The Jurkat FADD-DN cell line is a Jurkat-derived clone stably transfected 
with a pcDNA3 expression vector encoding a dominant-negative form of the FADD 
protein, was a kind gift from Dr. Lienhard Schmitz (Justus-Liebig-University, Giessen, 
Germany), and was maintained in complete RPMI-1640/10% FBS medium containing 
200 μg/ml G418. Jurkat cells were also transfected with control pcDNA3 empty 
vector using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. 
4.2.1. Fas-deficient Jurkat cells
 Fas-deficient Jurkat cells were generated following protracted cultures (over 10 
months) of parental Jurkat cells. 
4.2.2. MM patient-derived cells isolation
 Heparinized bone marrow aspirates obtained from patients with newly 
diagnosed MM and after signing informed consent, were provided by the Hematology 
Department of the Hospital Clinico Universitario (Salamanca, Spain). The study was 
approved by the Ethics Committee of the Hospital. Mononuclear cells were isolated 
by Ficoll-Hypaque (Amersham Biosciences, Upsalla, Sweden) density gradient 
centrifugation and subjected to positive selection using magnetic cell sorting (Miltenyi 
Biotec, Bergisch Gladbash, Germany). Purified CD138+ tumor cells (>95% plasma 
cells) and CD138- non-transformed cells were isolated as previously described, 
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resuspended in RPMI-1640/10% FBS medium, and used immediately for experiments.
4.2.3 Isolation of peripheral blood lymphocytes (PBLs)
 Mononuclear cells were isolated from fresh human peripheral blood by dextran 
sedimentation and centrifugation on Ficoll-Paque density gradients. Mononuclear 
cells at the interface were saved, washed twice with phosphate-buffered saline 
(PBS), and resuspended in RPMI-1640 culture medium containing 10% (v/v) heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 
24 µg/ml gentamicin, and incubated overnight at 37ºC in the humidified atmosphere 
of 5% CO2 and 95% air. Monocytes were depleted by culture dish adherence. After 
overnight incubation at 37ºC, the non-adherent cells (lymphocytes) were washed with 
PBS and collected. Lymphocyte preparations were typically 67-73% CD3+, 25-28% 
CD19+, and <0.4% CD14+. To further purify T-cells, the adherent non-adherent cells 
were washed with PBS and passed twice through a nylon wool column to deplete 
residual B-cells and monocytes. T-cell purity was checked by flow cytometry analysis. 
These purified T-cell preparations were typically >95% CD3+, <0.3% CD14+ and 
<4% CD25+. Further lymphocytes were incubated for 24 and 48 h with RESV at the 
indicated concentrations.
4.2.4. MM144 transfection with Bcl-XL
 MM144 cells were transfected by electroporation with the SFFV-Neo expression 
vector containing the human bcl-xL open reading frame driven by the long terminal 
repeat of the splenic focus-forming virus (pSFFV-bcl-xL). As a control, transfection 
was performed with empty SFFV-Neo plasmid. MM144 cells (4 x 107) were subjected 
to electroporation at 500 V, 1700 µF, 72 Ohm in a BTX electro cell manipulator 600 
(Biotechnologies & Experimental research, San Diego, CA, USA) and selected by 
growth in the presence of 400 µg/ml G418.
4.2.5. HS-5 co-culture with patient-derived MCL cells
 HS-5 stromal cells (2 x 105) were plated in 24-well plates and left to attach 
overnight, before adding 5 x 105 MCL patient-derived cells. ATLs were added at10 mM 
for 6 or 24 h, and then MCL cells were carefully collected and analyzed by western blot 
or flow cytometry (See flow citometry section).
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4.2.6. Isolation and culture of primary MCL cells
 Cells from 9 patients diagnosed of MCL according to the World Health 
Organization classification criteria were studied. Informed consent was obtained 
from each patient in accordance with the Ethics Committee of the Hospital Clinic 
(Barcelona, Spain). Cells were cryopreserved in liquid nitrogen in the presence of 10% 
(v/v) DMSO and 60% (v/v) heat-inactivated FBS. MCL primary cells were cultured 
immediately after thawing or isolation at a concentration of 1-3 x 106 cells/ml in 
RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin at 37ºC in a humidified atmosphere 
containing 95% air and 5% CO2.
4.3. Flow cytometry
4.3.1. Cell cycle analyses
 Cells (2.5-4 x 105/ml) were centrifuged and fixed overnight in 70% (v/v) ethanol 
at 4ºC. Then, cells were washed three times with PBS, incubated for 1 h with 1 mg/
ml RNase A and 20 µg/ml propidium iodide at room temperature, and analyzed with 
a FACSCan flow cytometer (Becton Dickinson; San Jose, DA, USA). Quantitation 
of apoptotic cells was calculated by flow cytometry as the percentage of cells in the 
sub-G1 region (hypodiploidy) in cell-cycle analysis.
4.3.2. Viability and annexin V
 To analyze apoptosis by annexin V binding in MCL patient-derived samples 
and cell lines, 5 × 105 cells were incubated with the indicated agents. Cells were then 
washed in Annexin-binding buffer and incubated in 50 μl Annexin-binding buffer 
with allophycocyanin-conjugated anti-CD3 and phycoerythrin-conjugated anti-
CD19 antibodies (Becton Dickinson) for 10 min in the dark. Cells were then diluted 
with Annexin-binding buffer to a volume of 150 μl and incubated with 1 μl FITC-
labeled Annexin V (Bender MedSystems, Vienna, Austria) for 15 min in the dark. A 
total of 10000 stained cells were then analyzed by flow cytometry on a FACSCalibur 
flow cytometer using CellQuest software (Becton Dickinson).
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4.3.3. Cytofluorimetric analysis of mitochondrial transmembrane potential and 
generation of reactive oxygen species
 To evaluate the mitochondrial transmembrane potential (ΔΨm) and the 
generation of reactive oxygen species (ROS), cells (106/ml) were incubated in PBS 
with 20 nM 3,3´-dihexyloxacarbocyanine iodide [DiOC6(3)]; (green fluorescence; 
Molecular Probes, Leiden, The Netherlands) and 2 μM dihydroethidine (DHE; red 
fluorescence after oxidation; Sigma) for 40 min at 37ºC, followed by analysis on a 
Becton Dickinson  fluorescence-activated cell sorting FACSCalibur flow cytometer as 
previously described.
4.3.4. Cell surface death receptor expression 
 To analyze Fas/CD95, DR4 and DR5 by flow cytometry assays, cells (2.5 x 
105) were incubated anti-human Fas SM1/1 IgG2a Mab (Bender MedSystems), or anti 
human monoclonal anti-DR4 and anti-DR5 (R&D Systems) in PBS (1:150 dilution) 
for 1h at 4ºC, washed with cold PBS, and incubated for 1 h at 4ºC with fluorescien 
isotithiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin (Dakopatts, 
Glostrup, Denmark). After washing, cells were fixed with 1.5% (w/v) formaldehyde, 
and subject to immunofluorescence flow cytometry in a FACSCan cytofluorometer 
(MFI values). Percentage of death receptor positive cells were estimated using P3X63 
myeloma supernatant as a negative control, provided by F Sánchez-Madrid (Hospital 
La Princesa, Madrid, Spain).  
4.4. Apoptosis quantification by the interaction of Fas/CD95-FasL/CD95L 
 The possible implication of Fas/CD95-FasL/CD95L interaction in RESV-
induced apoptosis was evaluated by using the blocking anti-Fas/CD95 SM1/23 IgG2b 
monoclonal antibody (Bender MedSystems). Cells (2.5 x 105/ml) were preincubated 
at 4ºC for 30 min in PBS containing 1% (w/v) BSA in the absence (controls) or in the 
presence of 100 ng/ml of the blocking SM1/23 antibody. Then, cells were resuspended 
at 2.5 x 105/ml in complete RPMI-1640 culture medium containing the same amount 
of blocking anti-Fas antibody, and treated with 50 ng/ml of cytotoxic anti-Fas CH 
11 IgM monoclonal antibody (Upstate Biotecnology, Lake Placid, NY, USA) or 70 
µM RESV at 37ºC for 48 h. Then, cells were collected by centrifugation and analyzed 
for apoptosis by flow cytometry analyses previous described. Experiments performed 
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with mock-irrelevant isotype immunoglobulins had no effect. Cells were preincubated 
with 100 ng/ml blocking SM1/23 antibody for 30 min before addition of 50 ng/ml 
cytotoxic anti-Fas/CD95 CH11 antibody, 100 ng/ml FasL/CD95L or 70 µM RESV 
for 48 h, or 10 µM edelfosine during 24 h. Untreated control cells and cells incubated 
only with SM1/23 antibody, CH11 antibody, FasL/CD95L or RESV for 48 h were run 
in parallel. Apoptosis was then quantitated as percentage of cells in the sub-G1 region 
by flow cytometry. Average values of two experiments are shown.
4.5. Western blot 
 Cells (4-5 x 106) were lysed with 60 μl of lysis buffer containing (20 mM HEPES, 
pH 7.5, 10 mM EGTA (ethylene glycol tetraacetic acid), 40 mM β-glycerophosphate, 
1% (v/v) NP-40, 2.5 mM MgCl2, 2 mM orthovanadate, 1 mM DTT) supplemented 
with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 20 μg/ml aprotinin, 
20 μg/ml leupeptin). After 30 min on ice, solubilized proteins were obtained 
by microcentrifugation at 14000 rpm. Proteins (20-50 μg) were run on SDS-
polyacrylamide gels under reducing conditions, transferred to PVDF membranes 
(Millipore, Billerica, MA, USA) blocked with 5% powdered (w/v) defatted milk in 
TBST (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% (v/v) Tween 20) for 1 h at room 
temperature, and incubated for 1 h at room temperature or overnight at 4ºC with the 
following specific antibodies: (See page 30)
 Antibody reactivity was monitored with HRP-conjugated anti-rabbit, anti-
mouse or anti-goat immunoglobulin G (IgG), using an enhanced chemiluminescence 
detection system (Amersham Biociences). 
4.6. INF-γ treatment
 To examine the effect of IFN-γ incubation on protein expression, 4-5 x 106 cells 
were treated with 50 ng/ml IFN-γ (Upstate Biotechnology, Lake Placid, NY, USA) in 
RPMI-1640/10% FBS complete culture medium for 24 or 48 h and Fas/CD95 and 
Caspase-8 expression were analyzed by western blot (See western blot section) 
 To analyze the effect of IFN-γ on apoptosis, cells (4 x 105) were pretreated with 
50 ng/ml IFN-γ in a final volume of 2 ml for 48 h in RPMI-1640/10% FBS complete 
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culture medium, before incubation with RESV or edelfosine. Then, the percentage 
of apoptotic cells was measured by flow cytometry in cell-cycle analysis (see flow 
cytometry section).
4.7. Confocal microscopy
4.7.1. Fas/CD95 and rafts co-localization
 Untreated and RESV, SAHA or MS-275 treated cells (1 x 106) were settled onto 
slides coated with poly-L-lysine, fixed in 4% (v/v) formaldehyde, and then incubated 
with anti-human Fas/CD95 SM1/23 mouse monoclonal antibody (diluted 1:150 in 
PBS; Bender MedSystems) for 1 h at room temperature. Samples were washed with 
PBS and incubated for 1 h with Cy3-conjugated sheep anti-mouse antibody (diluted 
1:150 in PBS; Jackson ImmunoResearch, West Grove, PA, USA), washed with PBS 
and stained with 8 μg/ml FITC-CTx B subunit (Sigma) as a raft marker. Samples 
were then analyzed by confocal microscopy using a Zeiss LSM510 laser scan confocal 
microscope (Oberkochen, Germany) for membrane raft and protein visualization as 
described. Colocalization assays were analyzed by excitation of the corresponding 
fluorochromes in the same section. Negative controls, lacking the primary antibody 
or using an irrelevant antibody, showed no staining.
4.7.2. Pervanadate stimulation and p-Akt detection by immunofluorescence
 Serum-starved Z-138 cells (4 x 105) treated without or with pervanadate (see 
pervanadate preparation) for 15 min were settled onto poly-L-lysine-coated slides, 
fixed with 4% (v/v) formaldehyde and permeabilized for 1 min with 0.1% (v/v) 
Triton X-100 in PBS. Cells were incubated with anti-Ser473 p-Akt rabbit polyclonal 
antibody (Cell Signaling; 1:100 dilution in PBS/1% BSA) at room temperature for 1 
h, followed by incubation with Cy3-conjugated sheep anti-rabbit antibody (Jackson 
ImmunoResarch; 1:150 dilution in PBS/1% BSA) for 1 h at room temperature, followed 
by 1 min incubation with 2 ng/ml DAPI (4´,6-diamidino-2-phenylindole) in PBS at 
room temperature. Samples were then analyzed by using Leica confocal microscope 
TCS-SP5 (Mannheim, Germany).
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Antibody Dilution Molecular weigth
 (kDa)
Company
4-EBP1 1:3000 20-15 Cell Signaling
Akt1/2/3 rabbit polyclonal 1:1000 60 Santa Cruz Biotechnology
Bad monoclonal 1:1000 23 BD Transduction 
Laboratories
BAP31 goat polyclonal 1:500 29 and 31 Santa Cruz Biotechnology
Bid goat polyclonal 1:500 23 Santa Cruz Biotechnology
Caspase-3 rabbit polyclonal 1:500 20 and 17 BD Pharmingen
Caspase-4 goat polyclonal 1:500 20 Santa Cruz Biotechnology
Caspase-7 monoclonal 1:1000 35,32 and 20 BD Pharmingen
Caspase-8 monoclonal 1:500 18 Oncogene Research 
Products
Caspase-9 rabbit polyclonal 1:1000 38 and 17 Calbiochem
DR4 goat polyclonal 1:500 56 Santa Cruz Biotechnology
DR5 goat polyclonal 1:500 48 Santa Cruz Biotechnology
ERK2 monoclonal 1:1000 44 Santa Cruz Biotechnology
FADD monoclonal 1:250 24 BD Transduction 
Laboratories
Fas/CD95 rabbit polyclonal 1:1000 48 Santa Cruz Biotechnology
GSK3 α/β rabbit polyclonal 1:1000 51 and 46 Cell Signaling
JNK1 rabbit polyclonal 1:500 46 Santa Cruz Biotechnology
mTOR rabbit polyclonal 1:1000 289 Cell Signaling
p-4EBP1 1:3000 15-20 Cell Signaling
p-Akt (Ser473) rabbit poly-
clonal 
1:1000 60 Cell Signaling
p-Akt (Thr308) rabbit poly-
clonal
1:1000 60 Cell Signaling
p-Akt substrate (RXRXXS/T) 
rabbit polyclonal
1:1000 Cell Signaling
PARP monoclonal 1:2000 116 and 85 BD Pharmingen
p-Bad (Ser136) rabbit poly-
clonal
1:1000 23 Cell Signaling
PDK1 rabbit polyclonal 1:1000 68-58 Cell Signaling
p-ERK1/2 monoclonal 1:1000 44 and 42 Santa Cruz Biotechnology
p-GSK3 α/β rabbit polyclonal 1:1000 51 and 46 Cell Signaling
PI3K 85 rabbit polyclonal 1:1000 85 Cell Signaling
p-JNK1/2 rabbit polyclonal 1:1000 54 and 46 Cell Signaling
p-PDK1 (Ser241) rabbit poly-
clonal 
1:1000 68-58 Cell Signaling
Procaspase-10 rabbit poly-
clonal 
1:500 58 Oncogene Research 
Products
Procaspase-8 monoclonal 1:500 55 Oncogene Research 
Products
α-Tubulina monoclonal 1:1000 60 Calbiochem
β-Actin monoclonal 1:5000 42 Sigma
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4.7.3. Pervanadate preparation
 Pervanadate (100x) was prepared fresh in PBS (2.12 ml) adding 100 µl of 
sodium ortovanadate (0.25 M) and 0.28 ml of 30% (v/v) H2O2 (Calbiochem/Merck). 
4.8. Cholesterol depletion
 For cholesterol depletion, 7 x 105 cells were washed in serum free medium for 
three times, and pretreated with 2.5 mg/ml MCD for 30 min at 37ºC in serum-free 
medium. Cells were then washed three times with PBS and resuspended in complete 
culture medium before RESV or HDAC addition.
4.9. Lipid raft isolation
 Lipid rafts were isolated by using lysis conditions and centrifugation on 
discontinuous sucrose gradients. Cells (108) were washed in ice-cold PBS and lysed for 
30 min on ice in TNEV buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA 
(Ethylenediaminetetraacetic acid), 1 mM sodium orthovanadate and 1% (v/v) Triton 
X-100) containing 1 mM phenylmethylsulfonyl fluoride. Cells were then homogenized 
with 10 strokes in a Potter-Elvehjem tissue grinder. Nuclei and cellular debris were 
pelleted by centrifugation at 1000 rpm for 8 min. Then, 1 ml of cleared supernatant 
was mixed with 1 ml 85% (w/v) sucrose in TNEV and transferred to the bottom of a 
Beckman 14 x 95-mm centrifuge tube. The diluted lysate was overlaid with 6 ml 35% 
(w/v) sucrose in TNEV and finally 3.5 ml 5% (w/v) sucrose in TNEV. The samples were 
centrifuged in a SW40 rotor at 38000 rpm for 18 h at 4ºC in a Beckman Optima LE-80K 
ultracentrifuge (Beckman instruments, Palo Alto, USA) and then 1-ml fractions were 
collected from the top of the gradient. Twelve fractions were colleted. To determine 
the location of lipid rafts and distinct proteins in the discontinuous sucrose gradient, 
20 µl of the individual fractions or a mix between raft fractions 4+5+6 and non-raft 
fractions 11+12 were subjected to SDS–polyacrylamide gel electrophoresis (PAGE) 
and immunoblotted as previously described (See western blot section and antibody 
list). The location of GM1-containing lipid rafts was determined using CTx B subunit 
conjugated to horseradish peroxidase (1:500 in TBST; Sigma).
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4.10. Xenograft mouse model
 Female CB17-severe combined immunodeficient (SCID) mice (Charles 
River Laboratories, Wilmington, MA, USA), were kept and handled according to 
institutional guidelines, complying with Spanish legislation under a 12/12 h light/dark 
cycle at a temperature of 22ºC, received a standard diet and acidified water ad libitum. 
CB17-SCID mice were inoculated subcutaneously into their lower dorsum with 107 
Z-138 cells in 100 μl PBS and 100 μl Matrigel basement membrane matrix (Becton 
Dickinson). When tumors were palpable, mice were randomly assigned to cohorts 
of 7 mice each, receiving a daily oral administration, of edelfosine (30 mg/kg body 
weight), perifosine (26.45 mg/kg body weight), or an equal volume of vehicle (water) 
for a 21-days period. The shortest and longest diameter of the tumor were measured 
with calipers at the indicated time intervals, and tumor volume (cm3) was calculated 
using the following standard formula: (the shortest diameter)2
 
x (the longest diameter) 
x 0.5. Animals were killed according to institutional guidelines, when the diameter of 
their tumors reached 3-4 cm or when significant toxicity was observed. Animal body 
weight and any sign of morbidity were monitored. Mice were killed 24 h after the last 
drug administration, and then tumors were extirpated, measured and weighed.
4.11. Measurement of caspase-8 and caspase-9 activities
Caspase-8 and caspase-9 activities were determined in the lysates using a 
colorimetric assay kit (Calbiochem/Merck) according to the manufacturer’s protocol. 
Briefly, the reaction mixture (total volume 100 μl) contained 50 μg of cell lysate and 5 
μl of the caspase-8 or caspase-9 substrate Ac-Ile-Glu-Thr-Asp-pNA and Ac-Leu-Glu-
His-Asp-pNA, respectively (final concentration of 100 μM), in the assay buffer. Assays 
were carried out in 96-well plates. Samples were incubated for 90 min at 37ºC, and 
absorbance was read at 405 nm using a spectrophotometer.
4.12. Statistical analysis
 Values are expressed as means ± SD of the number of experiments indicated. 
Between-group statistical differences were assessed using the Student’s t-test. A p 
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value of < 0.05 was considered statistically significant.
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5. RESULTS
5.1. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts 
in resveratrol-mediated antimyeloma and antileukemic actions
5.1.1. Introduction
 Hematopoietic malignancies are frequently characterized by a defective 
apoptosis. MM is a currently incurable B-cell malignancy characterized by the 
accumulation of plasma cells with a low proliferative index and an extended life 
span in the bone marrow 85,86. Thus, a therapeutic potential for MM and additional 
hematological cancers may lie in potentiating apoptosis 64,87.
 A new framework in apoptosis regulation is mediated by coclustering of 
Fas/CD95 death receptor and lipid rafts 38,72, leading to the concentration of Fas/
CD95-downstream signaling apoptotic molecules in membrane rafts that trigger 
a cell death response 39,67. This Fas/CD95-raft coclustering plays a key role in the 
proapoptotic action of some anticancer drugs, including edelfosine, perifosine and 
aplidin 38,37,39,42,57,69,74. Chemotherapeutic agent-induced recruitment of Fas/CD95 and 
downstream signaling molecules in membrane rafts leads to the generation of the 
DISC in lipid rafts, made up of Fas/CD95, FADD and procaspase-8 69,72, and eventually 
to apoptosis. Furthermore, TRAIL receptors are also translocated into rafts following 
incubation with distinct anticancer drugs 42,69. 
 Resveratrol (trans-3,4´,5-trihydroxystilbene) is a polyphenolic phytoalexin, 
abundant in grapes, berries and peanuts 88,89. Is a toxic compound produced by higher 
plants in response to infection or other stresses. It was first known as a cardioprotetive 
agent and then for its manifold beneficicial properties in wide list of diseases including 
cancer. The mechanism by which resveratrol exerts such a wide rande of beneficial 
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effects across species and disease models is not yet clear 90.  
 Resveratrol inhibits the growth of a wide variety of tumor cells and shows 
chemoprotective properties 88,89, and has been shown to induce redistribution of Fas/
CD95 and TRAIL receptors in lipid rafts in colon carcinoma cells 76,91.Resveratrol 
induces apoptosis in hematological malignant cells, including MM cells 92. On these 
grounds, we investigated the role of Fas/CD95 and lipid raft coclustering in the 
antimyeloma and antileukemic action of resveratrol.
5.1.2. Results
5.1.2.1. Resveratrol induces apoptosis in MM and T-cell leukemia cells, although spares 
normal lymphocytes
 We found that resveratrol induced apoptosis in the human T-cell leukemia 
Jurkat cell line as well as in the human MM cell lines MM144 and MM1S in a dose 
response manner (Fig. 7 A and B). This apoptotic response was further assessed by 
caspase-3 activation and cleavage of the typical caspase-3 substrate poly(ADP-ribose) 
polymerase (PARP), by using a polyclonal anticaspase-3 antibody that recognized the 
active 20- and 17-kDa subunits of caspase-3, and an anti-PARP monoclonal antibody 
that detected both the 116-kDa intact form and the 85-kDa cleaved form of PARP 
(Fig. 7 C).
 Resveratrol also induced apoptosis in primary cultures of MM cells derived 
from patients (Fig. 2 A), whereas peripheral blood normal lymphocytes from healthy 
volunteers were spared (<5% apoptosis) (Fig. 2 B). These data suggest a rather selective 
action of resveratrol against MM and T-cell leukemia cells.
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Figure 7. Induction of apoptosis in leukemic and multiple myeloma (MM) cells by resveratrol. (A) Jurkat cells (JK) 
and MM cell lines MM1S and MM144 (B) were incubated for 24 and 48 h with the indicated concentrations 
of resveratrol, and apoptosis was then quantitated as the percentage of cells in the sub-G1 region in cell-cycle analysis by flow cytometry. Untreated control cells were run in parallel and showed similar apoptosis basal 
values at both 24 or 48 h time points; mean values at these time points are shown means ± s.e. of at least three 
independent experiments. (C) Jurkat cells were untreated (Control) or treated with 70 μM of resveratrol (RESV) 
for 48 h and then analysed by immunoblotting with anti-caspase-3 (SDS-15% polyacrylamide gels; upper panel) 
and anti-PARP antibodies (SDS-8% polyacrylamide gels; middle panel). The migration positions of the 20- and 
17-kDa subunits of human active caspase-3 as well as of full-length 116-kDa poly(ADP-ribose) polymerase 
(PARP) and its p85 cleavage product are indicated. Immunoblotting for β-actin (lower panel) was used as an 
internal control for equal protein loading in each lane. Representative blots of three separate experiments are 
shown.
Figure 8. Resveratrol apoptotic effects on MM cells isolated from patients and normal PBLs.(A) Freshly 
isolated tumor MM cells from MM patients were treated with resveratrol for the indicated concentrations and 
incubation times, and then apoptosis was quantified by flow cytometry. Untreated control cells were run in 
parallel and showed similar apoptosis basal values at both 24 or 48 h time points.(B) Peripheral blood lymphocytes 
from healthy volunteers were treated with resveratrol for the indicated concentrations and incubation times, 
and then apoptosis was quantified by flow cytometry. Untreated control cells were run in parallel. Data shown 
are means ± s.e. of at least three independent experiments.
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5.1.1.2. Resveratrol-induced apoptosis in MM and T-cell leukemia cells is mediated by 
clustering of Fas/CD95 in lipid rafts
 Following a time-course analysis, we found that 50 μM resveratrol triggered 
apoptosis after 15–20 h incubation in Jurkat and MM144 cells. Resveratrol induced 
coclustering of rafts and Fas/CD95 in both Jurkat and MM144 cells (Figs. 9 A and B), 
as assessed by using the raft marker fluorescein isothiocyanate (FITC)-labeled cholera 
toxin (CTx) B subunit that binds ganglioside GM1 93, mainly found in rafts 94 and a 
specific anti-Fas/CD95 antibody. 
Figure 9- Coclustering of membrane rafts and Fas/CD95 in resveratrol-treated T-cell leukemia and multiple 
myeloma cells. (A) Jurkat (JK) and MM144 (B) cells were either untreated (Control) or treated with 50 μM 
resveratrol (RESV) for 15 h and then stained with a specific anti-Fas/CD95 monoclonal antibody, followed by 
CY3-conjugated anti-mouse immunoglobulin (Ig) antibody (red fluorescence), and fluorescein isothiocyanate-
labeled cholera toxin (FITC-CTx) B subunit to identify lipid rafts (green fluorescence). Areas of colocalization 
between membrane rafts and Fas/CD95 in the merge panels are yellow. Images shown are representative of 
three independent experiments. Bar, 10 μm.
 
 Disruption of lipid rafts by cholesterol depletion through methyl-β-cyclodextrin 
(MCD) treatment 38,95 inhibited resveratrol-induced apoptosis in both T-cell leukemia 
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and MM cells (Fig. 10 A and B). These results indicate that coclustering of Fas/CD95 
and membrane rafts mediates the apoptotic action of resveratrol in MM and T-cell 
leukemia cells.
Figure 10 - Involvement of lipid rafts in resveratrol-induced apoptosis. (A) MM1S cells were pretreated with 
methyl-β-cyclodextrin (MCD) and then incubated with 70 μM of resveratrol (RESV) for 24 h. Cells were 
stained with propidium iodide (PI), and their DNA content was analysed by fluorescence flow cytometry. The 
percentage of cells with a DNA content less than G1(sub-G1) is indicated in each histogram. Control untreated cells and cells treated only with MCD or resveratrol were run in parallel. Data are representative of three 
experiments performed. (B) MM1S and Jurkat (JK) cells were untreated (Control) or pretreated with MCD 
and then incubated in the absence or in the presence of 70 µM of resveratrol (RESV) for 24 h. Percentage of 
apoptotic cells was determined by flow cytometry as above. Untreated cells showed apoptosis mean values of 
<5%. Data shown are means ± s.e. of four independent experiments.
5.1.1.3. Resveratrol induces translocation of death receptors and downstream 
molecules into lipid rafts in MM and T-cell leukemia cells
 The above Fas/CD95 and raft coclustering was further confirmed by isolation of 
membrane rafts from Jurkat and MM144 cells, untreated and treated with resveratrol 
(Fig. 11 A and B). Lipid rafts were isolated based on their insolubility in Triton X-100 
lysis buffer at 4 ºC and fractionated by discontinuous sucrose gradient centrifugation 
38 GM1-containing lipid rafts, at the upper part (mostly in fractions 3–5) of the sucrose 
gradient (Fig. 11 A and B), were identified using CTx conjugated to horseradish 
peroxidase 38. Fas/CD95 was present in the non-raft fractions (fractions 10–12) of 
the sucrose gradient in untreated Jurkat and MM144 cells, but resulted dramatically 
translocated to the raft fractions on resveratrol treatment for 15 h (Fig. 11 A and B). 
MM144 cells express the TRAIL receptors DR4 and DR5, whereas Jurkat cells only 
express DR5, and all these TRAIL receptors were also translocated to rafts in both cell 
types following resveratrol treatment, although to a lesser extent than Fas/CD95 (Fig. 
11 A and B). Death receptor downstream signaling molecules FADD, procaspase-8 
and procaspase-10 were also translocated into rafts (Fig. 11 A and B). Interestingly, a 
40
portion of the active cleavedcaspase-8 and caspase-10 forms were also found in rafts 
following resveratrol treatment (Fig. 11 A and B), caspase-8 and caspase-10 forms 
were also found in rafts following resveratrol treatment (Fig. 11 A and B), suggesting 
that triggering of apoptosis is initiated at the membrane rafts. 
Figure 11- Recruitment of death receptors and downstream signaling molecules in membrane rafts following 
resveratrol treatment of Jurkat and MM144 cells. (A) Untreated Jurkat cells (Control) and Jurkat cells treated 
with 50 μM resveratrol (RESV) for 15 h were lysed in 1% Triton X-100 and fractionated by centrifugation on 
a discontinuous sucrose density gradient. An equal volume of each collected fraction was subjected to SDS–
polyacrylamide gel electrophoresis (PAGE) before analysis of the indicated proteins using specific antibodies. 
The migration positions of the 55-kDa procaspase-8 and the cleaved p18 product, as well as of the 58-kDa 
procaspase-10 and the cleavage products are denoted. Location of GM1-containing lipid rafts was determined 
using cholera toxin (CTx) B subunit conjugated to horseradish peroxidase. (B) Untreated MM144 cells (control) 
and MM144-treated cells treated with 50 μM resveratrol (RESV) for 15 h were lysed and analysed by western 
blotting as above. Representative blots of three separate experiments are shown.
These data show that all the constituents of DISC, namely Fas/CD95, FADD and 
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procaspase-8, are recruited into rafts; and this key apoptotic complex in death receptor 
signaling is activated in the membrane raft. We also found that Bid, which acts as a 
bridge between Fas signaling and 96, was translocated into rafts following treatment 
of Jurkat and MM144 cells with resveratrol (Fig. 11 A and B). In addition, JNK was 
recruited into lipid rafts on resveratrol incubation (Fig. 11 A and B). Our results show 
that resveratrol induces a reorganization of the raft protein content, translocating 
apoptotic proteins to these detergent-insoluble membrane domains in hematological 
cancer cells.
5.1.1.4. Involvement of caspases and JNK in resveratrol-induced apoptosis
 Incubation with the cell-permeable pan-caspase inhibitor benzyloxycarbonyl-
Val-Ala-Asp(OMe)-fluoromethylketone (z-VAD-fmk) abrogated the apoptotic 
response in resveratrol-treated Jurkat, MM144 and MM1S cell lines (Fig. 12). 
Preincubation with caspase inhibitors showing specificity for caspase-8 (z-Ile-
Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone, z-IETD-fmk) and caspase-10 
(z-Ala-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone, z-AEVDfmk), involved in 
the transmission of death receptor signaling, inhibited apoptosis (Fig. 12), suggesting 
their involvement in resveratrol-induced apoptosis. Pretreatment of Jurkat, MM144 
and MM1S cells with the JNK inhibitor SP600125 (SP) 97 inhibited resveratrol induced 
apoptosis to a rather variable degree (22–59% inhibition; Fig. 12). This partial inhibition 
suggests that JNK is acting in parallel to additional signaling pathways to increase cell 
death, but it does not seem to play an essential role in the apoptosis outcome.
 
 We next examined the effect of overexpressing Bcl-XL in MM144 cells to analyse 
the role of mitochondria in resveratrol-induced apoptosis. We stably transfected 
MM144 cells with pSFFV-bcl-xL (MM144-Bcl-XL), containing the human bcl-xL open 
reading frame, or with control pSFFV-Neo plasmid (MM144-Neo). MM144-Neo 
cells, that behaved similar to nontransfected MM144 cells, expressed small levels of 
endogenous Bcl-XL, whereas a high expression of this protein was detected in MM144-
Bcl-XL cells, as previously reported 69.
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Figure 12. Involvement of JNK and caspases in resveratrol-induced apoptosis.  JK, MM144 and MM1S cells were 
preincubated without or with 20 μM SP600125, 50 μM z-VAD-fmk, 50 μM Z-IETD-fmk or 50 μM z-AEVD-
fmk for 1 h, and then incubated in the absence or presence of 70 μM resveratrol (RESV) for 24 h and analysed 
by flow cytometry to evaluate apoptosis. Untreated control cells (C) were run in parallel. Data shown are means 
± s.e. of three independent experiments. 
Treatment of MM144-Neo cells with resveratrol led to apoptosis (Fig. 13 A) and 
mitochondrial transmembrane potential (ΔΨm) disruption (Fig. 13 B and C). However, 
overexpression of Bcl-XL by gene transfer in MM144 cells prevented both resveratrol-
induced apoptosis (Fig. 13 A) and ΔΨm loss (Fig. 13 B and C). These data indicate that 
mitochondria are involved in resveratrol-induced MM cell death.
 As shown in Figure 13 C, untreated cells showed high ΔΨm (DiOC6(3)high) 
and low levels of intracellular reactive oxygen species (ROS; HE-Eth)low. These values 
were taken as background data. Resveratrol induced an increase in the percentages of 
DiOC6(3)low/(HE-Eth)high and DiOC6(3)high/(HE-Eth)high cells, whereas the ratio of cells 
with disrupted ΔΨm and without producing ROS (DiOC6(3)low/(HE-Eth)low) was very 
small (about 1–2%) on resveratrol incubation (Fig. 13 C). Overexpression of Bcl-XL 
abrogated well-nigh entirely both ΔΨm disruption and apoptosis (80–92% inhibition; 
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Fig. 13 A–C), but did not inhibit the percentage of DiOC6(3)high/(HE-Eth)high cells after 
resveratrol incubation (Fig. 13 B).
Figure 13. Involvement of ΔΨm dissipation in resveratrol-induced apoptosis. (A) MM144-Neo and MM144-Bcl-XL cells were treated for 48 h with resveratrol at the indicated concentrations, and then apoptosis was assessed by flow cytometry. Data shown are means ± s.e. of three independent experiments. (B) MM144-Neo and MM144-
Bcl-XL cells were untreated and treated with 50 or 70 μM resveratrol for 48 h, and the percentages of cells with disrupted ΔΨm ((DiOC6(3)low) and generating reactive oxygen species (ROS (HE-Eth)high) were measured as described in Material and methods. Data shown are means ± s.e. of three independent experiments. (C) 
A representative experiment of three performed on the effect of resveratrol (RESV; 70 μM, 24 h) on ΔΨm disruption (DiOC6(3)low) and ROS generation (HE-Eth)high in MM144-Neo and MM144-Bcl-XL cells, assessed by flow cytometry as described in Materials and methods.
These results suggest that ΔΨm dissipation was critical for resveratrol-induced 
apoptosis in MM and T-cell leukemia cells, and that a minor portion of ROS may 
originate from additional sources, apart from mitochondria that plays no essential 
role in resveratrol-induced apoptosis.
5.1.1.5. Fas/CD95 signaling and mitochondrion connection in resveratrol-induced 
apoptosis
 As the above data showed that both Fas/CD95 and mitochondria signaling were 
involved in resveratrol induced apoptosis in hematological cancer cells, and the Fas/
CD95-mitochondrion bridging molecule Bid was recruited into lipid rafts together 
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with Fas/CD95 downstream molecules (Fig. 14), we wondered whether Fas/CD95 
and mitochondrial apoptotic signaling routes were acting in conjunction. Using stable 
transfection in Jurkat cells of a dominant-negative form of the FADD adapter protein 
(FADD-DN), which lacks the death effector domain and blocks Fas/CD95 signaling 
98, we found that blockade of Fas/CD95 downstream signaling prevented both ΔΨm 
loss (Fig. 14 A and B) and apoptosis (Fig. 14 C). In addition, Fas/CD95-deficient Jurkat 
cells, that preserved the expression of functional tumor necrosis factor receptor 1 
and DR5 39, were rather resistant to undergo apoptosis on resveratrol treatment (Fig. 
15). These data suggest a prevailing role of Fas/CD95 in resveratrol-induced ΔΨm 
dissipation and apoptosis in Jurkat cells.
Figure 14. Fas/CD95 signaling regulates mitochondrial downstream events in resveratrol-induced apoptosis. (A) 
Jurkat cells (JK) and Jurkat cells transfected with the dominant-negative form of Fas-associated death domain-
containing protein (JK-FADD-DN) were untreated (Control) and treated with 50 or 70 μM resveratrol for 
24 h, and the percentages of cells with disrupted ΔΨm (DiOC6(3)low) and generating reactive oxygen species (ROS (HE-Eth)high) were measured as described in Materials and methods. Data shown are means ± s.e. of 
three independent experiments. (B) A representative experiment of three performed on the effect of resveratrol 
(RESV; 70 μM, 24 h) on ΔΨm disruption (DiOC6(3)low) and ROS generation (HE-Eth)high in JK and JK-FADD-DN cells, assessed by flow cytometry as described in Materials and methods. (C) JK and JK-FADD-DN cells 
were treated for 48 h with resveratrol at the indicated concentrations, and then apoptosis was assessed by flow 
cytometry. Data shown are means ± s.e. of three independent experiments.
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Figure 15. Fas-deficient Jurkat cells are resistant to resveratrol. Induction of apoptosis in Jurkat (JK) and Fas-
deficient Jurkat cells was determined by flow cytometry after a 48 h incubation with 70 μM resveratrol (RESV). 
Untreated control cells were run in parallel. Data are representative of three experiments performed.
Figure 16.  Effects of interferon (IFN)-γ on Fas/CD95 and procaspase-8 expression and resveratrol-induced 
apoptosis. (A) MM1S cells were untreated (Control) or treated with 50 ng/ml IFN-γ for the indicated times, 
and the protein levels of Fas/CD95 and procaspase-8 were determined by western blot. β-Actin was used 
as a loading control. (B) Cell surface expression of Fas/CD95 was determined by immunofluorescence flow 
cytometry as mean fluorescence intensity (MFI) values in untreated control MM1S cells and MM1S cells treated 
with 50 ng/ml IFN-γ for the indicated times. Data shown are means ± s.e. of three independent experiments. 
(C) MM1S cells were pretreated with 50 ng/ml IFN-γ for 48 h, and then incubated with 70 μM resveratrol 
for 24 h. Apoptosis was assessed by flow cytometry as the percentage of cells with DNA content less than 
G1. Untreated control MM1S cells, and MM1S cells treated only with IFN-γ or resveratrol (RESV) were also 
analysed for apoptosis. Data shown are means ± s.e. of three independent experiments.
46
5.1.2.6. Interferon-γ upregulates Fas/CD95 and caspase-8, potentiating resveratrol-
induced apoptosis
 Following pretreatment of MM cells with interferon (IFN)-γ, we found an 
increase in both Fas/CD95 and procaspase-8 protein levels by western blot (Fig. 16 A). 
We found that MM cells pretreated with IFN-γ showed an increase in the cell surface 
expression of Fas/CD95 (Fig. 16 B) and were more sensitive to the apoptotic action of 
resveratrol (Fig. 16 C). These data suggest that an increase in Fas/CD95 potentiates the 
apoptotic response of resveratrol.
5.1.2.7. Resveratrol induces apoptosis and Fas/CD95-raft coclusters in Fas/CD95-
resistant U266 cells
 The MM cell line U266 expresses Fas/CD95, but addition of the agonistic 
anti-Fas/CD95 antibody CH11 induces less than 5% apoptosis 99,100. We found that 
U266 cells expressed Fas/CD95, DR4 and DR5 at their cell surface (Fig. 10 A), and 
underwent apoptosis following resveratrol treatment (Fig. 17 B). Interaction of Fas/
CD95 with either the agonistic anti-Fas/CD95 antibody CH11 or the physiological 
ligand FasL/CD95L did not induce apoptosis in U266 cells (Fig. 17 C). Thus, U266 
cells are deficient in mounting a Fas/CD95-FasL/CD95L interaction-dependent 
apoptotic response. Preincubation of U266 cells with the blocking SM1/23 anti-Fas/
CD95 antibody, which abrogates Fas/CD95-FasL/CD95L mediated killing 75, failed to 
inhibit resveratrol-induced apoptosis (Fig. 17 C), indicating that resveratrol-induced 
apoptosis is not mediated by FasL/CD95L. The combination of resveratrol with CH11 
or FasL/CD95L slightly potentiated the cell death outcome (Fig. 17 C), suggesting that 
resveratrol might partially circumvent the block in mounting a Fas/CD95-mediated 
apoptotic signal. Resveratrol induced a potent coclustering of rafts and Fas/CD95 
in U266 cells (Fig. 18 A). However, disruption of rafts by cholesterol depletion with 
MCD inhibited only weakly resveratrol induced apoptosis in U266 cells (23.4±2.4 
versus 16.8±2.3 apoptosis in untreated and MCD-pretreated cells, respectively, and 
then incubated with 70 μM resveratrol for 24 h, n=4) (Fig. 18 B). Thus, these data 
suggest that resveratrol is effective in promoting coclusters of Fas/CD95 and rafts, but 
additional mechanisms must play a role in the induction of apoptosis by resveratrol in 
U266 cells.
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Figure 17. Resveratrol induces apoptosis independently of FasL/CD95L in U266 cells. (A) Cell surface expression 
of DR4, DR5 and Fas/CD95 in U266 cells was determined by flow cytometry as the percentage of positive 
cells for each death receptor or mean fluorescence intensity (MFI). Average values of two experiments are 
shown. (B) U266 cells were incubated for 24 and 48 h with the indicated concentrations of resveratrol, and 
apoptosis was then quantitated as the percentage of cells in the sub-G1 region in cell-cycle analysis by flow cytometry. Untreated control cells were run in parallel and showed similar apoptosis basal values at both 24 or 
48 h time points; mean values at these time points are shown. Data shown are means ± s.e. of four independent 
experiments. (C) U266 cells were preincubated with 100 ng/ml blocking SM1/23 antibody for 30 min before 
addition of 70 μM resveratrol (RESV) for 48 h. Combinations of 50 ng/ml cytotoxic anti-Fas/CD95 CH11 
antibody + 70 μM resveratrol (RESV) and 100ng/ml FasL/CD95L + 70 μM resveratrol (RESV) were also assayed 
for 48 h. Untreated control cells and cells incubated only with SM1/23 antibody, CH11 antibody, FasL/CD95L 
or resveratrol (RESV) for 48 h were run in parallel. Apoptosis was then quantitated as percentage of cells in the 
sub-G1 region by flow cytometry. Average values of two experiments are shown.
Figure 18. Resveratrol induces co-clustering of rafts and Fas/CD95 in U266 cells (A) U266 cells were either 
untreated or treated with 50 μM resveratrol (RESV) for 15 h and then stained with a specific anti-Fas/
CD95 monoclonal antibody, followed by CY3-conjugated anti-mouse immunoglobulin (Ig) antibody (red 
fluorescence), and fluorescein isothiocyanate-labeled cholera toxin (FITC-CTx) B subunit to identify lipid rafts 
(green fluorescence). Areas of colocalization between membrane rafts and Fas/CD95 in the merge panels are 
yellow. Images shown are representative of three independent experiments. Bar, 10 μm. (B) U266 cells were 
untreated or pretreated with MCD and then incubated in the absence or in the presence of 70 µM of resveratrol 
(RESV) for 24 h. Percentage of apoptotic cells was determined by flow cytometry as above. Untreated cells 
showed apoptosis mean values of <5%. Data shown are means ± s.e. 
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5.1.2.8. Combination of resveratrol with perifosine or bortezomib potentiates apoptosis
 We next analysed the putative potentiation of apoptosis as a result of combining 
resveratrol with additional drugs acting through similar or distinct mechanisms of 
action. Perifosine has been reported to induce apoptosis in MM cells through Fas/
CD95-raft coclustering 69 and its antimyeloma activity is being tested in clinical trials 
101. The proteasome inhibitor bortezomib is currently used in clinic against MM and 
other hematological malignancies 102. We found that the combination of resveratrol 
and perifosine showed an additive effect, whereas the combination of resveratrol and 
bortezomib had a synergistic effect on apoptosis (Figs. 19 and 20). The additive effect 
observed following treatment with resveratrol and perifosine suggests that both drugs 
share, at least in part, similar modes of action. These data would support a mechanism 
of action mediated by Fas/CD95-raft coclustering. Unlike other assayed cells, U266 
cells showed a rather poor additive effect between resveratrol and perifosine (Figs. 
19 and 20), suggesting that the raft-mediated process is not so critical in cell death 
induction in this particular cell line. The synergistic effect observed following treatment 
with resveratrol and bortezomib indicates that both substances act through different 
mechanisms of action. The combined treatment of resveratrol and bortezomib highly 
potentiated the apoptosis outcome exerted by each individual drug (Fig. 20). Thus, the 
raft-mediated mechanism of action of resveratrol might be of interest for combination 
therapy in the treatment of blood malignancies.
Figure 19. The combination of resveratrol with perifosine potentiates apoptosis in T-cell leukemia and MM cells. 
Jurkat, MM144, MM1S and U266 cells were incubated for 48 h with 10 μM resveratrol (RESV),5 μM perifosine 
and with a combination of RESV+perifosine or RESV+bortezomib. Untreated control cells were run in parallel. 
Apoptosis was analysed by flow cytometry as the percentage of hypodiploid (sub-G1) cells following cell-cycle analysis. Data shown are means ± s.e. of three independent determinations.
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Figure 20. The combination of resveratrol with bortezomib potentiates apoptosis in T-cell leukemia and multiple 
myeloma cells. (A) Jurkat, MM144, MM1S and U266 cells were incubated for 48 h with 10 μM resveratrol 
(RESV), 10 nM bortezomib, and with a combination of RESV + bortezomib. Apoptosis was analysed by flow 
cytometry as the percentage of hypodiploid (sub-G1) cells following cell-cycle analysis. Data shown are means ± s.e. of three independent determinations. (B) Jurkat and MM1S cells were untreated (Control), treated with 10 
μM resveratrol (RESV), 10 nM bortezomib or the combination of both substances for 48 h, and apoptosis was 
analysed by flow cytometry. The percentage of apoptotic cells, assessed by a DNA content less than G1 (sub-G1) is indicated in each histogram. Data shown are representative of three separate experiments.
5.1.3. Discussion
 The data reported here show that resveratrol induces apoptosis in MM and 
T-cell leukemia cells through the recruitment of Fas/CD95 death receptor and 
downstream signaling molecules into lipid rafts. Our results demonstrate that Fas/
CD95 signaling and mitochondria are required for resveratrol-induced apoptosis, and 
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there is a sequence of Fas/CD95→mitochondrion in the signaling pathway underlying 
the apoptotic response triggered by resveratrol in hematological cancer cells. A putative 
linker between Fas/CD95 signaling and mitochondrion in resveratrol action might be 
the translocation of Bid to lipid rafts together with Fas/CD95 signaling molecules. 
Thus, our present data square with the following sequence of events in MM and T-cell 
leukemia cells that lead to resveratrol-induced apoptosis: coclustering of Fas/CD95 and 
lipid rafts→ recruitment of Fas/CD95 downstream signaling molecules to membrane 
rafts→Bid translocation to rafts→ΔΨm disruption→apoptosis (Fig. 20). Interference 
at critical stages of the above scheme, such as disruption of lipid rafts, inhibition 
of Fas/CD95 signaling by FADD-DN transfection and mitochondria protection by 
overexpression of Bcl-XL, prevented resveratrol-induced apoptosis (Figs. 13 and 15). 
As the blockade of Fas/CD95 downstream signaling by FADD-DN overexpression 
abrogates both ΔΨm loss and apoptosis, mitochondrial events are downstream of 
Fas/CD95 signaling in resveratrol-mediated apoptosis. Our data demonstrate that 
membrane rafts, Fas/CD95 signaling and mitochondria are crucial players in the 
apoptotic outcome delivered by resveratrol in MM and T-cell leukemia cells. 
 Resveratrol is effective in inducing the recruitment of Fas/CD95 in raft clusters 
even in U266 cells, which are resistant to undergo apoptosis on Fas/CD95 stimulation 
by either FasL/CD95L or agonistic anti-Fas/CD95 antibody. We have previously found 
that induction of clustering of Fas/CD95 in rafts leads to death receptor activation, 
independently of its ligand, even in cells that are resistant to undergo apoptosis 
following Fas/CD95 stimulation through its interaction with FasL/CD95L or agonistic 
anti-Fas/CD95 antibody 75. Thus, Fas/CD95 activation by its clustering in rafts seems 
to be more potent than the receptor activation elicited by its physiological ligand. 
However, the fact that raft disruption only inhibits about 28% of resveratrol-induced 
apoptosis in U266 cells suggests that additional mechanisms leading to resveratrol 
mediated killing are triggered in these particular cells. One of these mechanisms 
has been reported to involve downregulation of STAT3 and nuclear factor-kB 92. The 
present data also show that TRAIL receptors are translocated, in addition to Fas/
CD95, into rafts following resveratrol treatment of MM and T-cell leukemic cells. 
This recruitment and concentration of death receptors in specific domains of the 
cell surface has clear clinical consequences as it might sensitize cancer cells to death 
receptor ligands 69. This is of particular interest for TRAIL-mediated therapy, because 
TRAIL is under ongoing clinical trials 103. The recruitment of death receptors and 
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downstream signaling in membrane rafts promoted by resveratrol treatment may 
underlie previous observations reporting that this polyphenol sensitizes different 
cancer cell types to death receptor-mediated apoptosis 104,105.
 The findings reported here underline the role of Fas/CD95 recruitment into 
lipid rafts as a major mechanism in anticancer chemotherapy for the treatment of 
hematological malignancies. We have recently found that a number of anticancer 
drugs, including edelfosine, perifosine and aplidin, induce apoptosis in hematological 
cancer cells by bringing together Fas/CD95 and downstream signaling molecules in 
membrane rafts 38,39,42,69.
Figure 21. Schematic model for the mechanism of action of resveratrol in the induction of apoptosis in 
hematological cancer cells. This is a schematic diagram designed to portray the most significant events involved 
in resveratrol-induced apoptosis. Disruption of lipid rafts and overexpression of dominant-negative form of 
Fas-associated death domain-containing protein (FADD-DN) or Bcl-XL prevent resveratrol-induced apoptosis, highlighting the critical role of lipid rafts, Fas/CD95 signaling and mitochondria in the mechanism of action of 
the polyphenolic phytoalexin. For further details, see the text.
 Our data show that IFN-γ enhances the apoptotic response induced by 
resveratrol in hematological cancer cells, likely through an increase in Fas/CD95 
and procaspase-8 levels. On these grounds, the present data suggest that resveratrol 
is not only effective in killing by itself hematological cancer cells, but also it might 
be a valuable drug in combination therapy, in particular with agents modulating or 
activating death receptor signaling. The combination of resveratrol and perifosine, 
which has been shown to act through raft-Fas/CD95 coclustering 69, resulted in 
an additive effect, suggesting a shared mode of action for both drugs. In addition, 
the combination of resveratrol with the proteasome inhibitor bortezomib led to a 
synergistic apoptotic response. It is tempting to speculate that a putative interaction 
between raft mediated processes triggered by resveratrol and proteasome inhibition 
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might lead to a potent cell death response.
 Two naturally occurring resveratrol oligomers, ε-viniferin and miyabenol C, 
have been shown to promote apoptosis in lymphoid and myeloid cell lines at lower 
doses than resveratrol106. Further investigation on the mode of action of these natural 
oligomers might set new frameworks for cancer treatment.
 The mechanistic findings reported here suggest that resveratrol may have 
a potential in the treatment of MM and T-cell leukemia, and highlight the role of 
recruitment of Fas/CD95 signaling in lipid rafts in antimyeloma and antileukemia 
chemotherapy
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5.2. Lipid raft-mediated Akt signaling as a therapeutic target in MCL cells
5.2.1. Introduction
 
 MCL is a B-cell-derived neoplasia that constitutes ∼6% of all non-Hodgkin 
lymphomas, and is characterized by the chromosomal translocation t(11;14)
(q13;q32) leading to aberrant overexpression of cyclin D1 107,108. In addition to this 
initial oncogenic event, MCL may carry a high number of secondary chromosomal 
and molecular alterations that influence the aggressive behavior of this neoplasm and 
a poor survival outcome 107,108. Although conventional chemotherapy induces high-
remission rates, relapse within a few years is common, contributing to a median 
survival of 5-7 years 109. 
 Several signaling pathways are deregulated in MCL cells including the 
constitutive activation of the PI3K/Akt pathway, which mediates the effects of a 
variety of extracellular signals and is crucial for the maintenance and proliferation 
of MCL cells 110,111, thus attracting great interest as a possible therapeutic target. PI3K 
is activated by a wide range of tyrosine kinase growth factor receptors, and is the 
major activator of Akt, playing a central role in fundamental biological processes 
including cell growth, proliferation, migration and survival, through phosphorylation 
of a plethora of substrates 26,110. Akt is a protein kinase that belongs to the AGC family 
of serine/threonine kinases and has three conserved domains, namely: PH domain, 
which binds phosphoinositides with high affinity, as well as catalytic and regulatory 
domains 29. Akt suppresses apoptosis by direct phosphorylation of pro-apoptotic 
proteins such as Bad and pro-caspase-9 29. PI3K phosphorylates phosphatidylinositol-
4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), 
that binds to Akt PH domain and PDK1, recruiting them to the membrane. Once 
in the membrane, Akt is phosphorylated at two key residues, Thr308 and Ser473 28. 
Thr308 site is localized in the activation loop and is phosphorylated by PDK1, while 
Ser473 is localized in the C-terminal hydrophobic motif and is phosphorylated by 
PDK2 28. mTOR has been suggested as the main candidate for PDK2, but DNA-
dependent protein kinase (DNA-PK), beta-1-integrin-linked protein kinase (ILK) 
or even Akt itself through autophosphorylation have also been proposed to act as 
PDK2 28,112. mTOR forms part of two different complexes, mammalian TOR complex 
1 (mTORC1) and mTORC2, which exert their actions by regulating a number of 
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important proteins 113. mTORC2 acts upstream and is suggested to phosphorylate Akt, 
whereas mTORC1 acts downstream Akt 113.
 Insulin-like growth factor-1 (IGF-1)-mediated activation of Akt has been 
reported to be dependent on lipid rafts 34,114. Rafts are membrane microdomains highly 
enriched in cholesterol and sphingolipids, which act as scaffolds for signaling pathways 
in the cell membrane 17, and growing evidence shows their potential as therapeutic 
targets in cancer therapy 8,37,39,42,64,67,69,73,80,115. An endogenous raft-resident Akt has been 
reported in LNCaP human prostate cells that showed a different substrate affinity as 
compared to non-raft Akt, suggesting the presence of distinct Akt populations with 
differential signaling behavior 48.
 The ATLs are a family of compounds, initially synthesized as ether phospholipids 
and widely referred to as alkyl-lysophospholipid analogs, which are able to selectively 
induce apoptosis in tumor cells 58-60,64,69,70,75. These ATLs include the ether lipid edelfosine 
as well as perifosine, which accumulate in lipid rafts 39,67,116, promote co-capping of Fas/
CD95 death receptor and rafts 38,67,84 and inhibit PI3K/Akt survival signaling 83,84,117. 
Edelfosine shows affinity for cholesterol 61,63, likely due to geometry compensation of 
the “cone shape” of sterols and the “inverted cone shape” of edelfosine that leads to a 
stable bilayer 63. In vivo and in vitro experimental approaches have shown that ATLs 
selectively kill MCL cells as well as additional hematological cancer cells, including 
patient-derived primary cancer cells, by a lipid raft-dependent mechanism 64,69,70.
 In this work we provide evidence that MCL cell survival depends on raft-
mediated Akt activation for survival. We show here that ATLs inhibit PI3K/Akt 
signaling by displacing Akt and key enzyme regulators from lipid rafts, leading to Akt 
dephosphorylation and apoptosis. In contrast, Fas/CD95 death receptor was recruited 
to rafts upon ATL treatment. Our data suggest that raft environment is essential 
for Ser473 Akt phosphorylation in MCL cells. ATL oral treatment inhibited MCL 
tumor growth in xenograft animal models. Apoptosis induced by either edelfosine or 
perifosine was not blocked by tumor microenvironmental stimuli in MCL primary 
cultures and cell lines. These results highlight the importance of raft-mediated PI3K/
Akt targeting in MCL therapy.
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5.2.2. Results 
5.2.3.1. ATLs activate the intrinsic apoptotic signaling pathway and inhibit Akt signaling 
in MCL cells
 We have found that treatment of MCL cell lines Z-138, JVM-2 and Jeko-1 
with the ATLs edelfosine and perifosine induced ΔΨ
m
 disruption (Fig. 22) and ROS 
production (Fig. 23).Caspase-9 activation was also detected in Z-138 cells after ATLs 
incubation (Fig. 24).
Figure 22. Involvement of the intrinsic apoptotic pathway in the action of ATLs on MCL cells. (A) Z-138 cells were 
untreated (control) or treated with (-)10 µM perifosine or (-) edelfosine for 24 h, and the percentages of cells 
with disrupted ΔΨm [(DiOC6(3)low)]. Histograms shown are representative of three independent experiments.
 
Figure 23. ROS production following ATL treatment in Z-138, JVM-2 and Jeko-1 cells. Cells were untreated (-) or 
treated with (-) 10 μM perifosine  or (-) edelfosine for 24 h, and ROS production (DHE→Eth) was measured 
as described in Materials and methods. Fluorescence flow cytometryprofiles shown are representative of three 
independent experiments.
 
Figure 24. Caspase -9 activation following  ATL treatment. Z-138 cells untreated (control, C) or treated with 10 
µM of edelfosine or perifosine for 12 h were analyzed by immunoblotting for anti-capase-9 active fragments. 
Immunoblotting for β-actin was used as an internal control for equal protein loading in each lane.
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These events were related to the activation of the intrinsic apoptotic signaling that 
eventually led to cell death (Figs. 23 - 25). Mitochondrial depolarization was one of 
the first events triggered by ATLs, since this phenomenon was observed as soon as 
6 h of treatment (Fig. 25 A), prior to the onset of apoptosis after 24-h incubation, as 
assessed by an increase in the percentage of sub-G0/G1 
cell population (Fig. 25 B). The 
apoptotic response was caspase-mediated, as preincubation with the cell-permeable 
pan-caspase inhibitor z-VAD-fmk abrogated ATL-induced apoptosis (Fig. 26).
 
Figure 25. Early loss of mitochondrial transmembrane potential and time course of apoptosis induction following 
ATL treatment in Z-138 cells.(A) Cells were untreated (-) or treated with 10 μM (-) perifosine or (-) edelfosine 
for 6 h, and loss of mitochondrial transmembrane potential (ΔΨm) was measured as described in Materials and methods using DiOC6(3). (B) Cells were treated with 10 μM perifosine or edelfosine for the indicated times, and then apoptosis was quantitated as the percentage of cells in the sub-G0/G1 region following cell cycle analysis by flow cytometry. Data shown are means ± SD or representative experiments of three independent experiments. 
Asterisks indicate values that are significantly different from untreated control cells at p < 0.01 (**) level by 
Student’s t-test.
Figure 26. ATL-induced apoptosis in the MCL Z-138 cell line is mediated by caspase activation. Z-138 cells were 
preincubated without (Control) or with 50 mM z-VAD-fmk for 1 h, and then in the absence (Control) or 
presence of 10 mM perifosine (PRIF) or edelfosine (EDLF) for 24 h. Apoptosis was quantitated as the percentage 
of cells in the sub-G0/G1 region following cell cycle analyses by flow cytometry. Data shown are means + SD of three independent experiments. Asterisks indicate values that are significantly different from untreated control 
cells at p < 0.01 (**) level by Student’s t-test.
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 Because inhibition of PI3K/Akt signaling has been linked to activation of the 
intrinsic apoptotic pathway 29, we examined the time-dependent effect of edelfosine, 
which displayed a higher in vitro anti-MCL activity than perifosine (Fig. 25 B) 70, on 
Akt activation, Akt targets and related kinases. While 1-O-octadecyl-rac-glycero-
3-phosphocholine (ETOH), an inactive edelfosine analog 59,118, neither induced 
apoptosis nor inhibited Akt phosphorylation (Fig. 27), edelfosine-treated cells showed 
a dramatic decrease of Ser473 p-Akt at very early incubation times (3 h), followed 
by a reduction in Thr308 p-Akt after 15-h incubation (Fig. 28 A). Using a specific 
antibody that recognized p-Akt substrates with the motif RXRXXS/T 119, we detected 
a decrease in the phosphorylation of most Akt substrates after 3-h incubation (Fig. 28 
A). However, the level of Ser9/21 glycogen synthase kinase-3 (GSK3) phosphorylation 
was not inhibited, but slightly activated, and Ser136 dephosphorylation of Bad was 
detected after 24-h incubation with edelfosine (Fig. 28 A), when apoptosis was 
already triggered (Fig. 25 B). These results are in line with our previous observation 
that MCL cell exposure to ATLs did not modify the expression of cyclin D1 70, which 
is physiologically targeted to proteasomal degradation by GSK-3 110. In addition, 
arguing in favor of an Akt-independent regulation of GSK3 signaling in MCL cells, 
preincubation of Z-138 cells with the GSK3 inhibitor lithium chloride potentiated 
ATL-induced apoptosis (Fig. 28 B), suggesting that ATLs act through a signaling 
pathway independent of GSK3.
 
Figure 27. The inactive edelfosine analog ETOH fails to induce apoptosis and to inhibit Akt in Z-138 cells. (A)
Cells were untreated (Control) or treated with the indicated doses of ETOH for 24 h, and then apoptosis was 
quantitated as the percentage of cells in the sub-G0/G1 region following cell cycle analysis by flow cytometry. Data shown are means ± SD of three independent experiments. (B) Cells treated as above were analyzed by 
immunoblotting for p-Akt Ser473 and Akt protein levels (SDS-12% polyacrylamide gels), after 6 h incubation 
with ETOH at the indicated concentrations. Untreated control cells (C) were run in parallel. Representative 
blots of three separate experiments are shown.
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Figure 28. Inhibition of Akt signaling in the action of ATLs on MCL cells. (A) Z-138 cells were untreated (control, 
C) or treated with 10 mM edelfosine for the indicated times, and then analyzed by immunoblotting using specific 
antibodies against p-Akt (Ser473), p-Akt (Thr308), Akt, p-Akt substrates (RXRXXS/T), p-mTOR, mTOR, 
p-4E-BP1, 4E-BP1, p-GSK3a/b, GSK3a/b, p-Bad (Ser136) and Bad. Immunoblotting for tubulin was used as an 
internal control for equal protein loading in each lane. Representative blots of three separate experiments are 
shown. (B) Z-138 cells were preincubated without or with 20 mM lithium chloride for 1 h, and then incubated 
in the absence (control) or presence of 10 mM perifosine or edelfosine for 24 h, and analyzed by flow cytometry 
to evaluate apoptosis. Data shown are means±s.d. of three independent experiments (*P<0.05; **P<0.01). 
The indicated statistically significant differences were between cells untreated and treated with lithium inthe 
different experimental conditions, but they are equally statistically significant when we subtract the apoptotic 
percentages of controls with or without lithium from the respective ATL treatments. 
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 We also analyzed the phosphorylation of mTOR, which acts downstream Akt 
forming the complex mTORC1 113. We found that phosphorylation levels of mTOR 
(p-mTOR), as well as of its direct substrate 4E-BP1 (p-4E-BP1), were rapidly decreased 
after 3 h incubation with edelfosine (Fig. 28 A). The time-course of this inhibition 
paralleled that of Ser473 p-Akt (Fig. 28 A). Both mTOR and 4E-BP1 protein levels 
were diminished by the time DNA degradation was triggered (Figs. 28 A and 25 B). 
 Next we analyzed the levels of Ser473 p-Akt of distinct MCL cell lines in 
relationship to their ATL sensitivity. We found that MCL cell lines ranked HBL-2 >> 
Jeko-1 > Z-138 ≈ JVM-2 for their basal level of phospho-Ser473 Akt (Fig. 29 A). This 
order was inversely related to their sensitivity to ATLs, HBL-2 cells being resistant 
to their apoptotic action (Fig. 29 A). Although ATLs induced a rapid and complete 
dephosphorylation of Akt in Z-138 sensitive cell line (Fig. 28 A), the high levels of 
p-Akt in ATL-resistant HBL-2 cells were not decreased upon ATL treatment (Fig. 29 
B). 
Figure 29. MCL cell lines sensitivity to ATLs is dependent of p-Akt basal levels. (A, upper) HBL-2, Jeko-1, JVM-
2 and Z-138 cell lines were incubated without (control) or with 10 mM perifosine or edelfosine for 24 h, and 
analyzed by flow cytometry to evaluate apoptosis.Data shown are means±s.d. of three independent experiments. 
(e, lower) MCL cell lines HBL-2, Jeko-1, JVM-2 and Z-138 were analyzed by immunoblotting for p-Akt (Ser473) 
and b-actin. Blots were briefly exposed for autoradiography to highlight the high level of p-Akt in HBL-2 cells 
as compared with the other MCL cell lines.(B) HBL-2 cells were untreated (control, C) or treated with ATLs for 
6 h, and then analyzed by immunoblotting with specific antibodies against p-Akt (Ser473), p-Akt (Thr308) and 
Akt1/2/3. Representative blots of three separate experiments are shown.
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 However, as shown in Figure 28 A and Figure 30, we found a decrease in Ser473 
p-Akt levels after ATL-incubation in Z-138, JVM-2 and Jeko-1 MCL sensitive cells 
after ATL-incubation. These data support the notion that the extent of ATL- induced 
apoptosis in MCL cells is correlated with and depends on the Akt phosphorylation 
status at Ser473, suggesting the involvement of Akt dephosphorylation in the 
mechanism of ATL antitumor activity.
Figure 30. ATL incubation inhibits Akt in JVM-2 and Jeko-1 cells. Cells were untreated (C) or treated with 10 µM 
perifosine (P) or edelfosine (E), and analyzed by immunoblotting for Ser473 p-Akt and Akt protein levels (SDS-
12% polyacrylamide gels) after 6-h incubation. Representative blots of three separate experiments are shown.
5.2.3.2. Effect of edelfosine on ERK and JNK phosphorylation in MCL cells 
 Because JNK signaling has been involved in ATL-induced apoptosis 
118 and pathogenesis of MCL 120, and ERK activation has been described as a 
possible compensatory mechanism in Akt-compromised cells 121, we assessed the 
phosphorylation status of ERK and JNK activation in Z-138 cells exposed to edelfosine. 
As shown in Figure 31 A, the level of p-JNK was dramatically increased during 
edelfosine exposure, whereas the p-ERK level was not modified or resulted slightly 
enhanced during the first 9 h of treatment, and then decreased following induction 
of apoptosis. However, despite p-JNK could be efficiently inhibited by JNK inhibitor 
(SP)(Fig. 31 B), these latter inhibitor did not significantly modify the cytotoxicity of 
ATLs, the same for ERK inhibitor (PD), as assessed by hypodiploidy or Annexin V 
analyses (Figs. 31 C and D). 
 Altogether, our data suggested that ATL-induced apoptosis in MCL cells 
involved a rapid and main Akt dephosphorylation at Ser473, rather than at Thr308, 
with no significant involvement of the Akt targets GSK-3 and Bad, and independently 
of ERK and JNK signaling.
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Figure 31. Effect of ATLs on ERK and JNK signaling. (A) Cells were untreated (control, C) or treated with 10 
µM edelfosine for the indicated times, and then analyzed by immunoblotting for p-JNK, JNK, p-ERK, ERK2. 
Representative blots of three separate experiments are shown. (B) Cells were preincubated without (control, 
C) or with 1 µM SP600125 for 1 h, and then incubated in the absence or presence of 10 µM perifosine (P) 
or edelfosine (E) for 6 h, and analyzed by immunoblotting for p-JNK and JNK. Representative blots of three 
separate experiments are shown. (C) Cells were preincubated without or with 1 µM SP600125 (SP) for 1 h, and 
then incubated in the absence or presence of 10 µM edelfosine (EDLF) for 24 h. Apoptosis was then quantitated 
as the percentage of cells in the sub-G0/G1 region in cell cycle analysis by flow cytometry. Untreated control cells were run in parallel. Data shown are means ± SD of three independent experiments. (D) Cells were preincubated 
without or with 20 μM PD98059 (PD) for 1 h, and then incubated with 10 µM perifosine (PRIF) or edelfosine 
(EDLF) for 24 h. Cell viability was assessed as non-apoptotic cells in Annexin V analysis by flow citometry. Data 
are means of 2 independent experiments performed.
5.2.3.3. PI3K inhibition potentiates ATL-induced apoptosis 
 To further assess the involvement of PI3K/Akt signaling in MCL sensitivity 
to ATLs, we preincubated MCL cells with the PI3K inhibitor wortmannin before 
ATL addition. Preincubation of Z-138 cells with wortmannin for 1 h, followed by 
24-h incubation with perifosine or edelfosine, potentiated the effect of ATLs on the 
inhibition of Akt and mTOR phosphorylation after 6-h incubation (Fig. 32 A) as well 
as on apoptosis induction (Fig. 32 B), suggesting that inhibition of PI3K/Akt could 
increase the ATL-mediated apoptotic response.
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Figure 32. PI3K inhibition potentiates ATL-induced cell death in Z-138 cells. (A) Cells were pretreated without 
(control, C) or with 400 nM wortamnin (WN), and then incubated with 10 µM perifosine (P) or edelfosine (E) 
for 6 h and analyzed by immunoblotting for p-Akt (Ser473), and Akt1/2/3. (B) Cells were preincubated without 
or with 400 nM wortmannin (WN) for 1 h, and then incubated in the absence or presence of 10 µM perifosine 
or edelfosine for 24 h, and analyzed by flow cytometry to evaluate apoptosis. Data shown are means ± SD of 
three independent experiments (**, P < 0.01).
5.2.3.4. Akt inhibitors induce apoptosis in the Z-138 MCL cell line 
 Next we examined the action of specific Akt inhibitors as apoptotic inducers 
in Z-138 cells, namely: Akti-1/2, an allosteric PH domain-dependent inhibitor; Akt 
inhibitor III, a substrate-competitive phosphatidylinositol ether analog; and Akt 
inhibitor X, which prevents phosphorylation of Akt and downstream targets 122,123  (Fig. 
33). All these Akt inhibitors decreased Ser473 Akt phosphorylation as well as mTOR 
phosphorylation (Fig. 34 C), and induced apoptosis (Fig. 34 B) and ΔΨ
m 
disruption 
(Fig. 34 C), in Z-138 cells. In addition, the above Akt inhibitors induced JNK activation 
and a slight increase in the level of JNK, whereas GSK3 phosphorylation was not 
inhibited, but slightly activated (Fig. 35). These data resemble those obtained with 
ATLs (Figs. 28 A and 31 A), suggesting that Akt inhibitors and ATLs were targeting the 
same signaling pathway in MCL cells. 
Figure 33. Molecular structure of the Akt inhibitors (Akti) tested in this study.
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Figure 34. Akt inhibitors induce apoptosis in Z-138 cells. (A) Cells were incubated with Akt inhibitors for 24 h, 
and apoptosis was then quantitated by flow cytometry. Untreated control cells were run in parallel. Data shown 
are means ± SD of three independent experiments. (B) Cells were untreated (Control) or treated with 10 µM 
Akti-1/2, Akti-III or Akti-X, and disruption of ΔΨm [(DiOC6(3)low)] was measured as described in Materials and methods after 6 h incubation. Histograms shown are representative of three independent experiments.
(C) Cells were untreated (control, C) or treated with 10 µM of each Akt inhibitor for 6 h, and then analyzed by 
immunoblotting for p-Akt (Ser473), Akt, p-mTOR and mTOR. (inset, right) Bands from the above gel were 
quantitated using ImageJ software and phosphorylated/total protein ratio values for p-Akt and p-mTOR relative 
expression levels were calculated.
Figure 35. Effect of Akt inhibitors on JNK and GSK3 phosphorylation. Cells were untreated (control, C) or treated 
with 10 µM Akti-1/2, Akti-III or Akti-X for 24 h and then analyzed by immunoblotting for p-JNK1/2/3, JNK1, 
p-GSK3, GSK3 and β-actin antibodies (SDS 12% polyacrylamide gels). Immunoblotting for β-actin was used 
as an internal control for equal protein loading in each lane. Representative blots of three separate experiments 
are shown.
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5.2.3.5. CD40 stimulation does not protect MCL cells from ATL cytotoxicity 
 The microenvironment, including cytokines, has a central role on MCL 
survival and drug resistance, and the CD40 system acts as a growth-promoting 
stimulus 110,122. In this regard, we preincubated MCL cell lines JVM-2 and Z-138 
with anti-CD40 immunoglobulin for 1 h, and then ATLs were added for 24 h, before 
evaluating apoptosis as assessed by DNA degradation through cell cycle analyses (Fig. 
36 A). Pretreatment of MCL cells with anti-CD40 immunoglobulins did not prevent 
perifosine- or edelfosine-induced apoptosis and only a very slight decrease in the ATL-
induced apoptotic response was detected (Fig. 36 A). Pretreatment of MCL cells with 
anti-CD40 antibody increased Ser473 p-Akt level (Fig. 36 B), but ATLs induced Akt 
dephosphorylation in both untreated and anti-CD40-treated cells (Fig. 36 B). These 
data suggest that CD40 pro-survival signaling does not affect significantly the ATL 
proapoptotic activity in MCL cells. Similar results were obtained by using Annexin V 
binding assays to quantify apoptotic cells (Fig. 37). 
Figure 36. ATL-induced apoptosis in MCL cells is independent of microenvironmental stimuli. (A) JVM-2 and 
Z-138 MCL cell lines were preincubated without or with 500 ng/ml anti-CD40 antibody, and then incubated 
in the absence or presence of 10 mM perifosine (PRIF) or edelfosine (EDLF). After a 24-h treatment, apoptosis 
was then quantitated by flow cytometry. Untreated control cells were run in parallel. Data shown are means±s.d. 
of three independent experiments. (B) Z-138 cells were pretreated without (control, C) or with 500 ng/ml 
anti-CD40antibody, and then incubated with 10 mM perifosine (P) or edelfosine (E) for 6 h, and analyzed by 
immunoblotting with specific antibodies against p-Akt (Ser473) and Akt. Immunoblotting for b-actin was used 
as an internal control for equal protein loading in each lane. Representative blots of three separate experiments 
are shown.
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Figure 37. ATL-induced apoptosis in MCL cells is independent of microenvironmental stimuli. JVM-2 and Z-138 
MCL cell lines were preincubated without or with 500 ng/ml anti-CD40 antibody, and then incubated in the 
absence or presence of 10 µM perifosine or edelfosine for 24 h. Cell viability was assessed as non-apoptotic cells 
in Annexin V analysis by flow cytometry. Data shown are means of two independent experiments.
5.2.3.6. Localization of PI3K/Akt signaling in MCL cell lipid rafts 
 Because the PI3K/Akt pathway is constitutively activated in MCL cells 110,111, 
and proper activation of Akt has been suggested to be dependent on lipid rafts 34,114, 
we isolated lipid rafts from Z-138, JVM-2 and Jeko-1 cells based on their insolubility 
in Triton X-100 lysis buffer at 4ºC 39. GM1-containing lipid rafts, were identified 
using CTx B subunit conjugated to horseradish peroxidase (Figs. 38 and 39). Raft and 
non-raft fractions, prepared as described in Materials and methods, were analyzed. 
We observed that rafts from untreated control Z-138 cells were highly enriched in a 
subpopulation of Akt that was fully activated (Ser473 and Thr308 phosphorylation) 
(Fig. 38). Additional Akt signaling regulatory kinases were also detected in lipid 
rafts, including PI3K, PDK1 full active form (i.e. phosphorylated on Ser241), and 
mTOR. Non-phosphorylated Akt and PDK1, unlike their phosphorylated forms, were 
equally distributed in raft and non-raft fractions (Fig. 38). These data suggest that raft 
membrane domains can serve as key platforms for PI3K/Akt activation in MCL cells. 
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Figure 38. Involvement of raft-mediated Akt signaling in edelfosine-induced apoptosis in MCL cells. Z-138 cells 
untreated (control) and treated with 10 mM edelfosine (EDLF) for 15 h were lysed in 1% Triton X-100 and 
fractionated by centrifugation on a discontinuous sucrose density gradient. Equal volumes of collected raft (R) 
and non-raft (NR) fractions were subjected to SDS-polyacrylamide gel electrophoresis before analysis of the 
indicated proteins using specific antibodies. The migration positions of PI3K, mTOR, p-PDK1 (Ser241), PDK1, 
p-Akt (Thr308), p-Akt (Ser473), Akt, p-Akt substrate (RXRXXS/T) and Bad were examined by immunoblotting 
using specific antibodies. Location of GM1-containing lipid rafts was determined using cholera toxin (CTx) B 
subunit conjugated to horseradish peroxidase. 
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Figure 39. Involvement of raft-mediated Akt signaling in edelfosine-induced apoptosis in MCL cells. JVM-2 
and Jeko-1 cells untreated (control) and treated with 10 mM edelfosine (EDLF) for 15 h were fractionated 
as above to isolate raft (R) and non-raft (N-R) fractions. The migration positions of p-Akt (Ser473), Akt and 
p-Akt substrates (RXRXXS/T) were examined by immunoblotting. Location of GM1-containing lipid rafts was 
determined using CTx B subunit conjugated to horseradish peroxidase.
5.2.3.7. Regulation of raft-mediated Akt signaling is critical for MCL survival
 ATLs target lipid rafts and reorganize their protein composition 67,75,116. 
Following edelfosine incubation, we detected a dramatic displacement of upstream 
Akt kinases PI3K and p-PDK1, as well as mTOR to non-raft fractions (Fig. 38). Akt 
was also partially displaced from raft fractions upon edelfosine treatment (Figs. 38 
and 39). Interestingly, we found that edelfosine treatment inhibited p-Akt and the 
phosphorylation of Akt downstream substrates present in the raft fractions of Z-138 
cells (Fig. 38). Bad was mainly localized in non-raft fractions (Fig. 38), suggesting 
that its inhibition occurs at a later stage as shown in Figure 28A. Ser473 p-Akt was 
also inhibited in the raft fractions of the JVM-2 and Jeko-1 cell lines, together with a 
displacement of Akt from raft fractions (Fig. 39). These data suggest that edelfosine 
incorporation in rafts blocks PI3K/Akt signaling by displacing Akt and its regulators 
from rafts. 
 Next, we examined the subcellular localization of Ser473 p-Akt by 
immunofluorescence imaging of Z-138 cells treated with pervanadate, the most potent 
known Akt activator 123, in order to facilitate p-Akt visualization in the cell. 
68
Figure 40. Pervanadate prevents edelfosine-induced apoptosis. (A) Serum-starved Z-138 cells untreated (control) 
or treated with pervanadate (PERV) for 15 min were incubated with anti-p-Akt (Ser473) antibody, and then 
with CY3-conjugated secondary antibody (red fluorescence) and 40,6-diamidino-2-phenylindole (blue 
fluorescence), as described in Materials and methods. Bar, 10 mm. (B) Z-138 cells were preincubated without 
(control) or with pervanadate (PERV) for 15 min at 37 ºC, and then incubated in the absence or presence of 10 
µM edelfosine (EDLF) for 24 h to evaluate apoptosis induction by flow cytometry (d, upper), or in the presence 
of 10 µM edelfosine (EDLF) for 6 h to analyze p-Akt (Ser473) and Akt protein levels by immunoblotting (d, 
lower). Data shown are means ± s.d. Asterisks indicate values that are significantly different from edelfosine-
treated cells at P<0.01 (**) level by Student’s t-test
 
 Under basal conditions, localization of p-Akt was difficult to detect, but p-Akt 
Ser473 was readily visualized at the cell plasma membrane following pervanadate 
treatment (Fig. 40 A). Preincubation of MCL cells with pervanadate allowed to 
overcome edelfosine-mediated inhibition of Ser473 p-Akt and to abrogate almost 
totally the apoptotic effect of edelfosine (Fig. 40 B), thus supporting that membrane 
p-Akt downregulation is a crucial step in ATL-mediated cell death. In addition, we 
found that incubation of MCL cells with both edelfosine and perifosine induced 
recruitment of Fas/CD95 death receptor to rafts (Fig. 41). Thus, ATLs displaced 
survival Akt signaling from rafts, whereas apoptotic Fas/CD95 death receptor was 
translocated to these membrane domains. However, despite Fas/CD95 translocation 
to rafts, when we incubated Z-138 cells with agonistic cytotoxic CH-11 anti-Fas 
monoclonal antibody following edelfosine pretreatment, only a slight increase in 
apoptosis was detected, which was not statistically significant when compared to cells 
treated only with the ether lipid (Fig. 41). 
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Figure 41. Recruitment of Fas/CD95 in membrane rafts following edelfosine treatment. (upper) Z-138 and JVM-
2 cells were untreated (control) or incubated with 10 mM edelfosine (EDLF) or perifosine (PRIF) for 15 h, and 
then raft and non-raft fractions were obtained as above, and analyzed for Fas/CD95 using specific antibodies. 
(lower) Z-138 cells were preincubated for 1 h with edelfosine (EDLF), followed by treatment with 50-ng/ml CH-
11 for 48 h, and then apoptosis was quantitated by flow cytometry. Data shown are means±s.d.
5.2.3.7. In vivo efficacy of edelfosine and perifosine in MCL treatment 
 By using a xenograft MCL-bearing CB17-SCID mouse model, we found that 
daily oral treatment for 3 weeks with ATLs (30 mg/kg edelfosine, molecular mass, 
523.70 g/mol; 26.45 mg/kg perifosine, molecular mass, 461.67 g/mol) inhibited the 
growth of MCL cells. Serial caliper measurements were made to determine tumor 
growth, and showed a significant anti-MCL activity for both ATLs (Fig. 42 A). A 
comparison of tumors, isolated from drug-free control and ATL-treated MCL-bearing 
mice, at the end of treatment rendered a dramatic reduction of tumor weight and 
volume in mice treated with edelfosine or perifosine (Fig. 42 A and B). These results 
highlight the effectiveness of both edelfosine and perifosine in treating MCL in mice. 
No significant differences in mean body weight were observed between drug-treated 
and control animals during the in vivo assay (3-7% of body weight loss in the treated 
groups versus control groups), suggesting a low toxicity exerted by these two ATLs. 
This observation is in agreement with a previous report showing lack of significant 
toxicity of edelfosine in a rat model 124. 
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Figure 42. In vivo anti-MCL activity of edelfosine and perifosine. (A) CB17-severe combined immunodeficient 
mice were inoculated subcutaneously with 107 Z-138 cells, and once palpable tumors were detected, mice were 
orally treated with vehicle (control), 30 mg/kg edelfosine (EDLF) and 26.45 mg/kg perifosine (PRIF) for 3 weeks. 
Tumor size was recorded at the indicated times during drug treatment. (B) After completion of the in vivo assay, 
control mice and animals treated with edelfosine (EDLF) or perifosine (PRIF) were killed, and tumors were 
isolated and measured (weight and volume). Data in (A) and (B) are shown as mean values±s.d. (n=7). Asterisks 
indicate significant differences with respect to drug-free control values, at *P<0.05 and **P<0.01. (C) A notable 
reduction in tumor size was observed after edelfosine or perifosine treatment.
5.2.3.8. ATLs induce Akt inhibition and cell death in MCL patient-derived cells 
 In an attempt to extrapolate the above data to patient-derived cells, primary 
samples from nine MCL patients (Table 1) were incubated for 24 h with the ATLs 
perifosine and edelfosine at concentrations ranging from 1 to 50 μM, and cell viability 
was determined by cytofluorimetric quantification of Annexin V-negative cells. 
LD50 values for perifosine and edelfosine were then calculated. As shown in Table 
1, we observed a great variability in the capacity of ATLs to promote cell killing of 
MCL primary cultures,  seven out of  nine primary cultures being sensitive to ATL 
concentrations below 20 μM, whereas 2 cases (nos. 8 and 9) were resistant to 50 μM 
ATL. Concentrations of ATLs as low as 10 μM induced a remarkable cytotoxicity 
(between 25% and 95%) in most of the patient-derived tumor cells (Fig. 43 A).
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Figure 43. Effect of ATLs on MCL patient-derived cells. (A) Isolated primary tumor MCL cells from nine patients 
were treated with 10 mM perifosine or edelfosine for 24 h. Non-apoptotic cells were quantified as Annexin 
V-negative cells by flow cytometry, as described in Materials and methods. Untreated controls were run in 
parallel, and data are represented as percentage of cell viability (means of two experiments) with respect to each 
untreated control. (B) MCL cells derived from patient no. 3, showing high-sensitivity to ATLs, and from patient 
no. 8, showing low sensitivity to ATLs, were incubated without (control, C) or with 10 mM perifosine (PRIF) or 
edelfosine (EDLF) for 6 h, and then analyzed by immunoblotting for p-Akt (Ser473) and Akt.
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ATL cytotoxicity was closely linked to Akt dephosphorylation, as shown by comparing 
ATL-sensitive with ATL-resistant MCL cells (Fig. 43 B). We also co-cultured primary 
patient-derived MCL cells with the human bone marrow stromal cell line HS-5, which 
has been reported to be tumor cell protective against spontaneous and drug-induced 
apoptosis 125, in the absence or presence of edelfosine or perifosine, and stroma-related 
protection toward spontaneous and ATL-induced apoptosis was evaluated. About 60-
70% of spontaneous tumor cell apoptosis was reversed by MCL co-culture with HS-5 
cells, but this value decreased to 25-35% in the presence of perifosine or edelfosine, 
thus suggesting that the presence of stroma did not prevent the killing of MCL patient-
derived cells by ATLs. 
5.2.3. Discussion 
 Here, we have found for the first time the presence of the PI3K/Akt signaling 
pathway in the lipid rafts of MCL cells, and provide evidence for the critical role of 
raft-mediated PI3K/Akt signaling in MCL survival. Oral treatment with the ATLs 
edelfosine and perifosine at an equimolar concentration of 57.3 μmol/kg body 
weight achieved a strong anti-MCL activity in xenograft animal models, and the 
killing activity of ATLs was not prevented by tumor microenvironment stimuli. Our 
findings suggest that a major event in the ATL-induced cell death in MCL cells lies 
in the displacement of Akt and its upstream regulators PI3K, p-PDK1 and mTOR 
from lipid rafts. Figure 7 depicts a plausible model for the role of raft-mediated Akt 
activation in the control of cell survival and in the mechanism of action of edelfosine-
induced apoptosis in MCL cells, based on the results reported here. Edelfosine has 
been shown to accumulate in cholesterol- and sphingolipid-rich rafts, in part due to 
its high affinity for cholesterol 61,63. According to our model (Fig. 44), the interaction 
of edelfosine with lipid rafts would launch the following sequence of events leading 
eventually to apoptosis: edelfosine incorporation into rafts → displacement of Akt and 
the kinases PI3K, PDK1, and mTOR from rafts → inhibition of Akt phosphorylation → 
inhibition of Akt substrate phosphorylation → loss of mitochondrial potential → DNA 
degradation. 
 Akt pathway has been shown to affect the intrinsic apoptotic pathway through 
inhibition of pro-apoptotic proteins, by phosphorylation of Bad and caspase-9 on 
Ser136 and Ser196, respectively 29,126. Here, we found that incubation of ATLs with 
MCL cells led to caspase 9 activation, ΔΨm loss, and ROS production, compatible with 
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an effect of ATLs on the mitochondrial intrinsic pathway. Because there is an apparent 
connection between the extrinsic and intrinsic apoptotic pathways through lipid rafts 
65,72, the action of ATLs on the intrinsic signaling route could be secondary to the 
action of ATLs on lipid rafts. Inhibition of PI3K/Akt pathway can induce apoptosis in 
tumor cells through the recruitment of death receptors to lipid rafts 84. In this regard, 
we found that ATL treatment in MCL cells displaced Akt signaling from rafts, while 
recruited Fas/CD95 death receptor to rafts. Inhibition of Bad phosphorylation by 
ATLs was detected after rather long incubation times, and was concomitant with the 
triggering of apoptosis. This raises some doubts on the role of Bad in ATL-mediated 
apoptosis in MCL cells, either as a cause or consequence in the apoptotic response. In 
this regard PI3K/Akt-dependent survival in hematopoietic cells has been suggested 
to proceed independently of Bad phosphorylation 112. Lipid rafts have been shown 
to act as scaffolds for the recruitment of Fas/CD95 death receptor and downstream 
signaling molecules, playing a major role in the killing activity of ATLs against a 
number of hematological malignancies, including MCL 38,39,64,70. Thus, the action of 
ATLs on raft membrane domains leads to the inactivation of Akt survival signaling 
and activation of death receptor apoptotic signaling. However, we did not detect a 
statistically significant sensitization of MCL cells to the subsequent agonistic activation 
of Fas/CD95 receptor. Previous reports have shown a deficient apoptotic response to 
the external stimulation of Fas/CD95 by agonistic anti-Fas/CD95 antibodies or FasL/
CD95L in tumor B cells 127,128. In this regard, it is interesting to note that unlike the 
natural ligand Fas/CD95L or agonistic anti-Fas/CD95 antibodies that act through their 
interaction with the extracellular portion of the Fas/CD95 receptor, edelfosine induces 
activation of Fas/CD95 from within the cell in a FasL/CD95L independent manner 
39,43,75. In fact, our previous data suggest that edelfosine is even more efficient than 
FasL/CD95L in promoting apoptosis through Fas/CD95 activation by its recruitment 
in membrane rafts enriched in downstream signaling molecules 39,43,69,75, leading to the 
formation of clusters of apoptotic signaling molecule-enriched rafts 39,67,69,72, named 
CASMERs 42,72,73,80, which could trigger an apoptotic response in the absence of death 
receptor ligand. Thus, edelfosine could promote Fas/CD95 activation, although the 
receptor is hardly triggered by its natural ligand or agonistic antibodies. This could 
explain the herein reported lack of significant further sensitization of MCL cells to 
FasL/CD95L or agonistic antibodies after edelfosine treatment.
 Although ATLs inhibited PI3K/Akt pathway, inducing dephosphorylation of 
74
Akt and downstream substrates, we failed to detect dephosphorylation of GSK3, a 
typical substrate of Akt, thus suggesting that the raft-mediated PI3K/Akt pathway 
can act independently of GSK3 in this case. In this context, GSK3 has also been 
shown to be regulated by phospholipase C/protein kinase C in B cells 129. The fact 
that the GSK3 inhibitor lithium potentiates ATL-induced apoptosis further suggests 
that ATLs act through a GSK3-independent pathway. In prostate carcinoma cell lines, 
overexpression of myristoylated Akt, which bypasses the requirement for PH domain-
mediated membrane recruitment, abrogated perifosine effects 130. This oncogenic 
myristoylated Akt has been reported to locate in rafts, displaying no GSK3 affinity 
and a distinct substrate preference as compared with cytosolic non-raft Akt 48. Thus, 
the results reported here suggest that ATLs inhibit raft-mediated Akt that might 
regulate apoptosis, but not GSK3 phosphorylation. On these grounds, our findings 
suggest that part of the tumor traits of MCL cells could depend on the raft-located Akt 
signaling pathway which shows a particular substrate profile, and could be exacerbated 
by pervanadate-mediated activation. Our data suggest that ATL resistance in MCL 
seems to be related to raft-dependent Akt activation and overexpression.Specific Akt 
inhibitors, with different molecular structures and targeting distinct parts of the Akt 
molecule, reproduced ATL-mediated apoptotic events, suggesting that they target the 
same Akt signaling crucial for MCL cell survival as ATLs. Interestingly, Akt inhibitor 
III has a similar structure to edelfosine, but replacing the choline group for inositol 
(Fig. 33). These data further support the involvement of PI3K/Akt pathway in MCL 
survival.
 Because lipid rafts are known to be enriched in PI(4,5)P2 and PI(3,4,5)P3 
131, they provide a permissive milieu for the interaction between PDK1 and Akt. 
ATLs have been found to accumulate in lipid rafts in a number of hematological 
malignancies, altering the raft protein and lipid composition 39,69. Thus, it is tempting 
to envisage that ATLs might inhibit proteins with PH domains. The levels of PIP2 
and Ser473 phosphorylation are more predictors of Akt activation state than Thr308 
phosphorylation 112. In this regard, Ser473 phosphorylation of Akt seems to be more 
dependent on its location in lipid rafts, and to play a critical role in Akt activation. In 
fact, Akt Ser473 kinase activity has been identified associated to plasma membrane 
rafts 132. These data support the results reported here of a rapid inhibition of Ser473 
p-Akt following ATL action in MCL cells, whereas inhibition of Thr308 p-Akt was a 
secondary effect that required longer ATL incubation times. Likewise, higher levels of 
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Ser473 p-Akt than Thr308 p-Akt have been shown in mouse lymphoma ATL-resistant 
cells 133. Taking together, these data implicate a critical role for lipid rafts in Ser473 Akt 
phosphorylation in MCL. In this regard, we found a dramatic displacement from rafts 
of mTOR (Fig. 38), which could form the complex mTORC2, suggested to be PKD2, 
involved in the Ser473 phosphorylation of Akt 113, following edelfosine treatment. 
Thus, ATLs might inhibit the PI3K/Akt signaling pathway at the very early stages of 
the route leading to the series of downstream events reported here. Our data highlight 
raft-mediated PI3K/Akt signaling as a major target in MCL therapy, thus supporting 
a new raft-mediated strategy for MCL treatment. Inhibition of raft-mediated PI3K/
Akt signaling could lead to a decreased apoptotic threshold and to the induction of 
apoptosis.
Figure 44. Schematic model of raft-mediated Akt signaling in the regulation of cell survival and death in MCL cells 
during edelfosine treatment. This scheme highlights the importance of lipid raft membrane domains for PI3K/
Akt pathway activation in the regulation of MCL cell survival or death, based on the data reported here. For 
further details, see the text.
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5.3. The antitumor lipid edelfosine in combination therapy for MM 
5.3.1. Introduction
 MM is characterized by the accumulation of plasma cells in the bone marrow 
with a low proliferative index, an extended life span and a defective apoptosis 85-87. 
With an estimated overall survival rate of 54.4% and an event-free survival of 49.3% 
after 5 years, MM is still considered an incurable disease 136,137. At present, treatment 
for MM focuses on the reduction of tumor growth and the treatment of symptoms 137. 
Because resistance to apoptosis may play a crucial role in pathogenesis and resistance 
to treatment of MM, a therapeutic potential lies in circumventing antiapoptotic signals 
and/or potentiating apoptosis 87. The current clinical treatment in MM includes the 
combination of different agents, which has been shown to improve treatment for MM 
with rapid progression or aggressive relapse 137,138.
 The ATLs, are a family of compounds that target cell membranes and are able to 
selectively induce apoptosis in tumor cells, including MM cells 58,59,64,69,101. Edelfosine, 
considered as the prototype molecule of ATLs, has been shown as the most potent 
ATL in selectively killing hematological cancer cells in vitro and in vivo, including 
MCL, CLL and MM 64,69,70. Edelfosine shows affinity for cholesterol 61,63, accumulates 
in lipid rafts and promotes apoptosis by co-capping of Fas/CD95 death receptor and 
rafts in MM and additional cancer hematological cells 37-39,64,69,70. The initial studies 
conducted with edelfosine on lipid raft reorganization have led to consider membrane 
rafts as a promising novel target for apoptotic induction in hematopoietic cancer 
cells, as they can act as platforms for the recruitment of Fas/CD95 death receptor and 
proteins involved in apoptotic signaling 37,39,42,64,67,69,70,73,80,115,139. In the last few years, 
increasing accumulating evidence has shown that lipid rafts can be an important 
target for cancer therapy 8,73,80. The recruitment and aggregation of death receptors 
in lipid raft domains also enhance the proapoptoic responses elicited by their death 
ligands 69. The mechanism of co-clustering of rafts and Fas/CD95 is also observed 
after treatment with the death cytokines FasL 140 and CD28 141,142, suggesting that ATLs 
could be reactivating a physiological apoptotic mechanism 37,45. Due to the peculiar 
action of ATLs in reorganizing rafts and recruiting death receptors and downstream 
molecules in raft domains, ATLs might be promising agents in combined therapy. 
They can be used in combination with either conventional therapies or additional 
anticancer agents promoting cell death. In this regard, have been shown that ATLs 
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increase cancer cells sensitive to radiotherapy in vitro and in vivo 56.
 This work explores the possibility of using the raft-targeting-edelfosine as 
an adjuvant chemotherapeutic in MM. Here, we report that edelfosine can be an 
interesting antitumor drug for combination therapy in the treatment of MM, following 
its combined use with the proteasome inhibitor bortezomib and histone deacetylase 
(HDAC) inhibitors. Bortezomib is currently used in clinic, and has significantly 
improved the response and survival of patients in the last decade 102,143,144. HDAC 
inhibitors induce apoptosis in MM cells, show a synergistic effect with proteasome 
inhibitors and are in clinic evaluation for MM treatment 137,145-149. In addition, we have 
found that up-regulation of Fas/CD95 following IFN-γ treatment potentiates the anti-
myeloma activity of edelfosine.
5.3.2. Results
5.3.2. 1. HDAC inhibitors induce apoptosis in MM cells by a raft independent mechanism
 Here, we found that the HDAC inhibitors SAHA (10 μM) and MS-275 (1 μM) 
induced apoptosis in the human MM cell lines MM144 and MM1S, as assessed by an 
increase in the sub-G0/G1 population by cell cycle analysis (Fig. 45 A). As well as by 
caspase-3 activation and cleavage of the its typical substrate PARP, using a polyclonal 
antibody anti-caspase-3 that recognized the active 17-kDa subunit of caspase-3, and 
an anti-PARP monoclonal antibody that detected both the 116-kDa intact form and 
85-kDa cleavage form of PARP (Fig. 45 B). We also detected the activation of caspases 
8 and 9, measured by colorimetric substrate degradation following HDAC inhibitors 
treatment (Fig. 45 B). The faster and higher activation of caspase-9 rather than 8, after 
SAHA incubation in time-course analyses, suggested that HDAC inhibitors activated 
preferentially the intrinsic apoptotic pathway rather than the extrinsic signaling (Fig. 
45 C).
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Figure 45. HDAC inhibitors induce apoptosis in MM cell lines. (A) MM144 and MM1S cells were untreated or 
treated with 10 μM SAHA or 1 μM MS-275 for 48 h, and then apoptosis was quantitated as the percentage 
of cells in the sub-G0/G1 region (hypodiploidy) following cell cycle analyses by flow cytometry. Data shown are means ± SD of three independent experiments. (B) MM1S cells were untreated or treated with 10 μM 
SAHA or 1 μM MS-275 for the indicated times and then analyzed by immunoblotting using specific antibodies 
for the indicated proteins. β-Actin was used for equal protein loading in each lane. Representative blots for 
three separated experiments are shown. (C) Caspase-8 and caspase-9 activities were measured in MM1S cells 
untreated or treated with 10 μM SAHA at the indicated times by a colorimetric assay described in material and 
methods. Data shown are means of two experiments performed.
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 Edelfosine has been reported to induce apoptosis in MM cells through co-
clustering of lipid rafts and Fas/CD95 69,70 . This was further confirmed by the formation 
of big co-clusters of Fas/CD95 and rafts in edelfosine-treated MM144 cells (Fig. 46 A). 
However, in contrast to edelfosine, neither SAHA nor MS-275 induced rafts and Fas/
CD95 co-clustering in MM144 cells (Fig. 46 A), as assessed by using specific anti-Fas/
CD95 antibody and FITC-CTx B subunit that binds ganglioside GM1 93, mainly found 
in rafts 94. Furthermore, disruption of lipid rafts by MCD, which depletes cholesterol95, 
did not inhibit MS-275-induced apoptosis (Fig. 46 B), further supporting that HDAC 
inhibitors-induced apoptosis in MM cells is not lipid raft-mediated.
Figure 46. HDAC inhibitors induce apoptosis in MM cells by a lipid raft independent mechanism. (A) MM144 
cells were either untreated (Control) or treated with 10 μM SAHA and 1 μM MS-275 for 24 h, and then 
stained with FITC-CTxB subunit to identify lipid rafts (green fluoresce) and specific Fas/CD95 monoclonal 
antibody, followed by CY3-conjugated anti-mouse immunoglobulin (red fluorescence). Areas of colocalization 
between membrane rafts and Fas/CD95 in the merge panels are yellow. Images showed are representative of 
three independent experiments. (B) MM1S and MM144 cells were pretreated with 2.5 mg/ml MCD and then 
incubated with 1 μM MS-275 for 48 h. Percentage of apoptotic cells was then determined by flow cytometry 
as the percentage of cells at the sub-G0/G1 region. Untreated cells showed apoptosis mean values of <5% . Data shown are means ± SD of three independent experiments.
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5.3.2.1. Combination of edelfosine and HDAC inhibitors potentiates apoptosis in MM 
cells
 Because edelfosine and HDAC inhibitors seem to act through distinct molecular 
mechanisms, we tested whether the combination of both types of compounds could 
potentiate the apoptotic activity against MM cells. By combining low concentrations 
of edelfosine and HDAC inhibitors compounds, namely 5 μM edelfosine with 5 μM 
SAHA or 0.5 μM MS-275, we found an increase in the apoptotic response in MM1S 
cells, as assessed by the an enhancement in the sub-G0/G1 population by cell cycle 
analysis (Fig. 47 A). This was clearly supported by the early activation in MM1S cells of 
caspase-3 and PARP degradation following the co-treatment of MS-275 + edelfosine 
and SAHA + edelfosine, as compared to the single treatment of HDAC inhibitors or 
edelfosine (Fig. 47 B).
 
Figure 47. Combination of edelfosine and HDAC inhibitors potentiate apoptosis in MM cells. (A) MM1S cells were 
untreated or treated with 5 μM SAHA, 5 μM edelfosine, 5 μM SAHA + 5 μM edelfosine, 0.5 μM MS-275 or 0.5 
μM MS-275 + 5 μM edelfosine for the indicated times, and then  apoptosis was quantited by flow cytometry. 
Data shown are means ± SD of three independent experiments  (*, P < 0.05; **, P < 0.01). (B) MM1S cells were 
untreated or treated with 5 μM edelfosine, 5 μM SAHA, 0.5 μM MS-275, 5 μM SAHA + 5 μM edelfosine or 0.5 
μM MS-275 + 5μM edelfosine for the indicated times, and then analyzed by immunobloting for the indicated 
proteins.
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5.3.2.2. Combination of edelfosine with bortezomib potentiates the anti-myeloma 
activity
 Bortezomib induces apoptosis in MM cells through a mechanism of action 
different of that of edelfosine and independent of Fas/CD95 145,150,151. We found that co-
treatment of edelfosine and bortezomib highly potentiated the proapoptotic activity 
exerted by each individual drug against a number of MM cell lines, including MM144, 
as well as dexamethasone-sensitive MM1S cells and dextamethasone-resistant MM1R 
cells (Fig. 48). Because all the three MM cell lines showed similar percentages of 
apoptotic cell death (Fig. 48), it is suggested that edelfosine + bortezomib treatment 
circumvents dexamethasome resistance. Since the combined use of edelfosine and 
bortezomib had a synergistic effect on apoptosis (Fig. 48), this combination therapy 
procedure shows promise in the treatment of MM. 
Figure 48. Synergistic effect of the combination of edelfosine and bortezomib in the killing of MM cells. MM144, 
MM1S and MM1R cells untreated or treated with 1 nM bortezomib, 10 nM bortezomib, 7 μM edelfosine 
(EDLF), 1 nM bortezomib + 7 μM edelfosine (EDLF) or 10 nM Bortezomib + 7 μM edelfosine (EDLF) for 24 
h. Apoptosis was then assessed by flow cytometry as the percentage  of cells with a DNA content less than G0/G1. Data shown are means ± SD of tree independent experiments. Asterisks indicate values that are significantly different from untreated control cells or cells treated individually with edelfosine or bortezomib at p < 0.01 (**) 
level by Student’s t-test.
5.3.2.2. Combination of two raft-targeting drugs does not potentiate apoptosis induction
 We have previously found that resveratrol promoted apoptosis in MM cells by 
co-clustering Fas/CD95 and rafts in MM cells 115 in a similar way as edelfosine did64,69. 
Resveratrol was less efficient than edelfosine in the induction of apoptosis in MM cells, 
and the combination of both agents resveratrol and edelfosine did not significantly 
increased the apoptotic action of the ether lipid (Fig. 49). These data suggest that both 
drugs induce cell death through a similar raft-mediated process and therefore no 
significant antitumor action potentiation is observed upon their combined use.     
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Figure 49. Combination of resveratrol and edelfosine does not further potentiate apoptosis in MM cells. MM144 
cells were untreated or treated with 10 μM resveratrol, 5 μM edelfosine or 10 μM resveratrol + 5 μM edelfosine, 
and apoptosis were quantited by flow cytometry as the percentage  of cells with a DNA content less than G0/G1.
5.3.2.3. INF-γ potentiates edelfosine action in MM cells
 Previous reports have shown that pretreatment of tumor cells with INF-γ 
induced an increase in Fas/CD95 cell surface level, thus potentiating the anticancer 
action of resveratrol in MM cells 115 and Fas/CD95-FasL/CD95L-mediated apoptosis 
in allergen-activated T cells 152. Likewise, here we found that IFN-γ increased the 
expression of cell surface Fas/CD95 expression in MM144 cells (Fig. 50 A), and 
potentiated edelfosine-induced apoptosis (Fig. 50 B). Similarly, IFN-γ pretreatment 
also enhanced the apoptotic ability of edelfosine in MM1S cells (47% increase). 
Figure 50. IFN-γ potentiates edelfosine-induced apoptosis in MM144 cells. (A) Cell surface expression of Fas/
CD95 was determined by immunofluorescence flow cytometry as mean fluorescence intensity (MFI) values 
in cells untreated (Control) and treated with the indicated concentrations of IFN-γ for 24 h. (B) MM144 cells 
were pretreated with 200 ng/ml IFN-γ for 24 h, and then incubated with 7 μM edelfosine for 48 h. Apoptosis 
was assessed by flow cytometry as the percentage of cells with a DNA content less than G0/G1. Untreated control cells, and cells treated only with IFN-γ or edelfosine were also analyzed for apoptosis. Data shown are means of 
two experiments performed (A) or means ± SD of tree independent experiments.
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5.3.3.Discussion
 The data reported here show that bortezomib and HDAC inhibitors can 
potentiate the action of edelfosine on the killing of MM cells. Interestingly, the 
combination of bortezomib and edelfosine rendered a synergistic effect, which might 
be of interest as bortezomib is widely used in the current therapies for MM treatment 
102,143,144. The potentiation of the anti-myeloma activity of the above drug combinations 
seems to lie in the different mechanisms of action of each drug. Thus, edelfosine-
induced apoptosis is mediated by a raft-mediated, whereas bortezomib and HDAC 
inhibitors mainly use different signaling routes 145,150,151. This notion is supported by 
the weak potentiation of the combined use of resveratrol and edelfosine, as both 
agents have been shown to promote Fas/CD95 and raft co-clustering 64,69,115. While the 
combination of edelfosine and bortezomib led to a synergistic effect, the potentiation 
of the apoptotic activity following the combination of HDAC inhibitors and edelfosine 
was less dramatic. In this regard, a recent report has shown that MS-275 sensitizes 
osteosarcoma cells to FasL-induced cell death by increasing the localization of Fas/
CD95 in membrane lipid rafts 153. These authors showed that cholesterol depletion by 
MCD inhibited the sensitization of cells to FasL, but did not affect MS-275-induced 
cell killing in osteosarcoma cells 153. Here, we did not find co-localization of Fas/CD95 
and rafts upon HDCA inhibitors treatment in MM cells, suggesting that the intensity 
of the action of HDAC inhibitors on raft organization might be cell dependent. 
However, it might be envisaged that the mechanism of action of bortezomib differs 
more from the mode of action of edelfosine than HDAC inhibitors, thus explaining 
the synergistic effect of the combined use of bortezomib and edelfosine 
 ATLs are a family of compounds that do not target DNA but cell membranes, 
and quickly disseminate to membrane organelles 56,57,65,66,81,82. Edelfosine is considered 
the prototype of ATLs and accumulates in membrane rafts of hematopietic cancer 
cells, including MM cells 64,69. Membrane rafts function as platforms for recruitment 
of death signaling proteins, forming the so-called CASMERs 42,73,80,154, from which 
death signaling is launched. Edelfosine was the first chemotherapeutic agent shown to 
target lipid rafts in hematological cancers 38,39. Subsequently, a number of additional 
antitumor drugs have been shown to promote Fas/CD95 recruitment in lipid rafts 
37,80, including cisplatin 78, resveratrol 115, aplidin 42 and the ATL perifosine 69. On these 
grounds, it is envisaged that lipid rafts can constitute a major target for cancer therapy 
8,37,64,80. 
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Results
 Despite a number of advances in new treatments that improve patient 
survival, MM is still an incurable disease 154. ATLs have been shown as promising 
drugs in killing MM cells 64,69,87, and previous data have indicated that ATLs can 
circumvent drug resistance in MM. Thus, edelfosine readily induces cell death in 
MM cells resistant to dexamethasone 69, doxorubicin, melphalan, mitoxantrone, VP-
16, cytoxan, and vincristine  155; and perifosine has been reported to be cytotoxic 
to MM cells resistant to dexamethasone and melphalan 156. In addition, ATLs have 
been shown to be effective antitumor drugs in mouse MM models 64,156. Perifosine, in 
combination with bortezomib and dexamethasone, has shown encouraging activity 
in a multicenter phase I/II trial in relapsed/refractory MM, and a phase III clinical 
trial is underway 146,157. We have also found here that IFN-γ upregulated Fas/CD95 cell 
surface expression and potentiated edelfosine-induced apoptosis in MM cells, further 
supporting the involvement of Fas/CD95 in the action of edelfosine in MM.    
 The data reported here suggest that edelfosine might be a valuable drug in 
combination therapy. Particularly, the synergistic combination of bortezomib and 
edelfosine might be clinically relevant as bortezomib is currently used in the clinics. 
Thus, the raft-mediated mechanism of action of edelfosine seems to be an interesting 
and promising way to potentiate cell death in combination therapy regimens and to 
circumvent drug resistance.
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6. GENERAL DISCUSSION
 In this work we provide evidence that rafts can be an important target for 
cancer therapy. ATLs can use rafts as gateways and then accumulate into the cell. 
ATLs and resveratrol lead tumor cells to death by recruiting and activating apoptotic 
signaling in rafts (Fig. 9) 37,56,76,77. The use of MCD can be problematic to assess the 
role of rafts in Fas/CD95 triggering during ATL or resveratrol mediated-apoptosis. 
Since cholesterol is essential for raft formation/functionality, MCD interference 
with rafts can block drug incorporation in cancer cells and for that reason apoptosis 
could be abrogated 56. Data obtained with MCD need to be supported with additional 
experimental approaches because changes in cholesterol levels can lead to pleiotropic 
effects in cells. MCD assays demonstrate only cholesterol dependence 14,19. For that 
reason we additionally used FADD-dominant negative Jurkat cells to unravel the role 
of Fas/CD95 in resveratrol-mediated apoptosis. FADD-DN cells are specifically unable 
to trigger Fas/CD95 mediate apoptotic death. Following this approach, we were able 
to demonstrate that Fas/CD95 pathway is critical for edelfosine 67 and resveratrol-
mediated apoptosis in Jurkat cells (Fig. 15). In addition, silencing of Fas/CD95 by RNA 
interference prevented the apoptotic response triggered by edelfosine in Jurkat cells 67, 
further supporting the involvement of Fas/CD95-mediated signaling in the antitumor 
action of the ether lipid. Nevertheless, ATLs can induce death in cells lacking Fas/
CD95 or other death receptors such as yeast 66 and Leishmania 158, suggesting that Fas/
CD95 is not a pre-requisite for ATL-induced cytotoxicity. Furthermore, edelfosine 
induces apoptosis in a number of solid tumor cells through an ER stress response 
57,81,82. Thus, Fas/CD95 not an universal requirement for ATL citotoxicity, and several 
signaling routes could be involved depending on the cell type context (see Fig. 51).
 The putative use of the physiological FasL/CD95L as a cancer therapeutic agent 
is hampered because of its severe liver toxicity 159. However, ATLs have the potential 
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to active Fas/CD95 pathway in cancer cells even in the absence of FasL, by promoting 
death receptor clustering in lipid rafts. In this regard, it has been shown that Fas/CD95 
can became activated by proximity leading to a potent apoptotic response 37.
 It has been suggested that redistribution of Fas/CD95 into lipid rafts can be a 
consequence of PI3K/Akt pathway inhibition, since Akt inhibitors lead cancer cells to 
apoptosis by co-clustering of Fas/CD95 and rafts 84, similarly to what is observed after 
treatment with resveratrol (Fig. 9) and ATLs 38. In this regard, it is worth to note that 
one of the reported antitumor mechanisms of resveratrol 160 and ATLs is the inhibition 
of Akt pathway (Fig. 28), suggesting a relationship between Akt inhibition and Fas/
CD95 redistribution. An increased Akt activity can lead to JNK suppression, through 
a direct interaction of Akt with JIP-1 (c-Jun-amino-terminal kinase-interacting 
protein-1) a JNK interacting protein 28,161-163 . This can be related with our data on 
edelfosine-treated MCL cells, where JNK phosphorylation was increased whereas 
Akt phosphorylation levels decreased (Figs. 28 and 31). JNK activation has been also 
related with death receptor mediated apoptosis37, and edelfosine is a potent inducer of 
persistent JNK activation 118. 
 Taking together all data, it seems plausible to suggest that ATLs have multiple 
targets in cancer cells. They can induce ER stress, inhibit PC synthesis, inhibit survival/
proliferation pathways (Akt and ERK) and activate intrinsic and extrinsic apoptotic 
pathways. Interestingly, ATL and lipid accumulation in membranes can lead to stress 
responses promoting special damage of metabolizing lipid organelles such as ER and 
probably mitochondria. A kind of cell death called lipoptosis can be triggered 22, and 
some similarities can be found between this kind of cell death and ATL-induced death 
in solid tumors as ATLs are synthetic lipids. ATL incubation triggers an ER stress 
apoptotic response in solid tumors 81,82. During lipoptosis, the generation of ROS 
inactivates phosphatases leading to persistent activation of JNK 164 which in turn it has 
been described in many cancer cells after ATL-incubation 37. ROS generation can also 
promote apoptosis by upregulation of Fas/CD95 and FasL/FasC95L 22. In this regard, 
ATL incubation has been shown to generate ROS in cancer cells 71. Additional work 
is needed to understand the putative role of ROS in ATL-induced apoptosis and Fas/
CD95-raft co-clustering. Figure 51 summarizes the major pathways that ATLs can 
target in cancer cells. 
 Interestingly, we observed an increased in ERK phosphorylation levels, instead 
inhibition, in MCL cells at early ATL incubation times (Fig. 31). This could be explained 
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in part by a possible compensatory mechanism due to the ATL-induced inhibition 
of Akt signaling. However, it is also tempting to speculate that, similarly to what 
happens with Akt/PI3K signaling proteins, MAPK upstream molecules or receptors 
could also be displaced from rafts by the action of ATLs, thus leading to activation. 
This is consistent with the finding that the kinase activity of epidermal growth factor 
receptor (EGFR) is suppressed when associated with lipid rafts. It has been proposed 
that EGFR migration out of rafts allows changes in the structural configuration of the 
receptor promoting its phosphorylation and leading to the stimulation of ERK and 
JNK signaling pathways 1,165. ATLs displace proteins from MCL rafts and it could be 
envisaged that this process does not occur in a specific way for proteins only from the 
PI3K/Akt signaling pathway.
  
 
 
Figure 51- ATL mechanism of action is cell-type dependent. ATLs are able to activate a number of processes that 
eventually lead to cell death, namely: activation of apoptotic extrinsic, death receptor-mediated, and intrinsic, 
mitochondria-mediated, signaling pathways;  induction of ER stress response together with inhibition of PC 
synthesis;  and inhibition of survival pathways (Akt in the figure).  ATL incubation can lead to the activation 
and recruitment of death receptors and apoptotic signaling (forming the so-called CASMER) into lipid rafts.
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 Cancer cells can become “addicted to” some oncogenes 166. For  that particular 
reason, cancer cells might undergo apoptosis by targeting one gene or a signaling 
route. Because of that, cancer cells may be more dependent on the activity of specific 
oncogenes and more sensitive to certain growth-inhibitory effects 166. This could 
explain the fact that the inhibition of a single signaling pathway in MCL can lead cells 
to apoptosis (Figs. 28 y 33).
    Statins and cholesterol-depleting agents can inhibit Akt signaling in rafts 
48,49,51. Our data suggest that ATLs can also target Akt activation in rafts on Ser473 
phosphorylation being the most affected phosphorylation residue. Akt can become 
activated in other non-raft localizations in of cell membrane depending on the stimulus 
34. On these grounds, it is tempting to speculate that MCL cells are dependent on raft 
environment for Akt activation, and thereby MCL cells are sensitive to ATL therapy 
(Fig. 38). Our data support the notion that PDK2 activation is raft dependent 50, as the 
levels of p-Akt (Ser473) are rapidly decreased after ATL incubation. Consistent with 
our results on the critical role of Akt for MCL cell survival, it has been reported that 
ATL-resistant mouse lymphoma cells lack phosphoinositide phosphatase SHIP-1, a 
known regulator of the Akt survival pathway 135. 
  Edelfosine has affinity to cholesterol 61,63, and its saturated acyl chain probably 
facilitates its raft incorporation and subsequent internalization to intracellular 
membranes. In fact, edelfosine has been reported to locate in intracellular organelles, 
such as ER 57,81,82 and mitochondria 65. In vivo experiments have shown that edelfosine 
biodistribution is spread over several organs 167, but when a tumor was present, 
edelfosine accumulates in the xenograft tumors 64. The fact that edelfosine accumulates 
in the tumor tissue rather than in liver and kidney suggests that is affinity for cholesterol 
cannot explain by itself its selectivity for cancer cells, as liver and kidney are organs 
enriched in cholesterol.  Additional alterations in the tumor lipid profile as well as in 
certain proteins are probably the underlying basis for edelfosine selectivity for tumor 
cells 8,59. The selective mechanism of ATLs uptake remains to be fully understood.
 As mentioned above ATLs target cell membranes of cancer cells rather than 
DNA. For that reason ATL-incubation can have a synergistic or additive effect 
in combination with conventional chemotherapy that usually target DNA. ATLs 
sensitizes tumor cells to radiotherapy 56,168. Despite the promising potential of these 
compounds, the only clinical applications until now for ATLs in cancer therapy are 
purgation of leukemic cells from bone marrow before transplantation, and treatment 
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of skin metastasis in breast cancer and cutaneous lymphoma. So far, ATL clinical 
trials have not reveled an advantage of ATL therapy as compared to conventional 
therapies 56,58. However, the use of nanoparticules to deliver the drug seems to improve 
bioavailability and decrease toxicity 169,170. Furthermore, treatment with perifosine or 
edelfosine does not damage normal cells from bone marrow, which is one of the main 
adverse effects of conventional cancer therapy 38,56. In addition, the date presented 
here indicate that edelfosine could be a promising anticancer drug for combination 
therapy, in particular combination of edelfosine and bortezomib for MM.
 Recently, it has been reported that ATLs disrupt lipid rafts using model 
membranes 171. It may look contradictory, but previous studies have shown that when 
rafts cluster to form bigger platforms they become unstable, and then endocytosis 
occurs and raft constituents are recycled back to the plasma membrane 19.  Nevertheless, 
it could be also argued that rafts do not behave in model membranes the same way as 
in living cells. 
 Due to technical limitations related to lipid raft isolation, it is not possible 
to discriminate between rafts from plasma membrane and those from intracellular 
organelles. In spite of plasma membranes are especially enriched in cholesterol as 
compared to other membranes from intracellular organelles, rafts have been reported 
in additional organelles such as mitochondria, Golgi and ER, despite being less studied 
due to these technical limitations 13,65,165,172. In this regard, we cannot ensure that Bid 
and JNK are plasma membrane located after ATL or resveratrol treatment, since those 
proteins have been found in other intracellular organelles that might contain putative 
raft domains. New approaches are needed to discriminate between intracellular and 
plasma membrane rafts.
 The results reported in this work suggest that lipid rafts can be an important 
target for cancer therapy. As shown here, raft-targeting drugs can induce apoptosis 
through PI3K/Akt inhibition and death receptor activation; and additional evidence 
also suggests that they could prevent metastasis 18. 
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7. CONCLUSIONS
1- Resveratrol induces apoptosis in MM and T-cell leukemic cell lines by a raft- 
and Fas/CD95- dependent mechanism, inducing co-clustering of rafts and 
Fas/CD95 as well as recruiting downstream apoptotic signaling molecules into 
rafts.
2- ATLs displace PI3K/Akt signaling proteins from lipid rafts in MCL cell lines, 
leading to apoptosis. Akt phosphorylation at Ser473 takes place mainly in lipid 
rafts and is critical for MCL cell survival.
3- Microenvironment stimuli do not prevent ATL-induced apoptosis. Sensitivity 
of MCL cell lines and primary cultures to ATLs is highly dependent on the 
basal Akt phosphorylation level of the cells.  
4-Taking together, the data reported here support the involvement of lipid rafts 
as a promising target in cancer therapy, by regulating survival and death 
signaling pathways.  
5-This raft-targeted therapy seems to be promising also for combination therapy, 
especially through its combination with bortezomib in hematopoietic 
cancers, such as T-cell leukemia and MM, rendering synergistic effects.
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8. SPANISH SUMMARY
Lipid rafts como dianas terapéuticas en el tratamiento del cáncer
  
8.1. Introducción
  
8.1.1. Colesterol y cáncer
 La continua proliferación de las células tumorales implica una gran demanda 
de síntesis de los componentes lipídicos que forman parte de la membrana, siendo el 
colesterol uno de esos componentes esenciales. A principios del siglo XX se observó 
que tanto en las células tumorales, como los tejidos adyacentes, acumulan mayor 
cantidad de colesterol que los tejidos normales de donde derivan 2,3 (Fig. 1 A and B). 
Sin embargo, a día de hoy todavía no está claro si la acumulación de colesterol en los 
tejidos es la causa o la consecuencia de la aparición de neoplasia 4. Algunos estudios 
epidemiológicos apuntan a que el nivel de colesterol está asociado con el grado de 
malignidad tumoral. Así, el uso prolongado de estatinas (fármacos que reducen el 
nivel de colesterol) puede estar asociado con la prevención de ciertos tipos de tumores, 
sugiriendo estos datos que la acumulación de colesterol en los tejidos podría estar 
contribuyendo a la aparición de un estado tumoral maligno 5,6,9 .
 El aumento de colesterol en las células tumorales se debe a irregularidades en 
diferentes mecanismos de biosíntesis y metabolismo de este lípido, Así, se ha observado: 
1- aumento endógeno de la biosíntesis de colesterol, como consecuencia del aumento 
de la actividad de la enzima HMG-CoA-reductasa (3-hydroxy-3-methylglutaryl CoA-
reductase), enzima perteneciente a la vía metabólica del mevalonato; 2- mayor uptake 
de colesterol exógeno, debido a la sobreexpresión de receptores de lipoproteínas LDL 
96
(low-density lipoproteins), transportadores de colesterol en el torrente sanguíneo a 
los diferentes tipos celulares; 3- aumento de la actividad de la enzima ACAT (acyl-
coenzyme A:cholesterol acyltransferase), que promueve el almacenamiento intracelular 
de colesterol; 4- Menor flujo de colesterol desde la célula, mediado por el receptor de 
lipoproteínas HDL (high-density lipoproteins) 9 (Fig. 1 C).
 En condiciones normales, el colesterol es fundamental para la configuración 
de pequeños dominios en la membrana celular. El colesterol regula la organización 
lipídica promoviendo la segregación de los diferentes tipos de lípidos. Posibilita la 
organización de las cadenas acilo de los fosfolípidos formando plataformas más 
estables y rígidas en la membrana plasmática, estructuras conocidas por lipid rafts 4,7 
(Fig. 2 B). 
8.1.3. Lipid rafts
8.1.3.1. Historia
 Las membranas celulares están compuestas de una amplia variedad de lípidos, 
todavía no identificados en su totalidad 12. La membrana plasmática fue inicialmente 
definida como un mar de lípidos donde flotaban las proteínas que asumían el papel 
principal en la señalización. Este modelo fue conocido por el nombre de mosaico 
fluido o de Singer y Nicholson13,14 (Fig. 2 A). Hoy se sabe que las membranas celulares 
no están desordenadas,  sino compartimentadas en múltiples dominios con funciones 
especializadas 6. En el año 1997 Kai Simons y Eliana Ikonen postularon el modelo 
lipid raft (Fig. 2 B), en el cual se defendía la existencia de pequeños dominios ricos 
en colesterol en la membrana celular 16. Esta hipótesis fue desarrollada basándose 
en estudios de polaridad de membrana en células epiteliales (diferente composición 
lipídica en la parte apical y basolateral de la membrana) y en el comportamiento de 
mezclas lipídicas en membranas artificiales (segregación entre fases liquidas-ordenadas 
(Lo) y liquidas-desordenadas(Ld)) 14,16,17,19. La función de estos lipid rafts estuvo en 
primer lugar asociada al transporte de ciertos componentes de las membranas y 
señalización celular 12,16. 
8.1.3.2. Caracterización de los lipid rafts
 Aunque los lipid rafts  son más abundantes en la membrana plasmática  también 
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se encuentran en orgánulos intracelulares. La caracterización de los dominios rafts ha 
estado envuelta en una gran controversia durante muchos años por las limitaciones 
técnicas empleadas en su estudio 12-14,17. De hecho, se creía que se trataba de un artefacto 
ya que la resolución de los microscopios convencionales no permitia su detección sin 
recurrir a estímulos exógenos que conllevaban a la formación de plataformas-raft 14.
 
 Los lipid rafts son muchas veces referidos en la literatura como dominios 
líquidos-ordenados o porciones de membrana resistentes a detergentes (DRMs). Las 
fases líquidas ordenadas fueron descritas en membranas artificiales y normalmente se 
emplea ese término en ese contexto; las DRMs son membranas aisladas que resultan 
insolubles en detergentes no-iónicos. De hecho, esta es la técnica más utilizada para 
el aislamiento y estudio de los rafts. Sin embargo, los DRMs no solo contienen lipid 
rafts sino tambíen agregados raft o plataformas-rafts y dominios caveola 12,14,19 (Fig. 
3). Los dominios caveola se caracterizan por la presencia de la proteína caveolina las 
plataformas-raft se forman durante procesos de señalización, por ejemplo durante 
la sinapsis inmunológica. En términos de distribución parece que los lipid rafts son 
ubicuos en los diferentes tipos celulares; por el contrario, los dominios caveola son 
más abundantes en células musculares, endoteliales, adipocitos y fibroblastos. Las 
propiedades biofísicas de ambos dominios son similares y es posible que los lipid rafts 
reemplacen la función de los caveola en células en que éstos últimos no estén presentes 
6,8,13,20,23. 
  
8.1.3.3. Redefinición de los dominios raft y su función en la célula
 Las técnicas de alta resolución single particle tracking (SPT), single fluorophore 
video tracking (SFVT), fluorescence resonance energy transfer (FRET) y homo-FRET han 
permitido la detección de los dominios rafts antes de la formación de las plataformas 
células vivas. Teniendo en cuenta los últimos datos obtenidos con estas técnicas, 
los lipid rafts se definen en la actualidad como dominios ordenados de agregados 
lípido-proteicos,  altamente dinámicos, ricos en colesterol y esfingolípidos, de tamaño 
nanoscópico en reposo, que una vez estimulados pueden formar plataformas visibles 
en microscopios convencionales. Estas plataformas-raft se mantienen más estables 
mediante interacciones específicas entre lípidos y proteínas 14. Son estructuras 
organizadas y especializadas en señalización, endocitosis, exocitosis, transporte de 
membranas y están también implicados en la infección viral 13,14,19.
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8.1.3.4. ¿Cómo son seleccionadas las proteínas para los dominios rafts?
 Muchas proteínas parecen asociarse de forma transitoria a los lipid rafts en 
respuesta a diferentes estímulos tanto intra como extracelulares. Esta segregación 
física de las proteínas puede regular el acceso de las mismas a otras proteínas efectoras 
y reguladoras. Esta localización de complejos proteicos en los rafts parece asegurar la 
transmisión de señales 13,19. No se conoce todavía el mecanismo exacto por el cual las 
proteínas son seleccionadas en los lipid rafts. La hipótesis de los lipid shells o de las 
“capa/coberturas de lípidos” propone que las proteínas destinadas a los rafts estarían 
envueltas en una “cobertura de lípidos” que les conferiría especial atracción para 
los lipid rafts donde se fundirían. Sin embargo existe otra hipótesis que dice que las 
proteínas pueden estar funcionando como surfactantes que ayudan a estabilizar los 
lipid rafts, localizándose por lo tanto en los márgenes de estos dominios 19. 
 Existen otros factores que parecen condicionar la asociación de las proteínas a 
los  rafts. El mismo colesterol, que al inducir un aumento del grosor de los dominios 
raft en comparación con locales de la membrana no-raft, excluiría las proteínas 
con dominios transmembrana muy cortos 4,12,13. Existen, además determinadas 
modificaciones lipídicas en las proteínas (“colas hidrofóbicas”) que condicionan la 
localización de las mismas en la membrana. Por ejemplo, las proteínas con anclajes de 
GPI (gycosylphosphatidylinositol) y las proteínas miristiladas o palmitoiladas tienen 
especial preferencia por los rafts, una vez que sus “colas hidrofóbicas” son cadenas 
acilo saturadas que promueven la asociación a los rafts; mientras que proteínas con 
“colas” insaturadas isoprenil se localizan de forma preferente en dominios no-raft 
(Fig. 4) 4,13,24.
 Los dominios raft están involucrados en la señalización de numerosas rutas. 
Por lo tanto analizaremos en el siguiente apartado su papel en la señalización de la ruta 
de supervivencia/proliferación PI3K/Akt, y de la ruta muerte programada mediada 
por el receptor Fas/CD95. Posteriormente interpretaremos el efecto citotóxico de 
fármacos que interfieren con los rafts de las células tumorales, en función de estas 
rutas de señalización.
8.1.4. Rafts y señalización
8.1.4.1. Ruta de señalización de Akt
 Akt tiene múltiples sustratos, cuyas funciones se relacionan directamente con 
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la proliferación y con el bloqueo de la apoptosis 26,27. La ruta de Akt se encuentra 
sobreactivada en una gran cuantidad de tumores, favoreciendo la progresión de los 
mismos. Akt tiene un dominio PH que le confiere especial afinidad por los inositoles 
de membrana donde se ancla y se activa. En algunos tumores se ha observado una 
mutación en este dominio que conduce a una continua asociación de Akt con la 
membrana, resultando en una activación constitutiva de la proteína 27-30. 
 Las membranas plasmáticas de las células tumorales poseen una grand cantidad 
de dominios raft. Los dominios raft no solo son especialmente ricos en inositoles, 
factores clave para la activación de Akt 30-33, sino que además se han detectado algunas 
quinasas, como PI3K, mTOR y PDK1 30,32,34, reguladoras de la ruta de Akt. Por último y 
reforzando la hipótesis de que los rafts están implicados en la protección del complejo 
proteico involucrado en la activación de Akt, recientemente, se ha podido detectar 
detectar in vivo el reclutamiento de Akt en rafts 30,32,34.
8.1.4.2. Ruta de señalización de Fas/CD95 
 La muerte celular programada o apoptosis, puede ser llevada a cabo por la 
activación de una ruta intrínseca, mediada por la mitocondria y/o por una ruta 
extrínseca, en la cual están implicados los receptores de muerte 35. Uno de los 
receptores de muerte más importantes es el Fas/CD95, y su activación es necesaria 
para eliminación de células transformadas o con infecciones virales 36. Fas/CD95, su 
ligando natural (FasL) así como otros receptores de la familia TRAIL (tumor necrosis 
factor-related apoptosis-inducing ligand) pueden palmitiolarse y esta “cola hidrofóbica” 
parece conferirles afinidad por los rafts 22,33,46. De hecho, varios trabajos han detectado 
que los lipid rafts son importantes para la activación de Fas/CD95, ya sea inducida 
por su ligando, FasL36,40,41 o por fármacos quimioterapéuticos 38. Algunos de estos 
fármacos tienen la capacidad de inducir la distribución de Fas/CD95 en rafts de células 
tumorales conduciendo por lo tanto la apoptosis de la célula tumoral 35,37,38,44,45. 
 En el siguiente apartado se discute la posibilidad de utilizar como diana los lipid 
rafts en la terapia del cáncer, a través de fármacos que modulan los níveles de colesterol, 
u otros, cuya especial afinidad por rafts promueve la formación de plataformas-raft y 
el reclutamiento de la señalización apoptótica.
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8.1.5. Modulación de rafts en células tumorales
8.1.5.1. Modulación de la ruta de Akt mediante alteración de los níveles de colesterol 
por estatinas y agentes quelantes 
 La manipulación del contenido de colesterol en una célula tumoral regula la 
supervivencia celular. Así, la reducción de  los níveles de colesterol, ya sea inhibiendo 
su síntesis mediante el empleo de estatinas, o mediante su secuestro de la membrana 
por agentes quelantes de colesterol, provoca la muerte de algunos tipos de células 
tumorales 31,49-52. La falta de colesterol, llevaría a la desconfiguración de los rafts, y con 
ello la inhibición del anclaje y activación de Akt 31,49-52. 
 Por otra parte, los niveles elevados de colesterol en circulación pueden promover 
el crecimiento tumoral en modelos animales de cáncer de próstata. Se detectó en 
este contexto, que en las células tumorales de animales con dietas ricas en colesterol 
ocurría una expansión de los lipid rafts, asociada a un aumento de la actividad de la 
proteína Akt. 
 La fosfatasa supresora de Akt, PTEN (phosphatase and tensin homolog), 
se encuentra mutada en muchos tumores, lo que se relaciona comúnmente con la 
activación constitutiva de Akt. Sin embargo, los trabajos referidos, indican que 
utilizando estatinas o quelantes de colesterol es posible inhibir la actividad de Akt, 
aun cuando la fosfatasa usptream Akt se encuentre suprimida 48,49,51 (Fig. 5 A).  
  Una vez localizada en los lipid rafts, Akt parece tener afinidad por sustratos 
diferentes a los que tiene en zonas no raft. La funciónde Akt en rafts parece estar 
relacionada con señalización anti-apoptotica y con la síntesis de componentes lipídicos 
pertenecientes a los rafts, como es el caso del colesterol. De esta forma, Akt tendría un 
feedback positivo, promoviendo su propia activación vía rafts 48,53 (Fig. 5 B).
8.1.5.2. Alquilfosfolipidos antitumorales (APLs) o lípidos antitumorales (ATLs)
 Los ATLs son análogos metabólicamente estables de la fosfatidilcolina, sus 
propiedades antitumorales in vivo e in vitro fueron primeramente descritas por 
Munder y colaboradores 54,55. Estos compuestos tienen como diana la membrana de 
las células tumorales, no el ADN, como la mayoría de los quimioterapéuticos. Su 
estructura les permite una fácil incorporación en la membrana y poseen especial 
afinidad por el colesterol. Esta afinidad lleva a que estos compuestos que hace que se 
localicen preferentemente en los rafts 37,39,56,57,61,63,64. 
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8.1.5.3. Mecanismo de acción de los ATLs en tumores hematológicos
 El mecanismo de acción de los ATLs sobre las células tumorales es a través 
de  la activación de la vía apoptótica. En concreto, se conoce que en tumores 
hematológicos, los ATLs actúan a través de la activación y reclutamiento del receptor 
Fas/CD95 en plataformas raft, de forma independiente de su ligando natural (FasL/
CD95L). Además de Fas/CD95, el tratamiento con ATLs provoca la detección de 
otras proteínas apoptóticas que median la señalización downstream de este receptor. 
Algunas de estas proteínas incluyen a FADD (Fas-associated death domain-containing 
protein) y a procaspasa-8, que junto al receptor Fas/CD95 forman el complejo DISC 
(death-inducing signaling complex). Este cluster de proteínas apoptóticas en rafts ha 
sido llamado CASMER (cluster of apoptotic signaling molecule-enriched rafts), y su 
formación está relacionada de manera directa con la muerte celular de distintos tipos 
de canceres hematológicos 37-39,56,73 (Fig. 6).
 La formación de CASMERs no parece ser un mecanismo exclusivo inducido 
por los ATLs, sino también por otros compuestos, como el resveratrol, aplidina o 
anandamida, entre otros; tratándose por lo tanto de un mecanismo apoptótico común 
a distintos compuestos antitumorales 37,73,76,77,79,173. 
 En los últimos años, se ha establecido una relación directa entre la acumulación 
de colesterol en tumores, la expansión de dominios raft y la activación de rutas 
relacionadas con la proliferación y supervivencia tumoral. Estos datos indican que 
los lipid rafts pueden estar implicados en procesos de tumorigénesis. Por ello, nos 
propusimos analizar el mecanismo de acción de compuestos antitumorales cuya 
acción citotóxica parece relacionarse con cambios en el contenido proteico de los 
raft; utilizando como modelo de estudio líneas celulares de mieloma múltiple (MM), 
leucemia de células T y células de linfoma de manto (MCL). Estas líneas se caracterizan 
por poseer defectos en las rutas apoptóticas y por carecer de una terapia efectiva 85,86,64,87.
 En primer lugar evaluamos la implicación de los raft de membrana y del 
receptor Fas/CD95 en la apoptosis mediada por el resveratrol, en células de MM 
y leucemia de células T. Utilizamos el resveratrol un compuesto natural que ha 
demostrado tener propiedades antitumorales en células hematológicas 92 , activando 
mecanismos de muerte que implican a los rafts 76,91. Con el objetivo de encontrar una 
posible aplicación terapéutica combinamos compuestos cuyo mecanismo de acción 
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implica a los rafts (resveratrol y edelfosina) con otros compuestos de interés clínico en 
el tratamiento de las referidas enfermedades hematológicas (bortezomib, perifosina y 
interferón gamma) 137,145,146,87.
 Además, utilizamos células de MCL, en las cuales se ha descrito anteriormente 
la implicación de los dominios rafts en la acción antitumoral de los ATLs 70. En estas 
células la vía de Akt se encuentra constitutivamente activada y es fundamental para su 
supervivencia, incluso se ha discutido anteriormente la posibilidad de inhibir esta vía 
como medida terapéutica 110,111. Este modelo permite estudiar la ruta de activación de 
Akt y su relación con los rafts 34,114 en los procesos de muerte inducidos por ATLs.
103
8.2. Objetivos:
1. Conocer la implicación de los lipid rafts y del receptor de muerte Fas/CD95 en 
la citotoxicidad inducida por resveratrol en células de mieloma múltiple (MM) 
y leucemia de células T. 
2.  Caracterizar el papel de los lipid rafts en la activación de Akt y en la muerte 
inducida por ATLs en celulas de linfoma de manto (MCL). 
3. Evaluación in vitro de una terapia combinada entre moléculas cuyo blanco 
son los rafts (Resveratrol y ATLs) + moléculas que no interfieren con los rafts 
(bortezomib, inhibidores de histona deacetilasas, interferón gamma (IFN-γ)) 
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8.3. Resultados y discusión 
8.3.1. La acción apoptótica del resveratrol sobre células de mieloma múltiple y de leuce-
mia implica a la mitocondria y el reclutamiento de Fas/CD95 en lipid rafts 
8.3.1.1. El resveratrol induce apoptosis en líneas celulares de mieloma múltiple (MM) y 
leucemia de células T
 Para la consecución del primer y parte del tercero objetivo utilizamos líneas 
celulares de mieloma múltiple (MM144 y MM1S) y de leucemia de células T, (células 
Jurkat, JK) y las tratamos con resveratrol. La evaluación primera de la muerte 
celular por apoptosis se realizó mediante el análisis de la degradación del ADN. 
Nuestros resultados muestran que todas las líneas celulares estudiadas responden 
a concentraciones crecientes de resveratrol con un aumento en el porcentaje de 
degradación en su ADN. Además, las células JK tratadas con resveratrol presentan 
activación de caspasa-3 y del sustrato PARP (Poly(ADP-ribose) polymerase) (Fig. 
7), parámetros indicadores de apoptosis. Estos datos demuestran que este fármaco 
desencadena el proceso de muerte celular por apoptosis en los dos tipos celulares de 
interés. 
 Con vistas a una posible aplicación clínica, tratamos con las mismas condiciones 
de resveratrol a células derivadas de pacientes con MM y a linfocitos de sangre 
periférica de voluntarios sanos, utilizados como control. Este análisis demostró que el 
resveratrol tiene una acción selectiva sobre las células tumorales, ya que el porcentaje 
de degradación de ADN en las muestras control fue inferior al 5% (Fig. 8).
8.3.1.2. Los lipid rafts están funcionalmente implicados en la apoptosis mediada 
por resveratrol en líneas celulares de mieloma múltiple y leucemia de células T
 Algunos datos previos han demostrado que la incubación con resveratrol provoca 
la activación del receptor de muerte Fas/CD95 en lipid rafts 76.  Para comprobar si esto 
podía estar sucediendo también en los tumores hematológicos de estudio, realizamos 
inmunofluorescencia para la detección de Fas/CD95 y utilizamos la subunidad B 
de la toxina colérica unida a FITC (fluorescein isothiocyanate), cuya afinidad por el 
gangliósido GM1 nos permite localizar los rafts en la membrana plasmática de las 
líneas MM144 y JK. Nuestros resultados demuestran que el tratamiento con resveratrol 
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provoca la formación de plataformas raft y la redistribución en ellas del receptor de 
muerte Fas/CD95 (Fig. 9). Por otra parte, si impedimos la formación de rafts, mediante 
la pre-incubación con un quelante de colesterol (MCD-methyl-β-cyclodextrin), se 
inhibe la apoptosis inducida por resveratrol (Fig. 10). Todos estos datos sugieren que 
los lipid rafts están directamente implicados en el proceso apoptótico mediado por 
resveratrol, posiblemente mediante el reclutamiento del receptor Fas/CD95.
8.3.1.3. El resveratrol induce el reclutamiento en lipid rafts de receptores de muerte y 
proteínas apoptóticas señalizadoras downstream
 El aislamiento de lipid rafts de células JK y MM144 tratadas y sin tratar 
con resveratrol confirmó la translocación de Fas/CD95 a rafts tras el tratamiento 
con resveratrol. Además de Fas/CD95, en estas estructuras membranosas hemos 
detectado diversos receptores de la familia TRAIL, otros tipos de receptores de 
muerte. Así, en células JK se encuentra el receptor TRAIL 42, DR5 (death receptor 5) 
y en células MM144 los receptores TRAIL, DR4 (death receptor 4) y DR5. Además 
de los receptores, en los lipid rafts también se acumulan proteínas downstream a los 
receptores de muerte pertenecientes al complejo DISC (FADD y procaspasa-8) y 
otras proteínas involucradas en señalización apoptótica (caspasa-10, Bid y JNK). El 
complejo DISC es clave en la iniciación de la apoptosis y la proteína Bid puede servir 
de puente entre la apoptosis mediada por Fas/CD95 y la apoptosis mediada por la 
mitocondria. Estos resultados sugieren que el resveratrol induce una reorganización 
del contenido proteico de los lipid rafts (Fig. 11).
 Para analizar en detalle cuales podían ser las rutas implicadas en la apoptosis 
mediada por resveratrol llevamos a cabo la preincubación de las células con distintos 
inhibidores moleculares. Así, la preincubación con inhibidores de JNK y caspasas 
provocó una inhibición de la apoptosis inducida por resveratrol. El inhibidor general 
de caspasas (z-VAD-fmk) produjo la inhibición casi total de la apoptosis en células 
JK, MM144 y MM1S, implicando la activación de caspasas en la transmisión de la 
señal apoptótica. Sin embargo, el pre-tratamiento con el inhibidor de JNK (SP600125) 
inhibe la apoptosis de forma parcial. Estos datos indican que la activación de las 
caspasas es necesaria mientras que JNK contribuye, pero no parece ser esencial en la 
transmisión de la señal apoptótica inducida por resveratrol (Fig. 12).
8.3.1.4. La mitocondria está implicada en la apoptosis inducida por resveratrol
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 Para estudiar el papel de la mitocondria en la apoptosis inducida por resveratrol 
analizamos el papel de la proteína mitocondrial anti-apoptótica Bcl-XL en células 
MM144 tras el tratamiento con nuestro fármaco de interés. Para ello obtuvimos células 
MM144 transfectadas con el vector control pSFFV-Neo, y células transfectadas con 
Bcl-XL, que sobreexpresan la proteína. El tratamiento de las células control (MM144-
Neo) con  resveratrol conduce a la degradación del ADN, a la pérdida del potencial de 
membrana mitocondrial (ΔΨm) y a la formación de especies reactivas de oxígeno, ROS; 
mientras que el tratamiento con resveratrol en las células MM144-Bcl-XL no produjo 
ni degradación del ADN, ni pérdida en el potencial de membrana mitocondrial pero 
sí la formación de ROS. Estos resultados indican que la disipación de ΔΨm pero no la 
formación de ROS, es fundamental para que se dé el proceso apoptótico inducido por 
resveratrol (Fig. 13). 
 El hecho de que Bid se movilizara hacia los rafts tras el tratamiento de resveratrol 
estaba indicando que podría existir una conexión entre las rutas apoptóticas 96. 
Para demostrar esta hipótesis, utilizamos células JK que sobreexpresan una forma 
dominante negativa de FADD (FADD-DN), la proteína adaptadora de Fas/CD95. 
En estas células la señalización vía Fas/CD95 se encuentra bloqueada. Nuestros 
resultados muestran que el tratamiento con el resveratrol de las células JK-FADD-DN 
no produjo ni degradación del ADN, ni perdida del ΔΨm (Fig. 14). Además, células JK 
deficientes en Fas/CD95, las cuales se mostraron totalmente resistentes al tratamiento 
con resveratrol (Fig. 15). Estos datos indican que la falta de activación de Fas/CD95 
provoca el bloqueo de los eventos apoptóticos mitocondriales, ya que no ocurren 
cuando éste no se activa.
8.3.1.5. El interferon gamma (IFN-γ) induce la expresión de Fas/CD95 y de la casapasa-8 
y potencia la apoptosis inducida por resveratrol 
  Teniendo en cuenta que la activación de Fas/CD95 está directamente 
relacionada con el proceso apoptótico mediado por el resveratrol y que el IFN-γ 
induce la expresión de Fas/CD95 en células de MM 87,174 quisimos comprobar si el uso 
de IFN-γ tiene algún efecto sobre la apoptosis en nuestras células de interés. Nuestros 
resultados mostraron que el tratamiento de células MM1S con IFN-γ aumenta los 
niveles proteicos tanto de Fas/CD95 como de procaspasa-8. Este aumento puede estar 
directamente relacionado con la sensibilización de estas células a la apoptosis inducida 
por resveratrol observada en estas células cuando las pretratamos con INF-γ (Fig. 16).
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8.3.1.6. Resveratrol induce el reclutamiento de Fas/CD95 en lipid rafts en células 
U266 de mieloma múltiple
 La línea de mieloma múltiple U266 se caracteriza por expresar un receptor 
Fas/CD95 que no es activable por anticuerpos agonistas de Fas/CD95 ni por el 
ligando natural (FasL/CD95L). Por lo tanto, el  objetivo de esta parte del trabajo fue 
determinar si el reveratrol sigue ejerciendo su efecto apoptótico cuando el receptor 
Fas/CD95 no es capaz de activarse por su ligando natural. Como indicador de muerte 
celular por apoptosis cuantificamos la degradación del ADN. De manera similar que 
para las células JK, MM144 y MM1S, las células U266 responden a concentraciones 
crecientes de resveratrol con un aumento en el porcentaje de degradación de su ADN. 
Estos resultados estarían de acuerdo con datos previos obtenidos con ATLs, en los que 
se observó que la redistribución de Fas/CD95 en lipid rafts, con independencia de su 
activación por ligando para el desencadenar del proceso apoptótico 75. En concordancia 
con esto hemos observado la formación de plataformas-raft y redistribución de 
Fas/CD95 mediante tratamiento con resveratrol (Fig. 17). Sin embargo, mediante 
preincubación con MCD, que previne la formación de plataformas-raft, apenas hemos 
detectado una discreta inhibición de la apoptosis inducida por resveratrol. Estos datos 
indican que en células U266 el resveratrol induce la formación de plataformas-rafts y 
la redistribución de Fas/CD95 pero para que la apoptosis se produzca son necesarios 
otros mecanismos adicionales (Fig. 18), probablemente relacionados con la down-
regulation de STAT3 (signal transducer and activator of transcription 3) y del factor 
nuclear-kB previamente documentado durante la muerte apoptótica de células MM 
mediante tratamiento con resveratrol 92.
8.3.1.6.7. Efectos en la apoptosis por combinación del resveratrol con bortezomib ó 
perifosina 
 Debido a que el efecto apoptótico del resveratrol solo se consigue a dosis altas 
del mismo, quisimos saber si la combinación de resveratrol con otros compuestos 
de interés clínico resultaría en un incremento de la apoptosis en las líneas celulares 
utilizadas en el presente estudio. Con este fin hemos escogido la perifosina perteneciente 
al grupo de los ATLs, compuestos que parecen actuar de forma similar al resveratrol 
en las células de MM y JK; y el inhibidor de proteasoma bortezomib, utilizado en la 
actualidad en clínica en el tratamiento de diferentes neoplasias sanguíneas, incluido 
el MM 69,102. Tratamos a todas nuestras líneas de estudio (JK, MM144, MM1S y U266) 
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con las combinaciones anteriores. Nuestros datos demuestran que la combinación de 
resveratrol con perifosina (Fig. 19) resulta en un efecto apoptótico aditivo, mientras 
que la combinación con bortezomib resulta en un efecto apoptótico sinérgico (Fig. 20). 
El efecto aditivo resultante de la combinación del resveratrol con perifosina refuerza 
la idea de que estos compuestos comparten, al menos parte, el mismo mecanismo de 
acción. Nuestros resultados fueron similares en todas las líneas celulares utilizadas, 
excepto en las U266, en las cuales no se ha observado ningún efecto aditivo. La 
combinación entre el resveratrol y el bortezomib resultó en un efecto sinérgico 
probablemente porque el resveratrol ejerce su efecto apoptótico actuando sobre los 
rafts mientras que el bortezomib actua sobre el proteasoma. Estos resultados indican 
que la terapia combinada de resveratrol con otros compuestos podría ser considerada 
para su empleo en clínica. Para que el reveratrol ejerza su efecto citotoxico son 
necesarias dosis muy elevadas, siendo esta una de las limitaciones a su empleo clínico. 
Sin embargo, en combinación con otros compuestos, como hemos visto, dosis más 
bajas podrían ser consideradas. Además, dos oligomeros naturales del resveratrol, 
ε-viniferin y myabenol C se encuentra en estudio exactamente por el hecho de que 
a dosis más bajas están obteniendo resultados prometedores en líneas celulares de 
tumores linfoides y mieloides 106. 
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8.3.2. La activación de Akt mediada por rafts como diana terapéutica en células de 
MCL
8.3.2.1. Los ATLs inhiben la via de señalización de Akt y activan la vía apoptótica 
mitocondrial en líneas celulares de MCL
 Para alcanzar el segundo objetivo de esta tesis utilizamos las siguientes líneas 
celulares de linfoma de manto: Z-138, JVM-2 y Jeko-1, las cuales tratamos con los 
ATLs perifosina y edelfosina. Empezamos describiendo la sucesión de eventos 
apoptóticos después de la incubación con los referidos ATLs. Los primeros parámetros 
apoptóticos detectados se relacionan con la activación de la vía intrínseca: perdida de 
ΔΨm (Fig. 22), generación de ROS (Fig. 23) y activación de la caspasa-9 (Fig. 24). 
Por último, detectamos la degradación del ADN (Fig. 25). Para determinar el papel 
de las caspasas en este proceso de muerte, preincubamos las células con el inhibidor 
general de caspasas z-VAD-fmk, y  los resultados muestran que z-VAD-fmk inhibe la 
apoptosis inducida por ATLs (Fig. 26).
 Datos previos relacionan la inhibición de la ruta PI3K/Akt tanto con la 
activación de la vía intrínseca de la apoptosis como con la muerte celular inducida por 
ATLs 29,70. Por tal motivo, analizamos el efecto de la edelfosina sobre la fosforilación 
de Akt y de quinasas relacionadas, a diferentes intervalos de tiempo. Para realizar 
este ensayo seleccionamos las células más sensibles a la acción de los ATLs, según 
nuestros datos las células Z-138, y entre los dos ATLs (edelfosina y perifosina), la 
edelfosina que posee un efecto apoptótico fue potente (Figs. 25 y 29). Nuestros datos 
muestran que a las primeras horas (3 h) de tratamiento disminuyeron los niveles de 
fosforilación de Akt en Ser473. Además comprobamos que lo mismo ocorría con 
la mayoría de sus substratos, para ello utilizamos un anticuerpo que reconoce los 
sustratos de Akt fosforilados que poseen el motivo RXRXXS/T 119. Sin embargo, los 
niveles de fosforilación de Akt en el residuo Thr308 solo disminuyeron transcurridas 
15 h de incubación con la edelfosina (Fig. 28 A).
  Posteriormente quisimos saber que ocurría con dos de los sustratos más 
conocidos de Akt: GSK3 y Bad, durante el tratamiento con edelfosina. Normalmente 
Akt inhibe a ambos mediante fosforilación mientras este activada. Datos previos 
implican a GSK3 en la degradación proteosómica de la ciclina D1, la cual se encuentra 
sobreexpresada en células de MCL 110. Bad está relacionada con la activación de la 
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ruta intrínseca de la apoptosis 112, activada en nuestros ensayos mediante incubación 
con ATLs. Nuestros resultados muestran que los niveles de fosforilación de GSK3 no 
disminuyen. Incluso cuando preincubamos las células con el inhibidor de GSK3 LiCl 
detectamos un incremento en la apoptosis inducida por ATLs (Fig. 28 B), sugiriendo 
que los ATLs actúan sobre una vía independiente a GSK3. Esto coincide con resultados 
previos, donde el tratamiento de células de MCL con ATLs no disminuían los niveles 
de ciclina D1 70, lo que podría implicar que GSK3 sea regulada por una vía alternativa 
a la de Akt 131. Con respecto a Bad, se observó inhibición de su fosforilación 24 horas 
después de la incubación con los ATLs, cuando ya se habían iniciado los procesos 
apoptóticos, lo que sugiere que Bad no está implicada en la supervivencia de estas 
células por activación de Akt, como ya se ha descrito en células hematopoyéticas 112.
 Además, analizamos lo que ocurría con los niveles de fosforilación de mTOR 
(mammalian target of rapamycin), una vez que, cuando forma parte del complejo 
mTORC1 (mammalian target of rapamycin complex 1) se convierte en un sustrato 
downstream de Akt 113. Según nuestros datos, el tratamiento con edelfosina bajó 
los niveles de fosforilación tanto de mTOR como de 4E-BP1, proteína dowstream 
mTORC1, confirmando así, que el complejo mTORC1 se ve afectado por el tratamiento 
con edelfosina (Fig. 28). 
 A continuación, quisimos evaluar los niveles basales de fosforilación de Akt 
en Ser473 entre las diferentes líneas de MCL. Los niveles basales más altos fueron 
detectados en las células HBL-2, seguidas de Jeko-1, y luego de Z-138 y JVM-2, cuyos 
niveles detectados fueron similares. Después del tratamiento con ATLs, observamos 
que la línea celular HBL-2 era resistente al tratamiento (Fig. 29), indicando que altos 
niveles de p-Akt confieren resistencia al tratamiento por ATLs. Estos datos sugieren 
una relación entre los niveles de fosforilación de Akt y la sensibilidad o resistencia a la 
muerte inducida por ATLs.
8.3.2.2. Efectos de la edelfosina en la fosforilación de ERK y JNK  
 Datos previos relacionan la vía de señalización de JNK con la muerte inducida 
por ATLs 118 y con la patogénesis de MCL 120. Igualmente, la activación de ERK se ha 
descrito como un mecanismo de compensación en células donde la señalización vía 
Akt se encontraba comprometida 121. Por ello, quisimos analizar en detalle si estas 
rutas de señalización podrían estar implicadas en la apoptosis mediada por ATLs. 
Detectamos el estado de fosforilación de las proteínas JNK y ERK tras la incubación 
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con edelfosina a diferentes tiempos. Nuestros resultados mostraron un aumento de los 
niveles de fosforilación de la proteína JNK, sin embargo, al preincubar con el inhibidor 
de JNK, SP, se observó una disminución en la apoptosis inducida por ATLs, pero no 
una inhibición total. Con respecto a ERK, detectamos un pequeño incremento de los 
niveles de fosforilación de proteína, y la preincubación de las células con el inhibidor 
de ERK, PD98059 (PD) no indujo cambios en la viabilidad de las células con respecto 
a la muerte inducida por ATLs (Fig. 31). Estos resultados indican que las vías de 
señalización de ERK y JNK no son esenciales en la muerte celular inducida por ATLs 
en células de MCL.
8.3.2.3. La inhibición de PI3K potencia la apoptosis inducida por ATLs
 Teniendo en cuenta los datos previos presentados anteriormente en este trabajo, 
en los cuales detectamos inhibición de Akt y de algunos de sus sustratos downstream 
tras la incubación con ATLs, quisimos saber si la inhibición de PI3K (quinasa upstream 
Akt) tiene algún efecto en la muerte inducida por los ATLs. Detectamos un aumento 
de la apoptosis inducida por los ATLs, así como de un incremento en la inhibición de 
Akt y del sustrato mTOR. Estos datos sugieren que la inhibición de la ruta de PI3K/
Akt puede sensibilizar las células al tratamiento por ATLs, potenciando la respuesta 
apoptótica (Fig. 32).
8.3.2.4. Inhibidores de Akt inducen apoptosis en la línea celular de MCL Z-138
 Utilizamos diferentes inhibidores específicos de Akt (Fig. 33) con el objetivo 
de comparar sus efectos apoptóticos con respecto a los de los ATLs, tanto a nivel de 
degradación de ADN como de la activación/inhibición de las quinasas previamente 
descritas. Todos los inhibidores empleados indujeron pérdida del ΔΨm, degradación 
del ADN, disminución de los niveles de p-mTOR, aumento de los de p-JNK y un 
pequeño aumento en la fosforilación de GSK3. Todos los eventos observados son 
similares a los ya descritos con ATLs. Estos datos sugieren, que tanto los inhibidores 
de Akt como los ATLs estarían actuando sobre la misma vía de señalización para la 
inducción de apoptosis en células de MCL (Figs. 34 y 35). 
8.3.2.5. La estimulación por CD40 no protege las células de MCL de la muerte inducida 
por ATLs
 Los estímulos del microambiente tumoral son claves para la supervivencia 
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de las células de MCL y para su resistencia a agentes quimioterapéuticos 110,124. Para 
estudiar el efecto de uno de los estímulos del microambiente tumoral, preincubado 
dos líneas celulares JVM-2 y Z-138 con la inmunoglobulina anti-CD40, que funciona 
estímulando la proliferación celular por activación de CD40. Nuestros datos 
muestran que la fosforilación de Akt se incrementó mediante la incubación con 
la inmunoglobulina anti-CD40, sin generar cambios en el porcentaje de apoptosis 
entre células estimuladas y no estimuladas, tras la incubación con ATLs. Estos datos 
indican que este tipo de estímulación del microambiente tumoral de las MCL no sería 
suficiente para inhibir la muerte celular mediada por ATLs (Figs. 36 y 37). 
8.3.2.6. Los rafts están implicados en la señalización de Akt en células de MCL
 Nuestros resultados muestran una inhibición de Akt desencadenada por 
acción de los ATLs, dado que estudios previos han demostrado la implicación de 
rafts en la activación de la ruta PI3K/Akt 34, encontrándose esta vía constitutivamente 
activada en células de MCL 110,111, y que, una de las dianas descritas de los ATLs en 
células tumorales son los lipid rafts 73,  aislamos rafts de células de MCL control y 
tratadas con ATLs. En los rafts de células Z-138 control detectamos preferentemente 
Akt activada (fosforilada en Ser473 y Th308) así como otras quinasas reguladoras de 
la vía de señalización de Akt: PI3K, mTOR y p-PDK1 (Fig. 38). Sin embargo, Akt y 
PDK1 no fosforiladas se encontraron igualmente distribuidas entre las fracciones rafts 
y no-rafts. Estos datos indican que los dominios de membrana pueden tener un papel 
clave en la activación de la ruta PI3K/Akt en células de MCL.
 Se ha descrito que los ATLs tienen como diana los rafts de distintos tumores 
hematológicos 73. Nuestros resultados muestran que en distintas líneas de MCL tratadas 
con edelfosina ocurre un desplazamiento hacia las fracciones no-raft de las proteínas 
pertenecientes a la vía PI3K/Akt. De igual modo, los substratos downstream de Akt 
en rafts se vieron especialmente afectados, indicando que la edelfosina al incorporarse 
en los rafts estaría bloqueando la señalización de la ruta PI3K/Akt en células de MCL 
(Figs. 38 y 39).
 La preincubación de las células Z-138 con pervanadato, el activador más potente 
de Akt que se conoce 125, aumentó los niveles de fosforilación de Akt en la membrana, 
y además inhibió la muerte celular inducida por edelfosina de forma significativa. 
Estos datos apoyan la teoria de que la inhibición de la señalización de Akt, localizada 
en los rafts, es un paso importante para la inducción de muerte mediada por los ATLs 
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(Fig. 40). 
 Los datos presentados en este trabajo sugieren que la incorporación de 
edelfosina en los dominios rafts conlleva a un desplazamiento de las proteínas quinasas 
Akt, PI3K, PDK1 y mTOR  hacia zonas no-raft, inhibiendo la fosforilación de Akt y de 
sus sustratos, resultando en la pérdida ΔΨm, degradación del ADN y finalmente a la 
muerte celular (Fig. 44). 
 Se ha descrito que la inhibición de la ruta de Akt puede originar una distribución 
de receptores de muerte en lipid rafts 84, lo que coincide con los datos presentados en 
este trabajo y con datos anteriores en cuanto a la movilización de Fas/CD95 inducida 
por ATLs 70. Sin embargo, en la línea celular Z-138 no se detecto un aumento de la 
apoptosis en presencia del anticuerpo agonista de Fas/CD95, el CH11 (Fig. 41). Estos 
datos coinciden con estudios anteriores, donde se demuestra que la edelfosina es capaz 
de activar Fas/CD95 a nivel intracelular, aunque el receptor no responda al estimulo 
con el anticuerpo agonista o el ligando natural 39. 
 En estudios previos se ha localizado la quinasa responsable de fosforilación de 
Akt en la Ser473 en los dominos rafts 134. Este dato explicaría por qué en este trabajo 
detectamos en primero lugar una disminución de la fosforilación en Ser473, antes que 
en Thr308. La quinasa responsable de fosforilar Akt en Ser473 puede ser mTORC2, lo 
cual detectamos que se desplaza de los rafts hacia localizaciones no-rafts mediante el 
tratamiento con ATLs. 
8.3.2.7. Edelfosina y perifosina son eficaces en el tratamiento de MCL en modelos 
in vivo
 Con la idea de extrapolar la toxicidad obtenida in vitro con los ATLs a ensayos 
con animales, realizamos un ensayo in vivo en ratones SCID a través de un modelo 
animal xenograft. Después de la inoculación de la línea celular Z-138 y de la detección 
de la generación de tumores incipientes, los ratones fueron tratados por vía oral con 
perifosina y edelfosina durante 3 semanas. Comparando el índice de crecimiento 
tumoral de los ratones control (tratados solamente con el vehículo, agua) vs tumores 
de ratones tratados con ATLs observamos una disminución en peso y volumen de los 
tumores en aquellos animales tratados con ATLs (30 mg/kg edelfosina y 25.45 mg/kg) 
(Fig. 42).
8.3.2.8. Los ATLs inducen muerte celular e inhiben Akt en células derivadas de pacientes 
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con MCL
 Con el fin de extrapolar los datos obtenidos en líneas celulares a células derivadas 
de pacientes, recurrimos a células de  9 pacientes con MCL (Tabla 1). Las células de 
los pacientes 8 y 9 no respondieron al tratamiento y no se detectó una inhibición de la 
fosforilacion de Akt tras la incubación con ATLs, efecto igualmente observado en la 
línea resistente HBL-2. Por el contrario, en las células del paciente 3, sensible a ATLs 
se ha detectó una disminución en los niveles de p-Akt (Fig. 43), siendo estos datos 
similares a los obtenidos en las líneas celulares sensibles a los ATLs.
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8.3.3. Edelfosina en terapia combinada en el tratamiento del mieloma múltiple
8.3.3.1. Los inhibidores de histona deacetilasas (HDAC) inducen apoptosis in líneas 
celulares de mieloma múltiple
 Para alcanzar el último objetivo de esta tesis hemos utilizado las siguientes líneas 
celulares de mieloma múltiple: MM144 y MM1S y las tratamos con los inhibidores 
de histona deacetilasas (HDAC) SAHA y MS-275. Comenzamos por caracterizar el 
tipo de muerte celular inducida por los inhibidores de HDAC en células de mieloma 
múltiple. La incubación con SAHA y MS-275 resultó en la degradación del ADN, 
activación de la caspasa-3 y degradación de su típico sustrato PARP. Adicionalmente, 
recurriendo a un ensayo colorimétrico se detectó la activación de las caspasas 8 y 9, 
pertenecientes a las rutas extrínseca y intrínseca de la apoptosis respectivamente (Fig. 
45).
8.3.3.1. La activación de la apoptosis mediante inhibidores de HDAC en células de 
MM ocurre por un mecanismo independiente al reclutamiento de Fas/CD95 en 
plataformas-rafts
 En resultados anteriores observamos como compuestos como el resveratrol 
y los ATLs promueven la formación de plataformas raft y Fas/CD95 activando 
una respuesta apoptótica. Sin embargo, los inhibidores de HDAC no activan dicho 
mecanismo de muerte en células MM144. Además, si impedimos da formación de 
rafts, mediante la preincubación con en quelante de colesterol MCD, tampoco se 
inhibió la muerte inducida por los inhibidores de HDAC. Estos datos sugieren que los 
inhibidores de HDAC inducen una apoptosis independiente de raft en células de MM 
(Fig. 46).
8.3.3.2 La combinación entre edelfosina e inhibidores de HDAC tiene un efecto 
potenciador de la apoptosis 
 Con vista a una posible aplicación terapéutica, estudiamos el efecto en la 
apoptosis resultante de la combinación entre compuestos que tienen como diana 
los rafts de membrana, en este caso la edelfosina, en combinación con compuestos 
que actúan de forma independiente de rafts, los inhibidores de HDAC. Detectamos 
utilizando dosis bajas de cada uno de los compuestos SAHA, MS-275 o EDLF, un 
aumento de la aptoptosis cuando se añadían de forma combinada EDLF+SAHA o 
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EDLF+MS-275.  Comprobamos la activación temprana de la apoptosis mediante 
activación de caspasa-3 y la degradación de su sustrato PARP en los periodos de 3 a 6 
h posteriores a la incubación (Fig. 47).
8.3.3.3. La combinación entre edelfosina y bortezomib resulta en una respuesta 
apoptótica sinérgica.
 Quisimos saber si la combinación de edelfosina con el bortezomib, un 
inhibidor del proteasoma que se encuentra en clínica para el tratamiento del MM, 
resultaba en un aumento de la apoptosis. Para ello utilizamos líneas celulares de MM 
sensibles (MM1S y MM144) o resistentes (MM1R) al tratamiento por dexametasoma, 
compuesto igualmente utilizado en clínica. Combinamos bajas dosis de edelfosina 
y bortezomib solas o combinadas, en las referidas líneas celulares de MM. Todas las 
líneas celulares empleadas respondieron de forma similar, en términos de degradación 
de ADN (apoptosis), cuando se incubaron con los compuestos solos o en estudios 
combinatorios. Se obtuvo una respuesta sinérgica resultante de la combinación entre 
edelfosine y bortezomib, lo que podría ser de interés clínico para el tratamiento de 
pacientes resistentes al tratamiento con dexametasona (Fig. 48). 
8.3.3.4. La combinación entre dos compuestos cuya diana son los lipid rafts no tiene un 
efecto potenciador de la apoptosis
 La combinación entre el resveratrol y la edelfosina no se ha reflejado en el 
incremento de la apoptosis lo que sugiere que pueden estar actuando a través de la 
misma ruta apoptótica (Figura 49). 
8.3.3.5. La pre-incubación con interferón gamma potencia la acción apoptótica de la 
edelfosina en células de MM
 Datos anteriores (Fig. 16) demuestran que la incubación de células de MM con 
interferón gamma resulta en el aumento de Fas/CD95 y caspasa-8.Teniendo en cuenta 
el papel que desempeña Fas/CD95 en el proceso apoptótico mediado por edelfosina, 
utilizamos el IFN-γ en células de MM. Nuestros datos indican que el tratamiento de 
células MM con IFN-γ sensibiliza estas células a la apoptosis inducida por edelfosina 
(Fig. 50).
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8.4. Conclusiones:
1- El resveratrol induce apoptosis en células de MM y de leucemia de células T 
por un mecanismo dependiente de rafts y de Fas/CD95. Este mecanismo implica el 
reclutamiento en plataformas-raft de Fas/CD95 así como de proteínas apoptóticas 
downstream rafts.
2- Los ATLs en líneas celulares de MCL desplazan quinasas pertenecientes a la 
ruta PI3K/Akt de dominios de membranas raft  a otros no-raft, induciendo una muerte 
celular apoptótica. La fosforilación de Akt en el residuo Ser473 ocurre principalmente 
en dominios de membrana raft, lo que es fundamental para la supervivencia de las 
células de MCL.
3- Los ATLs en presencia de estímulos del microambiente tumoral mantienen 
su acción apoptótica en células de MCL. Su acción antitumoral en estas células es 
dependiente de los niveles basales de fosforilación de Akt, tanto en líneas celulares 
como en células aisladas de pacientes.
4- En su conjunto los datos presentados en este trabajo revelan que los rafts son 
potenciales dianas terapéutica en cáncer, estando implicados en la regulación de la 
señalización de rutas de vida y muerte.
5- Esta terapia dirigida a dominios raft parece mostrarse como una herramienta 
prometedora en terapia combinada para el tratamiento del cáncer. La combinación 
entre moléculas que tienen como diana los rafts y bortezomib resulta en un efecto 
apoptótico sinérgico en células de MM y leucemia de células T
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